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1. Resumen 
Introducción y objetivos 
El comportamiento anormal de las células cancerosas es el resultado de la 
acumulación de numerosos defectos de dos tipos: alteraciones genéticas 
(mutaciones, amplificaciones y deleciones génicas, etc) y desregulación de los 
mecanismos epigenéticos. Estos fenómenos colaboran durante la iniciación y 
progresión del cáncer. A diferencia de los trastornos genéticos, los defectos 
epigenéticos son potencialmente reversibles, lo que ha suscitado en los últimos años 
la búsqueda de fármacos que selectivamente causen cambios en los patrones 
epigenéticos de las células tumorales, con la consiguiente diferenciación, muerte y/o 
parada de crecimiento de las mismas. Se han estudiado con especial interés dos 
tipos de estas sustancias: inhibidores de metiltransferasas de DNA (DNMTs) e 
inhibidores de desacetilasas de histonas (HDACs) dependientes de Zn(II). Entre otros 
efectos, ambos grupos de compuestos consiguen recuperar la expresión de genes 
supresores de tumores. Los inhibidores de DNMTs posibilitan la reactivación de 
aquellos genes silenciados mediante hipermetilación de la isla CpG de su promotor y 
los inhibidores de HDACs, de aquellos genes silenciados a través de la hipoacetilación 
de las histonas asociadas a su promotor. 
A pesar de sus prometedores efectos en cultivos celulares, muchas de estas 
sustancias presentan inconvenientes que limitan su aplicación en quimioterapia: 
toxicidad, mutagenicidad, inestabilidad, etc. 
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Considerando estos antecedentes, se planteó como objetivo de esta tesis el 
estudio de compuestos cuya capacidad de alterar los patrones epigenéticos de las 
células tumorales no había sido analizada previamente. En concreto: 
1. Se han determinado los efectos del anestésico procaína (4-aminobenzoato de 2-
dietilaminoetilo, compuesto 15 en Fig.9) en la metilación de DNA genómico y en 
la proliferación celular. 
2. Se ha realizado un estudio comparativo de siete inhibidores de HDACs 
dependientes de Zn(II): ácido butanoico (compuesto 23 en Fig.10), ácido 
valproico (compuesto 26 en Fig.10), MS-275 (compuesto 28 en Fig.10), 
tricostatina A (TSA, (compuesto 16 en Fig.10), SAHA (compuesto 17 en Fig.10), 
CX (compuesto 20 en Fig.10) y CY (compuesto 21 en Fig.10). Debido al reciente 
desarrollo de CX y CY, al iniciar este trabajo no había datos publicados sobre sus 
efectos en líneas celulares. En esta tesis se han analizado los efectos de estos 
siete compuestos in vitro y en cultivos de MCF7, especialmente las alteraciones 
originadas en el ciclo celular, los cambios inducidos en la acetilación de histonas y 
la expresión de ciertos genes. 
 
Como modelo de células cancerosas se escogió la línea celular de cáncer de 
mama MCF7. 
 Resultados 
Procaína: un nuevo agente desmetilante con efecto inhibidor 
del crecimiento en células cancerosas 
El tratamiento de células MCF7 con procaína durante 3 días reduce la 
cantidad de 5-metilcitosina en DNA genómico proporcionalmente a la concentración 
del fármaco (ver Fig.15B y C). El máximo efecto se alcanza tras 24-48 h (ver Fig.17). 
Transcurridas 72 h, se observa la pérdida de 5-metilcitosina en el promotor de 
RARβ2 (Fig.18A y B), que se encuentra hipermetilado en MCF7, y el consiguiente 
aumento de expresión del gen (Fig.18C). Procaína también provoca la parada del 4
ciclo celular durante la mitosis (Fig.19B y Fig.20) y reduce la proliferación celular 
(Fig.19A y B). El empleo de procainamida (compuesto 14 en Fig.9) en las mismas 
condiciones produce similares efectos (Fig.17, Fig.19B y C, Fig. 20), si bien en este 
caso la inhibición de la proliferación celular no es tan marcada. Sin embargo, 5-aza-
2’-desoxicitidina (zdC, compuesto 4 en Fig.9) es mucho más potente y, aún cuando 
se utiliza en concentraciones dos órdenes de magnitud inferiores a las de procaína, 
en tratamientos de tres días causa mayores pérdidas de metilación que ésta (Fig.15B 
y C, Fig.16, Fig.17) y frena sensiblemente la proliferación celular (Fig.19A y C). La 
proporción de 5-metilcitosina en DNA global se reduce de manera continuada a lo 
largo de los tres días de tratamiento con zdC (Fig.17). 
Estudio comparativo de siete inhibidores de desacetilasas de 
histonas. 
Ensayos in vitro de actividad desacetilasa realizados con extractos nucleares 
de MCF7 muestran que todas las sustancias analizadas, inclusive CX y CY, bloquean 
la desacetilación de histonas aunque a distintas concentraciones (Fig.21): los ácidos 
hidroxámicos (TSA, SAHA, CX y CY) lo hacen dentro del rango de concentración 
micromolar y los ácidos carboxílicos de cadena corta (butanoico y valproico), a 
concentraciones milimolares. La concentración a la que MS-275 inhibe la 
desacetilación de histonas en este ensayo no se pudo encontrar puesto que cuando 
el compuesto está a concentración superior a 50 µM se forma un precipitado en la 
mezcla de reacción, mientras que a concentraciones menores a penas se aprecia 
inhibición. 
El IC50 de cada sustancia para tratamientos de 24 h en cultivos de la línea 
MCF7 es del mismo orden de magnitud que la concentración necesaria para inhibir la 
actividad desacetilasa en el análisis in vitro (Fig. 22A). El compuesto que más se 
desvía de este comportamiento es MS-275, cuyo IC50 es 5 µM, una concentración 
que apenas afecta la desacetilación de histonas en el ensayo in vitro. Los cambios 
causados en el ciclo celular no son iguales en todos los casos (Fig.22B y C): los 
ácidos hidroxámicos incrementan la proporción de células en fase G2/M; los ácidos 
carboxílicos de cadena corta detienen la progresión del ciclo en G1/G0 y en G2/M y la 
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benzamida MS-275 para el ciclo en G1/G0 solamente. Además, de acuerdo con los 
análisis de ciclo celular realizados mediante citometría de flujo, la proporción de 
células que pudieran encontrarse en apoptosis es despreciable en cualquiera de 
estos tratamientos. Excepto que se indique lo contrario, todos los resultados 
mencionados de aquí en adelante fueron obtenidos al tratar MCF7 durante 24 h con 
el IC50 de cada sustancia. 
En células vivas, estos siete inhibidores inducen un aumento similar en la 
acetilación de H3 (Fig.24A), siendo la forma diacetilada la especie predominante con 
todos los tratamientos (Fig.24C). También se incrementa de manera notable la 
acetilación de H4 (Fig.24B), pero mientras con CX, ácido valproico y SAHA la forma 
mayoritaria parece ser la monoacetilada, con MS-275 es la triacetilada y en los otros 
casos (TSA, ácido butanoico, CY) hay aproximadamente la misma proporción de 
formas mono-, di-, tri-, y tetraacetiladas (Fig.24D). Se escogieron tres sustancias, 
MS-275, ácido butanoico y CY, para estudiar los cambios en la acetilación de H4 al 
tratar las células con menores concentraciones de fármaco: un décimo del IC50 
(0,1·IC50), cuatro décimos del IC50 (0,4·IC50) y siete décimos del IC50 (0,7·IC50). Los 
resultados obtenidos con MS-275 y ácido butanoico son prácticamente idénticos 
(Fig.25). En ambos casos se observa que con 0,4·IC50 la distribución de H4 en no, 
mono-, di-, tri- y tetraacetilada es bastante similar a la obtenida cuando la 
concentración de estas sustancias es IC50. Los cambios inducidos por CY son 
ligeramente distintos (Fig.25). 
Se ha descrito que en ciertas líneas celulares algunos de estos compuestos 
alteran la expresión de las HDACs y/o inducen degradación de HDAC2. En las 
condiciones empleadas en este trabajo no se apreciaron cambios en la cantidad de 
proteína de las desacetilasas HDAC1 y HDAC2 (Fig.26). 
El tratamiento con estos compuestos consigue incrementar la expresión del 
gen CDKN1A (Fig.28A). Todas las sustancias reactivan JunD, si bien CY parece ser 
menos eficiente que el resto, y todas ellas salvo MS-275 producen un aumento de la 
transcripción de GADD45β e IGFBP3 (Fig.28A). Ninguno de los inhibidores parece 
alterar la expresión de MT1X y MT2A (Fig.28A). Los promotores de estos seis genes 
(CDKN1A, IGFBP3, JunD, GADD45b, MT1X y MT2A) carecen de metilación de DNA en 
la correspondiente isla CpG (Fig.28B), por lo que la ausencia de respuesta en 
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determinados casos no se puede atribuir a silenciamiento mediante hipermetilación 
aberrante de DNA. En los seis promotores el tratamiento con CY hace aumentar la 
proporción de H4 tetraacetilada y de H3 dimetilada en el residuo de lisina 4 (Fig.29), 
mientras parece que se reduce la presencia de HDAC2 (Fig.29). Asimismo, en los 
promotores de MT1X y MT2A se reduce la cantidad de H3 dimetilada en el residuo de 
lisina 9 (Fig.29). 
Discusión 
Procaína: un nuevo agente desmetilante con efecto inhibidor 
del crecimiento en células cancerosas 
El mecanismo a través del cual procaína ejerce sus efectos en la metilación 
de DNA genómico es distinto al de zdC. Este último compuesto es un nucleósido que, 
una vez dentro de la célula, es fosforilado e incorporado al DNA en lugar de 2’-
desoxicitidina durante la replicación. Una vez en el DNA, los residuos de 5-azacitosina 
inhiben de manera irreversible las metiltransferasas, lo que reduce la concentración 
de DNMTs activas en la célula. Debido a ello, en la siguiente ronda de replicación del 
DNA las hebras hijas no son metiladas con eficiencia y, por tanto, la proporción de 5-
metilcitosina en DNA genómico baja. Cuantos más ciclos de replicación pasen con la 
acción de las metiltransferasas bloqueada, menor será la cantidad de 5-metilcitosina 
de DNA. Por el contrario, procaína no es un nucleósido y no se incorpora como tal en 
DNA, de manera que probablemente no necesite que transcurra ninguna ronda de 
replicación para poder comenzar a interferir en la metilación. Este hecho puede 
explicar por qué el máximo efecto de procaína se alcanza en 24-48 h, mientras zdC 
necesita más tiempo para lograr la máxima desmetilación. Hay varias posibles 
maneras a través las que procaína podría actuar. Por ejemplo, tanto procainamida 
como hidralazina forman complejos in vitro con DNA de doble hebra, favoreciendo 
transiciones de estructura B a estructura Z. Se ha sugerido que este fenómeno in 
vivo evita la acción de las DNMTs sobre su sustrato, con lo que se reduce la 
proporción de 5-metilcitosina en DNA genómico (Thomas and Messner 1986, 7
Zacharias and Koopman 1990). Por otra parte, hay resultados que parecen indicar 
que procainamida es un inhibidor competitivo de las DNMTs, aunque no está claro 
cuál(es) de estos enzimas se ven afectados (Scheinbart et al. 1991, Deng et al. 
2003). Dado que procaína es un compuesto muy similar a procainamida, no sería de 
extrañar que alterase el funcionamiento de las metiltransferasas de la misma 
manera. Por último, no se deben excluir otros mecanismos de acción menos directos. 
Está descrito que hidralazina, un fármaco antihipertensivo, reduce la expresión de las 
metiltransferasas DNMT1 y DNMT3a, en consecuencia, la metilación de DNA (Deng 
et al. 2003).  
A pesar de la fuerte pérdida de 5-metilcitosina que induce en el DNA 
genómico, zdC posee propiedades que limitan enormemente su utilización como 
fármaco: es una sustancia poco estable en disolución acuosa, en el organismo es 
rápidamente degradada por deaminasas de citidina, daña el DNA al unirse 
covalentemente a las DNMTs, etc. Incluso se considera que la gran bajada de la 
proporción de 5-metilcitosina en DNA inducida por esta sustancia puede originar, a 
largo plazo, la transformación de células normales (Ehrlich 2002). Por ello, las 
cualidades de procaína resultan interesantes. Procaína es estable en disolución 
acuosa y presenta baja toxicidad (de hecho, se utiliza como anestésico). Al no ser un 
nucleósido, cabe esperar que no dañe al DNA de la misma manera que zdC. Por 
último, procaína recupera la expresión de genes supresores de tumores a 
concentraciones a las que casi no altera la metilación global de DNA, lo que podría 
suponer la parada de crecimiento y/o muerte de las células tumorales con un bajo 
riesgo de inducir inestabilidad cromosómica en células sanas. 
Estudio comparativo de siete inhibidores de desacetilasas de 
histonas 
Las siete sustancias estudiadas son capaces de inhibir la actividad HDAC in 
vitro y de inducir hiperacetilación de las histonas H3 y H4 en cultivos celulares. Se 
aprecia una clara relación estructura-actividad entre los compuestos, las 
concentraciones a las que inhiben la desacetilación en ensayos  in vitro y el IC50 en la 
línea MCF7. En ambos casos, los ácidos carboxílicos de cadena corta son mucho 
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menos efectivos que los hidroxámicos. Este hecho se puede explicar considerando la 
estructura del centro activo de las desacetilasas dependientes de Zn(II) y la forma en 
que estas sustancias lo bloquean (Finnin et al. 1999, Vannini et al. 2004). Por una 
parte, los ácidos hidroxámicos de este estudio son moléculas de mayor tamaño que 
los ácidos carboxílicos, lo que les permite establecer mayor número de interacciones 
no covalentes con los aminoácidos de los enzimas. Por otra, el grupo funcional ácido 
hidroxámico es más afín por los cationes Zn(II) que el ácido carboxílico. Estos dos 
factores contribuyen a una mayor estabilidad de los complejos inhibidor-enzima en el 
caso de los ácidos hidroxámicos que en el de ácido butanoico o ácido valproico y por 
tanto la inhibición es más eficiente con los primeros. La benzamida MS-275 parece 
no ser eficaz in vitro, pero concentraciones micromolares de este compuesto inducen 
hiperacetilación de las histonas H3 y H4 en cultivos de MCF7 en extensión 
comparable a otras sustancias. A pesar de ser un dominio altamente conservado, la 
composición de aminoácidos del centro activo de las HDACs dependientes de Zn(II) 
varía ligeramente de unos enzimas a otros, de manera que no en todos los casos el 
cation metálico es accesible a un grupo voluminoso como la benzamida. De hecho, 
está descrito que la desacetilasa HDAC8, cuyo centro activo es más estrecho que el 
de otros enzimas de su familia, no es inhibida por MS-275 aunque sí por TSA y 
SAHA. Sin embargo, MS-275 es capaz de inhibir HDAC1 y HDAC3, otras desacetilasas 
dependientes de Zn(II) (Vannini et al. 2004). El hecho de que MS-275 no pueda 
alterar el funcionamiento HDAC8 y quizás el de alguna otra desacetilasa dependiente 
de Zn(II) explicaría la falta de eficiencia del compuesto in vitro, donde los enzimas 
no inhibidos catalizan la reacción en condiciones no naturales: el sustrato son 
histonas libres en lugar de estar incluidas en cromatina, pueden haberse perdido 
factores que actúen como reguladores de la actividad desacetilasa, etc. Sin embargo, 
en células vivas podría suceder que HDAC8 no sea capaz de reemplazar a las otras 
desacetilasas cuando estas son inhibidas, bien por ser mucho menos activa en 
cromatina que en histonas libres, bien por no ser reclutada a las mismas posiciones, 
etc. En ese caso, basta que MS-275 inhiba parte de las desacetilasas dependientes 
de Zn(II) para inducir hiperacetilación de histonas H3 y H4. 
Las alteraciones producidas en el ciclo celular por estas siete sustancias 
también parecen estar relacionadas con su naturaleza química: MS-275 detiene el 
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ciclo en G1/G0, los ácidos hidroxámicos en G2/M y los ácidos carboxílicos, en ambas 
fases. No se puede olvidar que se han descrito 11 HDACs dependientes de Zn(II) 
humanas, algunas con variantes de splicing. A pesar de ser altamente homólogos 
entre sí, existen pequeñas variaciones entre estos enzimas, siendo probable que una 
misma sustancia no inhiba todas las desacetilasas con idéntica eficiencia. Además, 
dos compuestos diferentes no tienen por qué presentar la misma afinidad por el 
mismo enzima. Asimismo, hay que recordar que algunas desacetilasas también 
actúan in vivo sobre otras proteínas como α-tubulina o p53. Toda esta diversidad 
puede originar que los distintos inhibidores no tengan exactamente los mismos 
efectos en la célula viva. Tampoco hay que descartar la posibilidad de que alguna de 
estas sustancias interaccione con otras macromoléculas de la célula, alterando otras 
actividades metabólicas independientemente de la desacetilación de proteínas. 
Los efectos de los siete compuestos en la acetilación de H3 y H4 de MCF7 
parecen muy semejantes a nivel global. Sin embargo, la expresión génica no 
responde de la misma manera a todos ellos. Las siete sustancias consiguen reactivar 
el gen CDKN1A y todas salvo MS-275 incrementan la transcripción de GADD45β. Se 
ha propuesto que la sobreexpresión de CDKN1A debida al tratamiento con 
inhibidores de desacetilasas origina una parada de ciclo celular en G1/G0, mientras 
que si se reactiva GADD45β, el ciclo se detiene en G2/M (Hirose et al. 2003). Los 
resultados de este trabajo concuerdan con esa hipótesis, puesto que MS-275, el 
único compuesto que no altera la expresión de GADD45β, es la única sustancia que 
detiene el ciclo celular exclusivamente en G1/G0. 
Ninguno de los inhibidores consigue alterar la expresión de MT1X y MT2A, a 
pesar de que el tratamiento con CY induce aumento de acetilación de H4 y de 
dimetilación del residuo 4 en H3 (dos marcas que se encuentran en cromatina 
transcripcionalmente activa) en sus respectivos promotores, de forma similar a lo 
que sucede con otros genes cuya expresión sí se incrementa. Curiosamente, sólo en 
los promotores de MT1X y MT2A se observa la presencia de H3 con la lisina 9 
dimetilada, modificación que desaparece al tratar las células con CY. La metilación de 
Lys9 de H3 se considera una marca de heterocromatina y de genes silenciados y 
puede estar asociada a la hipermetilación de DNA. No obstante, el DNA de todos 
estos promotores carece de 5-metilcitosina. 
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Conclusiones 
Procaína: un nuevo agente desmetilante con efecto inhibidor 
del crecimiento en células cancerosas 
1. Procaína reduce la metilación de DNA en cultivos celulares, aunque no de una 
forma tan extensiva como 5-aza-2’-desoxicitidina. El máximo efecto de procaína 
se alcanza entre el primer y el segundo día de tratamiento. 
2. Procaína es capaz de reactivar genes silenciados por hipermetilación (RARβ2) a 
concentraciones a las que reduce muy poco el contenido de 5-metilcitosina en 
DNA. 
3. Procaína reduce la proliferación celular e induce parada del ciclo celular en mitosis. 
4. Estas propiedades, junto con el hecho de que procaína no se incorpora en DNA 
hacen de procaína una sustancia potencialmente interesante para su estudio 
como posible terapia antitumoral. 
Estudio comparativo de siete inhibidores de desacetilasas de 
histonas. 
5. TSA, SAHA, CX, CY, MS-275, ácido butanoico y ácido valproico son inhibidores de 
HDACs  dependientes de Zn(II) cuyos efectos en ensayos de inhibición in vitro y 
crecimiento celular muestran una clara relación estructura-actividad. Los ácidos 
carboxílicos son los compuestos menos eficaces. 
6. Las siete sustancias afectan de forma comparable la acetilación global de H3 y H4 
en cultivos de MCF7. 
7. Ninguno de los inhibidores altera la cantidad de las proteínas de HDAC1 y HDAC2 
en la célula. 
8. Los diferentes efectos de los inhibidores de HDACs en los niveles de expresión de 
CDKN1A y GADD45β pueden estar relacionados con los distintos efectos en el 
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ciclo celular: MS-275 produce parada en G1/G0 y aumento de la transcripción de 
CDKN1A pero no de GADD45β. El resto de inhibidores producen parada en G2/M 
y aumento de la transcripción de CDKN1A y GADD45β. 
9. A pesar de que todos estos compuestos inducen de manera similar la acetilación 
global de histonas, no todos inducen la reactivación de los mismos genes.  
10. La insensibilidad de MT1X y MT2A a estos tratamientos no se debe ni a 
hipermetilación de DNA de sus respectivos promotores ni a la no acetilación de 
las histonas asociadas a ellos. 
11. La inhibición de HDACs da lugar al aumento en la acetilación de la histona H4 
asociada a los promotores de los seis genes estudiados. 
12. La inhibición de HDACs produce acumulación de dimetil-lisina 4 y bajada en la 
proporción de dimetil-lisina 9 de H3 asociada a los promotores de los genes 
analizados en los que esta modificación está presente. Este hecho es una prueba 
más de la interrelación existente entre las distintas modificaciones post-
traduccionales de las histonas. 
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2. Abbreviations 
 
A220  absorbance at 220 nm 
A260  absorbance at 260 nm 
A280  absorbance at 280 nm 
APS  ammonium persulfate 
ATRX  α-thalassemia, mental retardation syndrome X-linked protein 
BSA  bovine serum albumin 
bp   base pairs 
CBP  CREB binding protein 
CDKN1A  cyclin-dependent kinase inhibitor 1A 
CREB  cyclic-AMP-response-element-binding protein 
DAPI 2-(4-amidinophenyl)-6-indolecarbamidine dihydrochloride also 
named 4’,6-diamide-2’-phenylindole dihydrochloride 
DEPC  diethylpirocarbonate 
DMEM  Dubelcco’s modified Eagle’s medium 
DMSO  dimethylsulfoxide 
DNMT  DNA (cytosine-5)-methyltransferase 
dsDNA  double stranded DNA 
DTT  (±)-threo-1,4-dimercapto-2,3-butanediol also named DL-
dithiothreitol 
ChIP  chromatin immunoprecipitation 
EDTA  ethylenediaminetetraacetic acid 
EGTA  ethylene glycol-bis(2-aminoethylether)-N,N,N′,N′-tetraacetic acid 
FBS  fetal bovine serum 
GADD45β growth arrest and DNA-damage-inducible, beta 
GAPDH  glyceraldehyde-3-phosphate deshydrogenase 
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HAT  histone acetyltransferase 
HDAC  histone deacetylase 
HEPES  4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid 
HPCE  high-performance capillary electrophoresis 
HPLC  high-performance liquid chromatography 
IGFBP3  insulin-like growth factor binding protein 3 
IP   immunoprecipitation 
K4H3  lysine 4 in histone H3 
K9H3  lysine 9 in histone H3 
kbp  kilo base pairs 
LAP2  lamina-associated polypeptide 2 
MAPK  mitogen-activated protein-threonin kinase 
MBD  methyl-CpG binding domain 
mdC  5-methyl-2’-deoxycytidine 
MSP  methylation-specific PCR 
MT   metallothionein 
NCoR  nuclear receptor corepressor 
NLS  nuclear localization signal 
NuRD  nucleosome remodelling and histone deacetylation complex 
o/n  over night 
PAGE  polyacrilamide gel electrophoresis 
PARG  poly(ADP-ribose) glycohydrolase 
PARP  poly(ADP-ribose) polymerases 
PBS  phosphate-buffered saline 
PCNA  proliferating cell nuclear antigen 
PCR  polymerase chain reaction 
PRMT  protein arginine methyltransferase 
RAR  retinoic acid receptor 
RIZ1  retinoblastoma interacting zinc-finger protein 1 
RCF  relative centrifugal force 
RNAi  RNA interference 
PBS  phosphate buffered saline 
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RT-PCR  reversed transcription followed by PCR 
SAHA  suberoylanilide hydroxamic acid 
SAM  S-adenosyl-L-methionine 
SDS  sodium dodecylsulfate 
SUMO  small ubiquitin-related modifier 
TBE  Tris-borate-EDTA buffer 
TdT  terminal deoxynucleotidyl transferase 
TFA trifluoroacetic acid 
TMEDA N,N,N’,N’-tetramethylethylenediamine 
TRD target recognition domain 
Tris 2-amino-2-(hydroxymethyl)-1,3-propanediol, also named 
tris(hydroxymethyl)aminomethane 
TSA  trichostatin A 
TUNEL  TdT-mediate dUTP nick end labelling 
vol   volume 
zdC  5-aza-2’-deoxycytidine 
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 3. Introduction 
3.1 Epigenetics in the context of chromatin 
The word epigenetics defines the study of mitotically and/or meiotically 
heritable changes in gene expression that occur without alterations in the DNA 
sequence (Wolffe and Matzke, 1999). Epigenetic regulation is essential to ensure 
proper cell differentiation during the development of multicellular organisms, which 
are constituted by cells that are genetically homogeneous but structurally and 
functionally heterogeneous. In mammals, except for controlled genomic 
rearrangements like the ones of the immunoglobulin and T-cell receptor genes in 
lymphocytes, all other differentiation processes are initiated and maintained through 
epigenetic mechanisms, including genomic imprinting and X-chromosome 
inactivation. In addition, epigenetic regulation is thought to be responsible for the 
silencing of transposable elements in somatic cells of plants, fungi and animals 
(Martienssen and Colot 2001; Bird 2002). 
Despite being inheritable, epigenetic modifications are reversible and can be 
affected by environmental stimuli such as the diet in animals or the temperature in 
plants (vernalization response). Moreover, epigenetic changes in mammals are 
associated with the aging process (reviewed in Jaenisch and Bird 2003; Liu et al. 
2003). Alterations in the normal function of the epigenetic machineries are involved 
in the generation and progress of different diseases, like cancer, atherosclerosis, 
systemic lupus erythematosus, disorders related with errors in the imprinting of 
specific genes, syndromes like ICF (immunodeficiency, centromeric region instability 
and facial anomalies), ATRX (α-thalassemia, mental retardation syndrome X-linked) 
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 and Rett and many others illnesses (for recent reviews, see Lund and van Louhizen 
2004, Zaina et al. 2005; Januchowski et al. 2004; Waterland and Jirtle 2004; Ehlrich 
2003; Tang et al. 2004; Kriaucionis and Bird 2003). 
Mammalian cells have several known systems responsible for the epigenetic 
control of gene transcription and chromatin structure: DNA methylation, covalent 
modifications of the canonical core histones (H2A, H2B, H3 and H4), deposition of 
variant histone proteins into the nucleosomes, local chromatin rearrangement and 
non-coding RNA expression. These mechanisms are not independent but cooperate 
to ensure proper gene transcription and chromatin structure (reviewed in Lund and 
van Lohuizen 2004).  
This Introduction is divided in three parts. The first one is an overview of 
the epigenetic mechanisms. The second part summarizes the epigenetic alterations 
that have been found in cancer cells and the third one reviews the drugs targeted to 
these abnormalities. All the three sections are focused on DNA methylation and 
histone deacetylation, since the reversion of these two modifications is the objective 
of this thesis. 
3.1.1. The nucleosome 
The context for the epigenetic regulation is the chromatin, a 
macromolecular structure which packs the genomic DNA in the eukaryotic cell. The 
building block of the chromatin is the nucleosome, an octamer of histone proteins 
(two copies of H2A, two of H2B, two of H3 and two of H4) with 146 bp of dsDNA 
wrapped around it in 1.65 turns. In average, a nucleosome is found every 160-240 
bp in all the eukaryotic genomes, constituting the principal packaging element of 
DNA within the nucleus. Nucleosomes are further organized in compact higher-order 
structures (such as the 30 nm-chromatin fiber) which contain additional 
macromolecules, like the linker histone H1 or the high-mobility group proteins 
(HMG). The dynamic folding and unfolding of these putative superstructures 
regulates DNA accessibility and influences transcription, replication, DNA repair and 
recombination. The epigenetic machineries are involved in the control of the 
chromatin structure. 
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 Fig. 1: Core histones sequences. A) The histone fold regions for H3, H4, H2A and H2B are 
aligned on the basis of their structured and labeled on the left (top). The α-helix (α1, α2, α3) 
and loop (L1, L2) secondary structural elements are labeled; α-helices are underlined and the 
overlying lines indicate β-strand hydrogen bonds between L1 and L2 loops. Some interaction 
sites are highlighted: H3-H4 α2-α2 (blue-green); H2A-H2B α2-α2 (orange); H3 4-helix bundle 
(blue); H4-H2B 4-helix bundle (brown). B) The histone fold extensions and tail (italics) regions 
are shown with the core histone name representing the histone fold. Sites of in vivo acetylation 
are indicated by the letter “a” and the site of ubiquitination is marked “U”. In both A and B, Λ 
designates an arginine side chain that is inserted into the DNA minor groove. Taken from Luger 
et al. 1997. 
A B
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 Core histones (H2A, H2B, H3 and H4) are small basic proteins highly 
conserved, found in all eukaryotes. These polypeptides have in common the histone-
fold, a structural domain characterized by three α-helices connected by two loops 
(see Fig. 1). The histone-fold acts as an assembly motif in the formation of histone  
heterodimers, that are further assembled to yield the histone octamer, around which 
the DNA superhelix is wrapped. The histone N- and/or C-termini protrude out of this 
compact structure (Luger et al. 1997). The structure based on the data obtained by 
Luger et al. is shown in Fig. 2. 
Nucleosomes suffer directly the action of epigenetic regulators in four ways: 
DNA methylation, histone post-translational modifications (PTMs), deposition of 
histone variants and chromatin remodeling (reviewed in Khorasanizadeh 2004). All 
these changes take place in a coordinate way to specify downstream events (see 
section 3.1.7). 
3.1.2 DNA methylation 
One of the most studied epigenetic marks is the methylation of the position 
5 of the cytosine ring in DNA. This feature is found in a wide scope of eukaryotic 
organisms, however the percentage of methylated cytosine, its distribution in the 
genome and the sequences where it is found vary between species. 
In mammals, DNA methylation is associated with transcriptionally inactive 
chromatin, mainly transposable and retrotransposable repetitive sequences (such as 
Alu), inactive X-chromosome and imprinted genes. Cytosine methylation occurs 
simultaneously at both strands of the palindromic CpG dinucleotides (reviewed in 
Colot and Rossignol 1999; Bird 2002). However, in embryonic stem cells 15-20% of 
global 5-methylcytosine is not in CpG dinucleotides (Ramsahoye et al. 2000). 
The proportion of CpG dinucleotides in the human genome is 1.2%, much 
smaller than the 4% expected from the abundance of cytosine and guanine (42% of 
the DNA bases). In addition, the distribution is not uniform: some areas, called CpG 
islands, are particularly rich in CpG whereas the rest of the genome is depleted in 
this dinucleotide (Takai and Jones 2002, Gardiner-Garden and Frommer 1987, Bird et 
al. 1985). CpG islands are mainly found in promoter regions. It is estimated that near 
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 Fig. 2: The atomic structure of the nucleosome core particle. Each strand of DNA is shown in 
different shade of blue. The DNA makes 1.7 turns around the histone octamer to form an 
overall particle with a disk-like structure. Histone H3 is colored in green, H4 in yellow, H2A in 
red and H2B in pink. Taken from Khorasanizadeh 2004. 
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 60% of the genes are associated to a CpG island (Lander et al. 2001, Venter et al. 
2001, Antequera and Bird 1993). Some repetitive sequences, like the Alu family, 
have also a relatively high proportion of CpG dinucleotides (Takai and Jones 2002). 
In healthy human somatic cells, 5-methylcytosine represents near 1% of the 
DNA base content, which means that most CpG dinucleotides are methylated, 
including those ones found in the body of the genes, intergenic regions and 
repetitive elements (Ehrlich et al. 1982). However, except for the X-inactive 
chromosome in females and the imprinted genes, CpG islands are devoid of 5-
methylcytosine (reviewed in Bird 2002). 
In mammals, DNA methylation patterns are established during embryonic 
development. First, after fertilization DNA demethylation takes place to erase the 
characteristic 5-methylcytosine distribution of the oocyte and the spermatocyte. After 
implantation, de novo methylation sets up the normal somatic DNA methylation 
patterns, whose maintenance is essential for the embryo development and 
differentiation (reviewed in Bird 2002, Bird and Jaenisch 2003, Li 2002). 
3.1.2.1. DNA-methyltransferases 
DNA (cytosine-5)-methyltransferases (DNMTs) are the enzymes which 
catalyze the transfer of the methyl group from S-adenosyl-L-methionine (SAM) to the 
position 5 in the cytosine ring. Up to now, four mammalian DNMTs have been 
identified (DNMT1, DNMT2, DNMT3A and DNMT3B). There is also a DNMT-like 
protein (DNMT3L). Human DNMT1 (Yen et al. 1992, Yoder et al. 1996), DNMT2 
(Yoder and Bestor, 1998), DNMT3A and DNMT3B (Xie et al. 1999) have in common 
the DNA (cytosine-5)-methyltransferase domain. This domain, found in (cytosine-5)-
methyltransferases from prokaryotes to human, is constituted by 10 conserved 
amino-acid sequence motifs (numbered from I to X) alternated with non-conserved 
regions. Of these sequence motifs, five (I, IV, VI, VIII and X) are highly conserved. 
The target recognition domain (TRD) resides in the variable region between motifs 
VIII and IX (Pósfai et al. 1989). DNMT3L lacks the motifs VII to X and the similarity 
to the DNMTs in motifs I, IV and VI is not complete (Aapola et al. 2000). The 
functional organization of the known human DNMTs is represented in Fig. 3. 
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  Fig. 3: Functional organization of mammalian DNA (cytosine-5) methyltransferases. A) 
Functionally mapped regions of the full-length human DNMT1 are illustrated along with the 
carboxy-terminal catalytic domain. Nuclear localization signal (NLS) (194–213), replication fork 
(RF) targeting peptide (320–567), Zn(II) binding region (652–670), and polybromo-1 homology 
regions are represented. The repressor domain shows homology to the mixed-lineage leukemia 
(trithorax homolog) protein (known as MLL or HRX or ALL1). Summaries of protein interaction 
regions are indicated. DNMT1 associated protein (DMAP1) binding (1–126), proliferative cell 
nuclear antigen (PCNA) binding (162–174), and histone deacetylase (HDAC1) binding (653–
812) regions lie in the repressor domain. HDAC2 binds to the N-terminus region. 
Retinoblastoma gene product, Rb, binding regions (Rb1: 416–913, Rb2: 1–336) are shown. De 
novo methyltransferases DNMT3A and 3b also bind to the amino terminus of hDNMT1 (1–148 
and 149–217). Methylated DNA dependent allosteric activation domain (MDDAAD) is identified 
at the amino terminal region of the enzyme (121–500). Methyl CpG binding protein (MeCP2) 
binding region (264–326) overlaps the RF region. Phosphoprotein p23, an associated factor for 
progesterone receptor, is bound with the catalytic region of DNMT1. Amino acid numbers 
representing different binding domains are in parentheses. Mapped DNA binding regions are 
indicated as DB1, DB2, and DB3. B) Architectural organization of DNMT2. The conserved motifs 
are indicated on top. Functionally mapped regions of the full-length hDNMT3A (C), DNMT3B (D) 
and DNMT3L (E) are illustrated along with the carboxy-terminal catalytic domain. Conserved 
motifs are indicated on top of the methyltransferase domain. Locations of interacting regions 
are on the bottom. HDAC, RP58 binding on DNMT3A and HDAC on DNMT3B and DNMT3L is 
indicated. PWWP and ATRX homology regions are indicated. Taken from Pradham and Estève, 
2004. 
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 Several experiments, including crystallographic and NMR studies performed 
on the bacterial enzyme M.HhaI, confirmed the mechanism proposed by Santi and 
colleagues in 1983 for the action of DNMTs (for reviews, see Christman 2002 and 
Jeltsch 2002). Essentially, in a first stage, the enzyme flips out the target base from 
dsDNA by rotating the adjacent phosphodiester bonds in the sugar backbone 
(Klimašauskas et al. 1994, O’Gara et al 1996, Klimašauskas et al. 1998, O’Gara et al. 
1998, Vilkaitis et al. 2000). Only the π stacking interactions between the cytosine and 
the contiguous bases as well as the hydrogen bonds between cytosine and the 
guanine in the opposite strand are broken in that process. Then, the methyl group 
transfer takes place in several steps. Initially, the 6 position in the base ring is 
attacked (1,4 addition) by the thiolate of the cysteine in motif IV. Glutamic acid in 
motif VI helps by stabilizing the charge on the ring. In this point, enzyme and DNA 
are covalently linked to each other. Then, carbon 5 in the cytosine ring attacks the 
methyl group in SAM, and finally, a β-elimination releases the enzyme at the same 
time that restores the π-bond between positions 5 and 6 in the base (O’Gara et al. 
1996, Sheikhnejad et al. 1999, Zhou et al. 2002). The scheme is shown in Fig. 4A. 
Human DNMT1 is the largest DNA-methyltransferase found in this species. The 
catalytic domain is in the C-terminal region, like in DNMT3A and DNMT3B, separated 
from the N-terminal regulatory region by a series of GK repeats (see Fig. 3). The 
catalytic domain becomes inactive if large parts of the N-terminal region are deleted. 
The N-terminal part of the enzyme contains a nuclear localization signal (NLS) and a 
DNA replication foci-targeting peptide (RF), together with sequences that bind 
diverse proteins, like DNA-methyltransferase associated protein 1 (DMAP1), 
proliferating cell nuclear antigen (PCNA), retinoblastoma protein (Rb), DNMT3A or 
DNMT3B (see Fig. 3). There is also a methylated DNA dependent allosteric activation 
domain (MDDAAD), a Zn(II) binding region with homology to the mixed lineage 
leukaemia protein (MLL or HRX or ALL1) and another sequence homologous to the 
chicken protein polybromo-1 (Pradhan and Estève, 2003). 
In vitro, DNMT1 shows preference for the hemimethylated DNA (i.e., only 
one of the DNA strands is methylated) over the unmethylated substrate and in vivo 
colocalizes with the replication foci during S phase (Leonhardt et al. 1992). For this 
reason DNMT1  is  considered  to  be  the DNMT  responsible  of  conserving  the 
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 Fig. 4: A) Scheme showing the reaction pathway of the DNMTs based on the crystallographic 
data obtained with the bacterial enzyme M.Hha I by Zhuo and coworkers (Zhuo et al. 2002). 
Once the base is flipped out from DNA and inserted in the DNMT catalytic pocket, the 6-position 
carbon is attacked by a cystein residue from the enzyme (EnzS-). An acidic residue in the 
enzyme helps to stabilize the negative charge of the base ring (EnzCOOH). Then the methyl 
group is transferred from SAM (MeS+R1R2) to the 5 position in the base and the resulting 
intermediate suffers then a syn, β-elimination to release the methylated cytosine and the 
enzyme (EnzSH). AdoHcy stands for S-adenosylhomocysteine. B) Methyl-CpG binding proteins 
in mammals. The black boxes indicate the position of the MBD domain. Taken form 
Prokhortchouk and Hendrich, 2002. 
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 methylation pattern over cell division, the “maintenance DNMT”. However, partially 
overlapping functions with other DNMTs cannot be excluded (Rhee et al. 2002). On 
the one hand,  overexpression  of  DNMT1  leads  to  de  novo  methylation  in  cell  
lines, suggesting a possible role not only maintaining but also in generating 
methylation patterns (Vertino et al. 1996). On the other hand, in cell lines lacking 
DNMT1 the loss of 5-methylcytosine in DNA is not as dramatic as it would be 
expected if this enzyme would be the only responsible for maintenance methylation 
(Rhee et al. 2000, Espada et al. 2004).  
DNMT1 is the predominant DNA-methyltransferase in human tissues 
(Robertson et al. 1999). In somatic cells, two splicing variants, DNMT1a and 
DNMT1b, have been detected. Both proteins are identical except for a 16 amino 
acids insertion in the N-terminal region of DNMT1b (Hsu et al. 1999). Both 
transcripts are present in comparable amounts, but DNMT1a is more abundant than 
DNMT1b (Bonfils et al. 2000). In mouse, two gamete-specific splicing variants have 
been described, one present only in oocytes and another one in spermatocytes and 
skeletal muscle cells (Mertineit et al. 1998, Ratnam et al. 2002, Aguirre-Arteta et al. 
2000). 
Very little is known about mammalian DNMT2. The human enzyme has 391 
amino acids and its only domain is the catalytic one. A wide range of eukaryotic 
organisms, including Drosophila melanogaster and Schizosaccharomyces pombe, has 
DNMT2 homologs, all of them with a conserved sequence of 41 amino acids between 
motifs VIII and IX (Dong et al. 2001). The methylating activity of this enzyme has 
been controversial for several years, since it shows very low activity in vitro, mice 
lacking it are viable with no major defects (Hermann et al. 2003) and Dnmt2-
deficient mouse stem cells appear to be normal (Okano et al. 1998). However, recent 
experiments demonstrate that endogenous DNMT2 can bind DNA in human living 
cells, suggesting that it has methyltransferase activity in vivo (Liu et al. 2003). 
Both DNMT3A and DNMT3B proteins belong to the same family of DNA 
methyltransferases. In their N-terminal region there is a PWWP domain followed by a 
cystein rich region similar to ATRX zinc finger. The PWWP domain, also found in a 
variety of chromatin-related proteins like WHSC1 (Wolf-Hirschhorn syndrome 
candidate 1) or MSH6 (mutS (E. coli) homolog 6), is able to bind DNA in vitro, but in 
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 vivo it rather seems to be involved in protein-protein interactions. In mouse 
embryonic cells, the PWWP domain is required for the targeting and the activity of 
Dnmt3a and Dnmt3b (Stec et al. 2000, Qiu et al. 2002, Chen et al. 2004). The ATRX-
homology domain of murine Dnmt3a, whose sequence is 98% identical to human 
DNMT3A, interacts with HDAC1 (Fuks et al. 2001). In mice, both Dmt3a and Dnmt3b 
can repress transcription also by other mechanisms different to DNA methylation and 
both enzymes are essential for de novo methylation during development (Dodge et 
al. 2005; Kaneda et al. 2004, Chen et al. 2003; Okano et al. 1999, Bachman et al. 
2001, Fuks et al. 2001, reviewed in Li 2002). In humans, there are different splicing 
variants of both genes, but their function is not clear (Weisenberger et al. 2002, Xie 
et al. 1999, Robertson et al. 1999). Mutations in different regions of DNMT3B are 
responsible of the ICF (immunodeficiency, centromeric region instability and facial 
abnormalities) syndrome in near 60% of patients. The most characteristic hallmark 
of this disease is the centromeric instability, which correlates with a severe 
hypomethylation of satellites 2 and 3. The patients with mutations in DNMT3B also 
have hypomethylated alpha satellites and the females, also hypomethylated X-
inactive chromosome (Jiang et al. 2005). 
As mentioned before, DNMT3L has a truncated methyltransferase catalytic 
domain, so it is not enzymaticaly active. The N-terminal part of the protein is similar 
to that of DNMT3A and 3b, having also an ATRX homology domain (Aapola et al. 
2000). Despite the inability to methylate DNA, DNMT3L is directly involved in 
epigenetic repression by recruiting HDAC activity (Aapola et al. 2002, Deplus et al. 
2002), stimulation of DNMT3A activity in living cells (Chédin et al. 2002), and 
stimulation of both murine Dnmt3a and Dnmt3b in vitro (Gower at al. 2005, Suetake 
et al. 2004). Moreover, the phenotype of Dnmt3a conditional knockout mice and 
Dnmt3L knockout mice are indistinguishable (Kaneda et al. 2004). Dnmt3l is also 
implicated in the establishment of genomic imprinting in mice and spermatogenesis 
(Bourc’his et al. 2001, Webster et al. 2005, Bourc’his and Bestor 2004, reviewed in Li 
2002).  
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 3.1.2.2. Demethylation 
As mentioned above, the establishment of DNA methylation patterns during 
embryonic development involves genome wide demethylation. Demethylation also 
takes place during normal gametogenesis (reviewed in Bird 2002, Li 2002, Bird and 
Jaenisch 2003). Two different models have been proposed to explain how 
mammalian cells reduce the amount of 5-methylcytosine present in their DNA: 
passive demethylation and active demethylation (Jeltsch 2002). 
Passive demethylation is produced when the cell goes trough a second 
replication round before maintenance methylation has been completed. This yields 
one of the daughter dsDNA molecules completely unmethylated and the other one, 
hemimethylated. Passive demethylation is slow and requires cell cycle progression. 
The active demethylation requires enzyme(s) or complex(es) that either 
remove only the methyl group in the position 5 of the cytosine or replace the whole 
5-methylcytosine ring for unmethylated cytosine in a repair-like way. Battacharya 
and coworkers found that MBD2, one of the methyl-CpG binding domain (MBD) 
proteins (see 3.1.2.3), hydrolyses the 5-methyl group in the cytosine ring without 
affecting DNA base sequence; however this result remains controversial (Battacharya 
et al. 1999). Another protein containing the MBD, MBD4 (also known as MED1) is a 
thymine glycosylase. MBD4 binds to the mCpG·TpG mismatch due to 5-
methylcytosine deamination and removes the thymine ring. The resulting is an abasic 
site on DNA is later filled with unmethylated cytosine by other enzymes and 
complexes (Hendrich et al. 1999). MBD4 has also a small 5-methylcytosine 
glycosylase activity in vitro (Zhu et al. 2000) and even can remove other modified 
bases from DNA (reviewed by Parsons, 2003). However, it seems that the main 
biological function of MBD4 is rather the protection of the genome against the 
possible mutations caused by 5-methylcytosine deamination than the demethylation 
itself (reviewed in Hendrich and Tweedie 2003). Another tymine glycosylase (TDG) 
without MBD has been found to act on C/T mismatches in CpG sequences 
(Neddermann et al. 1996). 
Appart from thymine glycosylases and MBD2, no other protein or complexes 
with DNA demethylating activity have been described. 
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 3.1.2.3. Sensors of DNA methylation 
The presence of 5-methylcytosine residues on DNA influences the 
recruitment of different enzymes, transcription factors and repressors to the affected 
DNA sequence. Several proteins, like Kaiso and the proteins containing the MBD, 
recognize methylated DNA and recruit different repressor complexes to their target 
sequence (see next paragraph). Also, DNA methylation interferes with the binding of 
certain transcription factors, such as CREB (cyclic-AMP-response-element-binding 
protein) or SP1, or proteins involved in the establishment of genomic imprinting, 
such as CTCF (CCCTC binding factor) or BORIS (brother of the regulator of the 
imprinted sites) (Mancini et al. 1999, Klenova et al. 2002, reviewed in Lewis and 
Murrell 2004, Jaenisch and Bird 2003). On the other hand, there are some proteins 
that selectively bind unmethylated DNA sequences, like CGBP (CpG-binding protein), 
and that may protect CpG islands from methylation (see below). 
There are 5 known human proteins containing the MBD: MeCP2, MBD1, 
MBD2, MBD3 and MBD4 (Fig. 4B). Three of them, MBD1, MBD2 and MBD3, have 
splicing variants. Except for MBD3, all these proteins (MeCP2, MBD1, MBD2 and 
MBD4) bind methylated CpG dinucleotides in DNA through the MBD motif. Even 
though MBD3 does not bind specifically methylated DNA, it is a member of the 
repressor complex NuRD/Mi2, interacting through the MBD domain with MTA2 
(metastasis-associated gene family, member 2) and HDAC1 (Hendrich and Bird 1998, 
Saito and Ishikawa 2002). The involvement of MeCP2, MBD1 and MBD2 in 
transcriptional repression of methylated DNA sequences is widely reported (for 
reviews, see Ballestar and Wolffe 2001, Jaenisch and Bird 2003, Hendrich and 
Tweedie 2003). This fact does not exclude the participation of these proteins (for 
instance, MBD1) in silencing of non-methylated DNA through other complexes 
(Jørgensen et al. 2004). As already mentioned, MBD4 is involved in DNA mismatch 
repair and not in transcriptional repression. 
Kaiso, a protein belonging to the BTB/POZ family of transcription factors, 
does not have the MBD domain (Fig. 4B) but binds selectively DNA sequences with at 
least two methylated CpG dinucleotides (Prokhortchouk et al. 2001). Kaiso recruits 
the repressive NCoR complex to certain methylated promoters (Yoon et al. 2003). 
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 However, Kaiso has also methylation-independent DNA binding capacity, at least in 
vitro (Daniel et al. 2002). 
MBD3-like protein 1 (MBD3L1) and MBD3-like protein 2 (MBD3L2) are two 
proteins with homology to MBD2 and MBD3 but with no MBD domain (Jiang et al. 
2002). The first one, MBD3L1, associates with components of the MeCP1 and 
NuRD/Mi2 complexes (Jiang et al. 2004). The other one, MBD3L2, also interacts with 
NuRD/Mi2, but the resulting MBD3L·NuRD complex is either involved on methylation-
independent transcriptional repression or not repression at all (Jin et al. 2005). 
CpG-binding protein (CGBP) binds specifically unmethylated CpG motifs in 
vitro and acts as an activator of genes whose promoters reside within CpG islands 
(Voo et al. 2000). In vivo, this protein colocalizes with euchromatin and is essential 
for embryonic development in mouse (Lee and Skalnik 2002, Carlone and Skalnik 
2001). It has been proposed that CGBP might protect CpG islands from methylation 
(Bird 2002). 
3.1.3. Histone post-translational modifications 
The N-terminal portion of the four core histone proteins is flexible, rich in basic 
amino acids, and highly conserved across eukaryotes. These tails protrude out of the 
nucleosome, and therefore are accessible for interaction with other proteins, 
including contacts with adjacent nucleosomes, as well as for different enzymatic 
machineries that cause several types of covalent post-translational modifications: 
acetylation of lysine residues, methylation of lysine and arginine side-chains, 
phosphorylation of serine and threonine, ADP-ribosylation of glutamic acid residues, 
ubiquitylation, sumoylation and biotinylation of lysine side-chains. Not only the N-
termini but also some residues in the histone fold, like lysine 79 in H3, and the C-tails 
are exposed to interactions with other macromolecules and suffer post-translational 
modifications. The sequence of the tails of the canonical core histones and the best 
documented post-translational modifications are shown in Fig. 5. Such post-
translational histone modifications correlate with various nuclear activities, including 
replication, chromatin assembly and transcription (Khorasanizadeh 2004). 
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 Fig. 5: The best known post-translational covalent modifications of the core histones (H2A, 
H2B, H3 and H4). Lysine methylation (Me) is represented in red. Acetylation (Ac), 
phosphorylation (P) and ubiquitination (Ub) are indicated in green, blue and orange, 
respectively. Arginine methylation is represented in black. Modifications shown above each 
amino acid correlate with activation, whereas the lysine methylation shown below correlates 
with repression. The highest degree of methylation possible for each residue is displayed. 
Taken from Sims III et al. 2003. 
3.1.3.1. Lysine acetylation 
The ε-amino group of certain lysine residues in the core histone tails (see 
Fig. 5) is acetylated under certain circumstances. In general, it is assumed that 
histone acetylation associates with transcriptional activation, whereas the silent and 
more compact chromatin is enriched in deacetylated histones. Two non-exclusive 
models try to explain this fact. The first one proposes that acetylation interferes in 
the contact between histone tails and DNA and/or between histones and the 
adjacent nucleosomes, thus altering the higher-order chromatin structure and 
allowing the access of transcription factors to DNA. The second model considers that 
acetylation and deacetylation of histone tails are recognized by different proteins that 
recruit transcription activators or repressors, respectively (reviewed in Hasan and 
Hottiger 2002). 
Histone acetylation is reversible and highly dynamic. Two major sets of 
enzymes with opposite activity, histone acetyltransferases (HATs) and histone 
deacetylases (HDACs), are responsible for the establishment and maintenance of 
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 histone acetylation patterns. Histone acetylation and deacetylation equilibrium is 
thought to be involved in the regulation of different nuclear processes, like global 
basal transcription, replication timing, repair of DNA double-strand breaks and gene-
specific transcription, including both initiation and elongation (reviewed in Kurdistani 
and Grunstein 2003, Hasan and Hottiger 2002). 
Histone acetylation happens both in the cytoplasm and in the nucleus. In 
the cytoplasm, recently synthesized histones become modified by B-type HATs 
enzymes. The importance of this acetylation for histone deposition in nucleosomes is 
not well understood (reviewed in Verreault 2000). In the nucleus, A-type HATs 
modify histones that are packed in nucleosomes. According to the amino acid 
sequence and the homology of the different regions, A-type HATs can be grouped 
into different families (see Table 1), conserved from yeast to human. All of them 
share the catalytic domain, which transfers the acetyl group from acetyl-CoA to the 
ε-amino group of the target lysine. In vivo most of the A-type HAT proteins are part 
of multisubunit complexes that regulate the activity and substrate specificity of the 
enzymes. Moreover, some of the A-type HATs can acetylate protein others than 
histones, like the high-mobility group proteins (HMGs), general transcription factors, 
the ATPase BRM, Werner helicase, other HATs or p53 (reviewed in Yang 2004, 
Kurdistani and Grunstein 2003, Hasan and Hottiger 2002, Marmorstein 2001). 
There are three known classes of human HDACs, named class I (similar to 
yeast Rpd3), class II (similar to yeast Hda1) and class III (similar to yeast Sir2). As in 
the case of the HATs, some HDACs deacetylate several proteins other than histones, 
such as p53, E2F, or α-tubulin. Class I and II enzymes (HDAC1-11), also known as 
the classical family of HDACs, share the deacetylase core, a region of about 390 
amino acids that contains the catalytic site. The catalytic site, conserved in 
eukaryotic cells, consists of a tubular pocket with hydrophobic walls and a Zn(II) 
cation in the bottom. Once the acetylated lysine residue is inserted the pocket, the 
metallic cation facilitates the hydrolysis of the amide by orientating and polarizing the 
carbonyl group in the N-acetylamide, as represented in Fig. 6 (Finnin et al. 1999, 
Vannini et al. 2004). Most of these enzymes associate with other proteins which can 
target and modulate the HDACs (deRuijter et al. 2003, Yang and Seto 2003). 
32
 Table 1: Human A-type HATs 
Family Enzyme Substrate (1) Established role 
Gcn5/PCAF PCAF H3/H4, TFs, E1A, TAT transcriptional coactivator 
 GCN5L H3/H4, TFs transcriptional coactivator 
P300/CBP CBP histones, TFs, E1A transcriptional coactivator 
 P300 histones, TFs, E1A, TAT transcriptional coactivator 
MYST TIP60 H3/H4, androgen receptor transcriptional co-regulator, DNA 
repair and apoptosis 
 MOF H4 transcriptional coactivator 
 HBO1 H3/H4 DNA replication, transcriptional 
co-repressor 
 MOZ H3/H4 transcriptional coactivator 
 MORF H3/H4 transcriptional coactivator 
p160 SRC-1 H3/H4 transcriptional coactivator 
 ACTR H3/H4 transcriptional coactivator 
CIITA CIITA H4 transcriptional coactivator 
TAFII250 TAFII250 H3/H4 transcription initiation, kinase and 
ubiquitin ligase 
TFIIIC TFIIIC subunits H3/H4 transcription initiation 
CDY CDY H4  
 CDYL H4 histone-to-protamine transition 
during spermatogenesis 
(1) TFs stands for transcription factors, E1A is the adenoviral oncoprotein E1A and TAT stands 
for HIV TAR RNA-binding protein 
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 Fig. 6: The proposed catalytic mechanism for the deacetylation of acetylated lysine. HDLP 
(histone deacetylase-like protein, from Aquifex aeolicus) active-site residues and their proposed 
HDAC1 counterparts (in parenthesis) are labelled. From Finnin et al. 1999. 
OH
N
NH
O
O
-
N
NH
+
H
O
O
-
Zn
2+
NH3
+
O
O-
D258
(D264)
H170
(H178)D168
(D176)
Y297
(Y303)
H132
(H141)
H131
(H140)
D166
(D174)
D173
(D191)
NH
O
OH
N
NH
H
O
O
-
N
NH
O
O
-
Zn
2+
H
O
H
D258
(D264)
H170
(H178)D168
(D176)
Y297
(Y303)
H132
(H141)
H131
(H140)
D166
(D174)
D173
(D191)
NH
O
-
OH
OH
N
+
NH
H
O
O
-
N
NH
+
H
O
O
-
Zn
2+
D258
(D264)
H170
(H178)D168
(D176)
Y297
(Y303)
H132
(H141)
H131
(H140)
D166
(D174)
D173
(D191)
34
 Class I enzymes (HDAC1, HDAC2, HDAC3, HDAC8) localise into the nucleus 
and are ubiquitously expressed. HDAC1, HDAC2 and HDAC3 are part of repressor 
complexes such as SIN3, NuRD/Mi2, CoREST (REST corepressor), NCoR and SMRT 
(silencing mediator of retinoic acid and thyroid hormone receptor), but, to date, no 
interaction partner or endogenous complex for HDAC8 has been found. Moreover, it  
is not clear that HDAC8 deacetylates histones in vivo (Waltregny et al. 2005, Hu et 
al. 2003). 
The expression of class II HDACs is in general tissue dependent. This group 
of proteins can be subdivided in class IIa (HDAC4, HDAC5, HDAC7 and HDAC9) and 
class IIb (HDAC6 and HDAC10) enzymes. Class IIa HDACs share the amino-terminal 
region that includes domains for interaction with transcription factors such as the 
ones in MEF2 (myocyte enhancer factor 2) family and CtBP (C-terminal binding 
protein), etc. All the class IIa HDACs shuttle between cytoplasm and nucleus and all 
of them interact through their C-termini with SMRT and NCoR complexes. Class IIb 
enzymes have duplicated catalytic domains and both are primarily cytoplasmic. 
These enzymes only translocate to the nucleus in response to certain stimuli 
(reviewed in Verdin et al. 2003). 
Human HDAC11 shares features of both groups, so its inclusion in one or 
another family is not clear.  
The human HDACs belonging to class III have been recently discovered. It 
is reported the existence of 7 proteins (Sirt1-7) in this group, but the biological role 
of most of them is not yet known. Moreover, it is unclear whether any of these 
proteins have catalytic activity (reviewed in Blander and Guarente 2004). Unlike class 
I and class II HDACs, these enzymes are NAD+ dependent. The reaction subproducts 
are nicotinamide and O-acetyl-ADP-ribose (Jackson and Denu 2002, Tanner et al. 
2000). 
Acetylation of lysine residues influences the interaction of histone with other 
macromolecules. On the one hand, the positive charge of the lysine side-chain 
disappears with acetylation and the hydrogen bonds in which the ε-amino group is 
involved become different. Therefore, acetylation interferes with the contact of 
histone with DNA, RNA or certain proteins. On the other hand, acetylation represents 
a docking site for other molecules, especially proteins containing the bromodomain. 
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 The bromodomain is a region of roughly 110-amino-acid, conserved in eukaryotes. It 
functions as an acetyl-lysine-recognition module, binding not only histones but also 
other acetylated proteins, such as p53. This domain is commonly found in diverse 
transcription-regulatory factors, like HATs and chromatin-remodelling proteins. These 
factors are usually part of multisubunit complexes with diverse transcription-related 
functions (reviewed in Yang 2004; Marmorstein 2001). 
3.1.3.2. Lysine methylation 
Methylation of histone lysine residues is involved in the regulation of specific 
gene expression at euchromatic loci and in the organization of bulk eu- and 
heterochromatin. To date, six lysine residues in the canonical core histones have 
been found to be methylated in different contexts: lysines 4, 9, 27, 36 and 79 in H3 
(K4H3, K9H3, K27H3, K36H3 and K79H3 respectively) and lysine 20 in H4 (K20H4). 
In addition, each ε-amino group can be modified with 1, 2 or 3 methyl groups, 
resulting in a high number of theoretically possible combinations. In contrast to 
acetylation, methylation does not alter the charge of the side-chain but increases its 
bulkiness and hydrofobicity (for recent reviews see Peters and Schübeler 2005, Sims 
et al. 2003, Lachner and Jenuwein 2003). 
Methylation of K9H3, K27H3 and K20H4 correlate with transcriptional 
silencing. Di- and trimethylation of K9H3 and K20H4 as well as trimethylation of K27 
are modifications involved in silencing the inactive X chromosome in mammalian 
females (Chadwick and Willard 2004, Rougeulle et al. 2004, Plath et al. 2003). 
Trimethylation of K9H3 and monomethylation of K27H3 colocalize with pericentric 
heterochromatin  and also methylation of K20H4 has been found in heterochromatic 
domains (Peters et al. 2003, Rice et al. 2003, Schotta et al. 2004; Kourmouli et al. 
2004). Di- and monomethylation of K9H3 accumulate in silent areas of euchromatin 
(Rice et al. 2003). Moreover, dimethylation K9H3 is sufficient to repress transcription 
in a reporter gene in Xenopus laevis oocytes (Stewart et al. 2005). 
On the other hand, the transcription start of expressed genes is enriched in 
di- and trimethyl K4H3 not only in higher eukaryotes, but also in yeast (Kouskouti 
and Talianidis 2005, Liang et al. 2004, Schneider et al. 2004, Ng et al. 2003a). These  
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 Fig. 7: Possible mechanism for LSD1-catalyzed demethylation of dimethyl K4H3 is shown, but 
the proposed reactions are also compatible with monomethylated lysines or methylated 
arginines. Taken from Shi et al. 2004. 
 
modifications may constitute the molecular memory for recent transcription events 
(Ng et al. 2003a). Also, the 3’ region of active genes contains more di- and trimethyl 
K36H3 compared to the constitutively inactive ones. It seems that methylation in this 
position is coupled to elongation and maybe RNA processing (Bannister et al. 2005, 
Kizer et al. 2005, reviewed in Hampsey and Reinberg 2003). Finally, dimethylation of 
K79H3 appears at the transcription start of active genes, like methylation of K4H3, 
and it is not present in heterochromatin (Kouskouti and Talianidis 2005, Ng et al. 
2003). 
All the known lysine methyltransferases use SAM as methyl-donor cofactor. 
Except for DOT1L (the enzyme that methylates K79H3) and its homologues all the 
other histone lysine methyltransferases share a conserved catalytic module, the SET 
domain, found in a large number of eukaryotic proteins and even in bacteria. The 
SET domain can be subdivided in 3 regions, the amino terminal area (SET-N), the 
carboxy terminal module (SET-C) and a highly variable region in between (SET-I). It 
is thought that at least part of the substrate specificity of these enzymes is owed to 
the SET-I module, whereas the post-SET domain determines the number of methyl 
groups (one, two or three) that the enzyme can add. The histone lysine 
methyltransferases can be grouped in several families according the amino acid 
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 sequences surrounding the SET domain: SUV, SET1, SET2, EZ and RIZ (reviewed in 
Cheng et al. 2004, Xiao et al. 2003, Kouzarides 2002). 
For a long time it was thought that lysine methylation was the most stable 
histone modification because no strong experimental evidences supported the 
existence of lysine demethylases, despite several theoretical possibilities and putative 
enzymes were suggested (Trewick et al. 2005). It was proposed that only the 
removal of the modified tail (proteolytic cleavage) or the replacement of the whole 
histone for an unmodified version could revert methylation (reviewed in 
Bannister et al. 2002). However, recently a homolog of the amine oxidases, LSD1 
(lysine specific demethylase 1), was found to catalyse the demethylation of di- and 
monomethylated lysine amino groups in vitro and in human cultured cells. According 
to the postulated mechanism, first the lysine amino group is oxidized, to yield an 
imine that is further hydrolysed to release formaldehyde. The cofactor FAD is 
required for the oxidation (see Fig. 7). Database search allowed the identification of 
another human protein similar to LSD1 as well as different LSD1-like proteins present 
in other species, like Drosophila melanogaster, Arabidopsis thaliana or 
Schizosaccaromyzes pombe (Shi et al. 2004, Forneris et al. 2005). 
Certain methylated lysine residues in core histones are specifically 
recognized by the chromodomain of some proteins. For instance, HP1α 
(heterochromatin protein 1α) chromodomain binds selectively methylated K9H3 and 
Polycomb chromodomain binds methylated K27H3. To now, no other domain has 
been reported to bind selectively histones methylated at lysine residues, but not all 
the proteins containing a chromodomain show affinity for methylated histones. There 
are 11 families of chromodomains and the interaction partner of many of them is not 
yet clear. Moreover, it is reported that some of these domains can bind non-histone 
proteins, DNA or RNA (reviewed in de la Cruz et al. 2005; Brehm et al. 2004; Sims et 
al. 2003). 
3.1.3.3. Arginine methylation 
Histone arginine methylation is related with both transcriptional activation 
and repression. Arginine residues 8 and 17 in H3 (R8H3, R17H3) and 3 in H4 (R3H4) 
have been found to be methylated in cells. Additionally, PMRT1 is able of methylate 
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 in vitro arginine residue 26 in H3 (R26H3), but this modification has not been found 
in vivo. (Pal et al. 2004, reviewed in Cheng et al. 2004, Kouzarides 2002). 
In humans, seven protein arginine methyltransferases (PRMT) have been 
described, but not all of them are fully characterized and not all of them act on 
histones. It is known that the major substrate in vivo for PMRT4 (also known as 
CARM1) is R17H3, whereas PMRT1 prefers R3H4. These methyltransferases use SAM 
as source for methyl groups and have a conserved PMRT core, consisting in a 
methyltransferase domain, a β-barrel and a dimerization domain. It seems that 
dimerization is necessary for activity. There are two families of PMRTs, type I and 
type II. Both catalyze the formation of monomethylarginine, but type I PRMTs 
(PRMT1-4, PRMT6) also form asymmetric dimethylarginine and type II PRMTs 
(PRMT5 and PRMT7) form symmetric dimethylarginine (Lee et al. 2005, reviewed in 
Cheng et al. 2004, Kouzarides 2002). 
No proper “arginine demethylases” are known. However, two laboratories 
have found independently that human PAD4 (peptidylarginine deiminase-4) converts 
a monomethylated arginine residue in a citrulline one, releasing monomethylamine 
(reviewed in Denman 2005). 
3.1.3.4. Serine and threonine phosphorylation 
Phosphorylation of the core histones is a post-translational modification 
related with mitosis and transcriptional activation, although its function is not clear. 
In human cells, phosphorylation of serine 10 and 28 in H3 (S10H3, S28H3), serine 1 
in H4 (S1H4), serine 1 in H2A (S1H2A) and threonine 11 (T11H3) takes place in late 
G2 phase and/or different stages of the mitosis (Goto et al. 2002, Barber et al. 2004, 
Preuss et al. 2003, reviewed in Nowak and Corces 2004). Aditionally, phosphorylation 
of serine 14 in H2B (S14H2B) is related with chromatin condensation during 
apoptosis and phosphorylation of threonine 3 in H3 (T3H3) has been found in avian 
cells during prophase and metaphase (Cheung et al. 2003, Polioudaki et al. 2004). In 
any case, the most studied is phosphorylation of S10H3, which is not only involved in 
mitosis but also plays a role in gene activation through the MAPK (mitogen-activated 
protein-threonin kinase) pathway (Dunn and Davie 2005, reviewed in Nowak and 
Corces 2004, Prigent and Dimitrov 2003). 
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 3.1.3.5. Poly(ADP-ribosyl)ation 
Poly(ADP-ribosyl)ation is the attachment of a poly(ADP-ribose) polymer to a 
protein, most likely via the γ-carboxy groups of glutamic acid residues. The ADP-
ribose units are linked to each other through glycosidic bonds 1’’->2’. The chain can 
be either linear or branched. This modification is found in the core histones (mainly 
H2B, but also H3 and H4) as response to DNA damage. Also, poly(ADP-ribosyl)ation 
is important for the transcriptional activity of certain inducible genes and, in other 
cases, it is involved in silencing. 
In vivo, poly(ADP-ribosyl)ation has a fast turnover. The poly(ADP-ribose) 
polymerases (PARPs) are the enzymes which catalyze the successive transfer of ADP-
ribose units to protein acceptors, using NAD+ as substrate, to produce linear and/or 
branched polymers of ADP-ribose. The poly(ADP-ribose) glycohydrolase (PARG) 
hydrolyses the bond between two consecutive units of ADR-ribose and the poly(ADP-
ribose) lyase hydrolyses the bond between the monomer directly attached to the 
protein and the glutamic acid residue (reviewed in D’amours et al. 1999, Kraus and 
Lis 2003). 
3.1.3.6. Lysine ubiquitination and sumoylation 
Ubiquitin and the small ubiquitin-related modifier (SUMO) family are 
peptides that can be covalently attached to core histones. Despite all these peptides 
can form polymeric chains, ubiquitin and SUMO peptides conjugated to histones are 
usually monomers. In higher eukaryotes, lysine 119 in H2A (K119H2A) and lysine 
120 in H2B (K120H2B) are the main ubiquitinated residues within core histones. 
Some studies show that mammalian ubiquitinated H2A is involved in telomeric 
silencing, X chromosome inactivation and in the formation of XY bodies during 
spermatogenesis (Smith et al. 2004; Baarends et al. 2005). However, according to 
other reports, histone ubiquitination is located in nuclease-sensitive sites and 
transcriptionally active chromatin. In any case, the levels of ubiquitinated H2A 
change during the cell cycle: this modified histone disappears during G2->M phase 
transition and is restored in the M->G1 transition. Regarding SUMO peptides, 
mammalian H4 has been reported to be modified by SUMO-1 and SUMO-3 in a 
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 higher extent than H2A, H2B and H3. This modification seems to be associated with 
transcriptional repression (Shiio and Eisenman 2003). 
The machinery that attaches ubiquitin to proteins is very similar to that one 
which links SUMO. In both cases, three enzymes are necessary. The activating 
enzyme E1 forms a thioester bond with the corresponding modifying peptide. The 
conjugating enzyme E2 takes the peptide from E1 and the ligase E3 drives the 
formation of an isopeptide bond between the C-terminal group in the peptide and 
the ε-amino group of a lysine residue in the target protein. Specific isopeptidases 
remove ubiquitin and the different SUMO peptides from the proteins (for reviews see 
Gill 2004, Zhang 2003, Jason et al. 2002). 
3.1.3.7 Lysine biotinylation 
In humans, all the canonical core histones can be biotinylated. In H4, this 
modification takes place in positions K8 and K12 (Camporeale et al. 2004). 
Biotinylation of histones is more abundant in proliferating than in quiescent cells and 
associates with silent chromatin (Stanley et al. 2001, Peters et al. 2002). Additionally, 
UV light has been found to increase the proportion of biotinylated histones in Jurkat 
cells (Peters et al. 2002). Holocarboxylase synthetase could be the enzyme (or one of 
the enzymes) that catalyses these modifications (Narang et al. 2004). 
3.1.4. Histone variants 
As mentioned above, the exchange of the different core histones isoforms 
constitutes part of the epigenetic regulation. In humans, it has been reported the 
existence of variants for all the histones except for H4. The best characterized ones 
are represented in Fig. 8.  
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 Fig. 8: Canonical core histones and their best characterized variants. The major core histones 
contain a conserved histone-fold domain (HFD). In addition, they contain N- and C-terminal 
tails that harbour sites for various post-translational modifications. For simplicity, only well-
established sites for lysine methylation (red flags) and serine phosphorylation (green circles) 
are shown (other types of modifications, such as ubiquitylation, are not shown). In the histone 
H3.3 variant, the residues that differ from the major histone H3 (also known as H3.1) are 
highlighted in yellow. Three of these residues are contained in the globular domain and one 
resides in the N terminus. This N-terminal residue (Ser31) has been speculated to be a potential 
site for phosphorylation on H3.3. The centromeric histone CENPA has a unique N terminus, 
which does not resemble other core histones. Two sites of phosphorylation have been identified 
in this region, of which Ser7 phosphorylation has been shown to be essential for completion of 
cytokinesis. The region in the globular domain that is required for targeting CENPA to the 
centromere is highlighted in light blue. Histone H2A variants differ significantly from the major 
core H2A in their C terminus. The C terminus of H2AX harbours a conserved serine residue 
(Ser139), the phosphorylation of which is an early event in response to DNA double-strand 
breaks. A short region in the C terminus of H2AZ is essential for viability in Drosophila 
melanogaster. MacroH2A has an extended C-terminal macro domain, the function of which is 
unknown. Finally, the H2ABBD is the smallest of the H2A variants and contains a distinct N 
terminus, which lacks all of the conserved modification sites that are present in H2A. The C 
terminus is also truncated and lacks the docking domain that is found in other H2A species. The 
histones H4 and H2B are also shown, including their known methylation and phosphorylation 
sites. Taken from Sarma and Reinberg, 2005. 
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 Among the several isoforms of H3, the best known are H3.3 and CENPA 
(centromere protein A). The first one, H3.3 is found in transcriptionally active loci. It 
is deposited into chromatin in both replication dependent and replication 
independent ways, in contrast to the canonical H3 (H3.1), which is only placed into 
nucleosomes during S-phase. CENPA, located in centromeres, is essential for proper 
chromosome segregation during mitosis. 
Human histone H2A has four known variants. H2AX is scattered all over the 
genome, and its phosphorylation during the early steps of DNA repair is necessaryfor 
an efficient response to DNA damage. H2AZ may be involved in the maintenance of 
facultative heterochromatin and in preventing the spreading of heterochromatin. 
MacroH2A is only found in vertebrates and, despite been enriched in the inactive X 
chromosome, is not essential for the maintenance of its silencing. The C-terminal 
domain of macroH2A is a leucine zipper, which could be involved in the 
establishment of inter-nucleosome interactions and so promoting the compaction of 
chromatin. The mammalian specific H2A-Barr-body-deficient (H2ABBD) localizes in 
autosomes and the active X chromosome, being excluded of the inactive X in 
females. 
Histone H2B has a testis-specific variant (TSH2B or HIST1H2BA) whose 
function is not yet know (Li et al. 2005). 
These variants can also suffer post-translational modifications, like the 
canonical core histones (for reviews, Sarma and Reinberg 2005, Kamakaka and 
Biggins 2005). 
3.1.5. Chromatin remodeling 
Nucleosome remodeling defines a large number of ATP-dependent 
alterations of the canonical nucleosome structure. These perturbations of the DNA-
histone interactions may lead to the relocation of histone octamers from a particular 
DNA fragment to available acceptor DNA in cis or trans, establishing a “fluid” state of 
chromatin in which the overall packaging of DNA is maintained, but individual 
sequences are transiently exposed to interacting factors (Becker and Hörz 2002). The 
remodeling is involved in all major reactions that occur on chromatin, including gene 
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 transcription and repression, positioning of the nucleosomes in the replication origin, 
DNA repair, etc. 
The common feature to the diversity of chromatin remodeling complexes is 
the presence of an ATPase from the Snf2-like family. According to the existence of 
different domains, the Snf2-like ATPases are grouped in several subfamilies. In 
humans, there are five subfamilies. The SNF2 (sucrose nonfermenting protein 2) 
subfamily proteins, like BRG1 (BRM/SWI2-related gene 1, also named SMARCA4) or 
BRM (also named SMARCA2), contain a bromodomain. The members of the ISWI 
(imitation of Swi) subfamily, such as SNF2H (sucrose nonfermenting protein 2 
homolog, also known as SMARCA5), SNF2L (sucrose nonfermenting, yeast, homolog-
like 1, also named SMARCA1) or CHRAC1 (chromatin accessibility complex 1), have a 
SANT domain. The proteins of the CHD1 (chromodomain helicase DNA binding 
protein 1) subfamily have a chromodomain. The other subfamilies are CSB (Cockayne 
syndrome group B) and RAD54, which contains ATRX. For reviews see Eberharter 
and Becker 2004, Längst and Becker 2004, Lusser and Kadonaga 2003, Becker and 
Hörz 2002, Narlikar et al. 2002. 
3.1.6. Non-coding RNAs 
The synthesis of non-coding RNA molecules is also involved in the 
epigenetic control of gene expression. The best known example in mammals, 
including humans, is the transcription of XIST (X inactive-specific transcript), the only 
gene expressed in the inactive X chromosome in females. The coating of the inactive 
X chromosome with XIST RNA is necessary and sufficient to initiate and spread the 
silencing. In order to maintain the X chromosome inactivated, XIST RNA coordinates 
chromosome-wide chromatin modifications, including remodeling, changes in histone 
post-translational modifications, deposition of histone variants and DNA methylation. 
Together with another non-coding RNA, TSIX, XIST controls the choice of the active 
X chromosome (reviewed in Plath et al. 2002). 
Another sort of RNAs involved in regulation of gene expression are the 
microRNAs (miRNA), RNA molecules of about 22 nucleotides in length found in 
metazoan. The mechanism by which these nucleic acids act is not completely 
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 understood. It is known that miRNA molecules are not fully complementary to their 
mRNA targets. Depending on the degree of mismatch, miRNA inhibit the translation 
of the targeted transcript or induce its degradation (see Meister and Tuschl 2004; 
Lippman and Martienssen 2004, Bartel 2004). In human cells, transfection with 
exogenous RNA fully complementary to its target causes not only mRNA degradation, 
but also DNA methylation at the promoter of the targeted gene (Morris et al. 2004). 
Furthermore, chicken cells with defective machinery to process miRNA show 
heterochromatin defects (Fukugawa et al. 2004). 
3.1.7. A cross-talk between epigenetic modifications 
All the features above mentioned (DNA methylation, histone post-
translational modifications, histone variants, chromatin remodeling and non-coding 
RNA) act in an orchestrated manner to control gene expression and chromatin 
structure throughout the cell cycle. These marks are dependent on each other and 
interconnected through various mechanisms, resulting in a very complex network 
that allows the cell to store and inherit non-DNA-encoded information. 
Theoretically, each modification can exert its action through “loss of 
function” and/or “gain of function” mechanisms. In the first case, the modification 
interferes with the binding of proteins and factors that recognize the unmodified 
species, whereas in the second case, the modification generates a docking site that 
is specifically recognized by certain protein modules (reviewed by Yang 2004). For 
instance, DNA methylation prevents the binding of CGBP protein and CTCF to their 
target sequences (“loss of function”), whereas it is recognized for the MBD proteins 
(“gain of function”). Other examples for “gain of function” are the interaction 
between bromodomain-containing proteins and acetylated histones or between some 
chromodomains and histones methylated at certain lysine residues. 
Three models have been suggested to explain how the combination of 
modifications of chromatin, especially histone post-translational modifications, is 
translated. The first one, known as the “histone code” proposes that multiple histone 
modifications, acting in a combinatorial or sequential fashion on one or multiple 
histone tails, specify unique downstream functions (Strahl and Allis 2000). This 
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 concept can be extended to a higher level, assuming that the distinct domains in 
higher-order chromatin structure are dependent on the local concentration and 
combination of differentially modified nucleosomes (Jenuwein and Allis 2001). 
However, other researchers consider that the combinatorial aspect of the histone 
modifications is not supported by the experimental data and so the histone code is 
not a valid model (Kurdistani and Grunstein 2003, Schreiber and Bernstein 2002). 
The second model, known as the “signaling network model of chromatin”, postulates 
that there are parallelisms between other signaling pathways in the cell (such as the 
receptor tyrosine kinases) and the chromatin function. Among the common features 
of these signalling networks, the most relevant are the robustness, resulting from 
feedback loops and redundant mechanisms to propagate the signal; the bistability or 
switch-like behaviour, due to feedback loops; and the adaptability. Despite these 
parallelisms, chromatin function has unique characteristics, such as inheritance 
through cell division (Schreiber and Bernstein 2002). Finally, another alternative to 
the “histone code” is the “histone surface” model. Given that covalent modifications 
of histones are not independent of each other and that histone marks do not function 
in a combinatorial way, it has been suggested that different sets of modifications on 
a nucleosome generate different binding surfaces that can interact with various 
proteins. Diverse combinations of modifications can generate a similar surface and so 
be recognized by the same proteins (Kurdistani and Grunstein 2003). 
In any case, some relationships between the different epigenetic 
mechanisms are documented (reviewed in Fischle et al. 2003). Some enzymes 
recognize certain epigenetic modifications and catalyze the addition of a different one 
in the same region. The ATPases in the SNF2 subfamily are targeted through their 
bromodomain to chromatin areas rich in acetylated histones. There, these ATPases 
take part in the acetylation-dependent nucleosome assembly and remodeling 
(reviewed in Yang 2004). On the other hand, some enzymes are inhibited by certain 
modifications, like p300, which cannot acetylate H3 if the same tail is methylated on 
K9H3, or Suvar3-9 histone lysine methyltransferases, which cannot methylate K9H3 if 
the same tail is methylated on K4 (reviewed in Fischle et al. 2003). The existence of 
complexes containing different epigenetic regulator proteins constitutes another way 
of connecting the epigenetic marks. For instance, MBD1 recruits SETDB1 to 
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 methylated DNA, establishing a link between DNA methylation and K9H3 methylation 
(Sarraf and Stancheva 2004). The association of MBDs with HDACs in complexes, 
such as MeCP1, links DNA methylation and histone deacetylation (reviewed in 
Hendrich and Tweedie 2003). Finally, there are some data about the cascade of 
modifications in a few cases, like X chromosome inactivation in females or the 
activation of certain promoters. The events involved in the silencing of the inactive 
chromosome in females begin with XIST RNA expression. Once the coating of the 
inactive X chromosome by XIST RNA starts, in the already coated regions K9H3 
becomes methylated at the same time that K4H3 methylation decreases. Then, the 
affected genes become silenced and their replication timing moves to the late S-
phase. Also H4 becomes hypoacetylated. Next, deposition of macroH2A takes place 
onto the inactive chromosome and finally, DNA is methylated. DNMTs and HDACs 
collaborate with XIST to maintain the inactive X chromosome silenced (reviewed in 
Plath et al. 2002). Another example is the time-sequence of modifications on an 
exogenous pS2 promoter after estrogen stimulation of human cells. In this case, the 
stimulation induces the acetylation of K18 in H3 at the promoter. Next, PRMT4 is 
recruited, methylates R17H3 and then CBP acetylates K23H3 (Daujat et al. 2002). 
Despite all the research done in the last few years, the interplay between 
the different epigenetic modifications is far from been completely known and 
understood. 
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 3.2. Role of epigenetic alterations in cancer 
The abnormal behaviour of cancer cells reflects the qualitative and 
quantitative alterations in their gene expression profile. Changes in DNA sequence 
and deregulation of the epigenetic mechanisms collaborate for the tumor initiation 
and progression. Epigenetic aberrations are directly involved in silencing tumor-
suppressor genes, reactivation of genes that can promote cancer development and 
generation of chromosomal instability. The changes in DNA methylation patterns are 
the best documented epigenetic abnormalities of the cancer cell. During the last few 
years, alterations in histone acetylation have also been characterized and it is 
expected that, in the future, the accumulation of data about other epigenetic 
mechanisms will lead to a better understanding of the epigenetic deregulations 
related to cancer (reviewed in Laird 2005; Lund and van Louhizen2004). 
3.2.1. Causes of the epigenetic alterations in cancer cells 
The origin of the altered epigenetic patterns in cancer cells is not yet well 
understood, but it is known that errors in recruitment of the epigenetic machineries, 
expression of non-functional alleles, inadequate transcription levels of epigenetic 
related proteins and environmental factors underlie the aberrant epigenetic control of 
gene expression. 
3.2.1.1. Errors in targeting epigenetic mechanisms 
The best known examples of errors in the recruitment of epigenetic 
mechanisms are found in leukemias. Diverse chromosomal translocations generate 
chimera proteins that, in response to certain stimuli, target repressor complexes to 
the promoters of genes that should be activated. One of the many examples is the 
AML-ETO fusion protein. This chimera contains the DNA binding domain of AML1 
(acute myeloyde leukemia 1 gene, also named RUNX1), a protein which can act as 
transcriptional activator, fused to ETO (eight twenty one), a protein that binds to the 
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 repressor complexes NCoR and Sin3A. As result, genes that should be activated by 
AML1 become repressed (reviewed in Lund and van Louhizen 2004).  
3.2.1.2. Expression of non-functional epigenetic regulator proteins 
Certain epigenetic regulator proteins are inactivated due to mutations in a 
variety of cancers. Some examples are the histone methyltransferase RIZ1, the 
histone acetyltransferases p300 and CBP, and the subunits of chromatin remodelling 
complexes BRG1 and SNF5. The alterations in gene expression caused directly by 
these mutant proteins have not been studied in detail, but experiments in mice 
and/or cultured cells show the tumor-suppressor properties of these enzymes 
(reviewed in Lund and van Louhizen 2004). 
3.2.1.3. Changes in the expression of epigenetic regulator proteins. 
Some of the proteins involved in epigenetic regulation are overexpressed in 
cancer cells. That is the case of the histone methyltransferase EZH2 (enhancer of 
zestes homolog 2), overexpressed in breast, prostate and liver cancer (Sudo et al. 
2005), or HDAC2, overexpressed in gastric cancer (Song et al. 2005). The way by 
which these alterations contribute to cancer development is not clear. For EZH2, 
some data suggest that the excess of protein could have dominant negative effects 
in the functions of the Polycomb repressor complex 2 (PRC2), but other results do 
not support this hypothesis (reviewed in Lund and van Louhizen 2004). 
Other enzymes, such as RIZ1, p300, CBP or the remodelers BRG1 and BRM 
are not transcribed in certain types of cancer due to deletions and/or promoter DNA 
hypermethylation. In addition, the downregulation of some microRNA genes in 
tumors may affect chromatin structure and lead to chromosomal instability (reviewed 
in Lund and van Louhizen 2004). 
3.2.1.4. Environmental factors 
Some diet components and virus infections are known to influence the 
epigenetic patterns. For instance, cadmium inhibits DNMT activity, inducing global 
DNA hypomethylation. Also, mice fed with diets poor in methionine and choline 
suffer a decrease in DNA methylation and hepatocellular carcinoma. 
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 Fermentation of the dietary fibre in the intestine yields diverse short chain 
fatty acids, including butanoic acid, a substance that inhibits HDACs (see 3.3.2.2). It 
has been suggested that butanoic acid protects colon against cancer, probably due 
to its effects on HDACs, but these chemopreventive properties remain controversial 
(reviewed in Lupton 2004, Hassig et al. 1997). 
3.2.2. Direct consequences of epigenetic alterations in cancer 
cells 
3.2.2.1. Silencing of tumor-suppressor genes 
Tumor-suppressor genes are defined as the genes whose products are 
required for the normal cell function and whose loss of function contributes to the 
initiation or the development of the cancer. Two hits, one affecting each allele, are 
necessary for the complete loss of function of a tumor-suppressor gene in a cell 
(Knudson’s hypothesis). Each one of these two hits can be either a genetic change, 
like mutation or deletion, or an epigenetic alteration. The best known epigenetic 
deregulations involved in the silencing of tumor-suppressor genes in cancer cells are 
DNA hypermethylation and histone hypoacetylation. Both alterations lead to the 
recruitment of repressor complexes that reduce or completely abolish the expression 
of the affected genes. 
DNA hypermethylation is the increase in the proportion of 5-methylcytosine 
in a given DNA sequence. In cancer cells, DNA hypermethylation silences tumor-
suppressor genes whose promoter is a CpG island. Some examples are CDKN2A 
(cyclin-dependent kinase inhibitor 2A, also p16ARF/INK4a), MLH1 (mutL homolog 1), 
VHL (von Hippel-Lindau tumor suppressor), E-cadherin and the retinoblastoma gene 
(reviewed in Esteller 2005, Feinberg and Tycko 2004, Jones and Laird 1999). 
Histone hypoacetylation is the reduction in the number of acetyl groups 
attached to the histones in a given chromatin region. In cancer cells, the expression 
of certain tumor-suppressor genes, such as CDKN1A (cyclin-dependent kinase 
inhibitor 1A, also named p21WAF/Cip), is often lost because of the hypoacetylation of 
histones at their promoters (reviewed in Johnstone and Licht 2003). 
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 3.2.2.2. Derepression of genes that promote tumor growth 
Changes in the epigenetic patterns can also lead to the reactivation of 
genes which are silent in the normal somatic cell. The 5-methylcytosine content at 
the promoters of oncogenes such as H-RAS or BCL2, testis-specific genes such as the 
melanoma antigen family of genes (MAGE) and imprinted genes such as IGF2 
(insulin-like growth factor-II) is diminished in many human cancers, resulting in an 
increase of their expression that contributes to tumor growth and development 
(reviewed in Ehrlich 2002, Feinberg and Tycko 2004, Lund and van Louhizen 2004). 
3.2.2.3. Chromosomal instability 
Karyotypic instability allows cancer progression by facilitating genome 
variability and so the emergence of mutant cells with selective advantages. 
Alterations in the epigenetic mechanisms can promote chromosomal instability. The 
best studied phenomenom is the hypomethylation of repetitive DNA sequences, 
especially pericentromeric satellites. These repetitive elements in the normal somatic 
cells are usually heavily methylated, associated with histone hypoacetylation and 
packed in heterochromatic regions, but in several cancers these satellites loss 5-
methylcytosine. This fact is thought to reduce the compaction of the chromatin, 
resulting in a more accessible DNA for interaction with other DNA sequences and 
thus favouring the recombination. Indeed, satellite recombination is thought to be 
responsible for the translocations t(1;16) found in Wilms tumors and in some ovarian 
and breast carcinomas (reviewed in Ehrlich 2002, Feinberg and Tycko 2004). 
Retrotransposable sequences, like LINE-1, are also heavily methylated in normal 
somatic cells, probably to repress their transcription. However, in cancer cells 
(prostate, bladder, liver, lung and breast cancer among others), these elements are 
hypomethylated, which may cause an increase in their activity thus leading to 
genomic instability (Florl et al. 2004, Chalitchagorn et al. 2005, reviewed in Esteller 
2005, Feinberg and Tycko 2004).  
51
 3.3. Epigenetic drugs for cancer therapy 
In contrast to genetic alterations, epigenetic modifications are reversible, 
therefore the correction of aberrant epigenetic patterns is theoretically possible. This 
assumption has driven, during the last few years, a vast research to find novel 
anticancer drugs able of restoring, at least partially, the normal gene activity of the 
cells. Most of the efforts have been devoted to the development of chemicals that 
recover the expression of tumor-suppressor genes silenced by either promoter DNA 
hypermethylation and/or histone hypoacetylation. Inhibitors of the enzymatic activity 
of DNMTs or class I and class II HDACs have been or are currently tested for their 
use as cancer chemotherapy drugs (see 3.3.1 and 3.3.2). Inhibitors of DNMTs cause 
a drop in global DNA methylation and so are able to revert promoter 
hypermethylation. Inhibitors of Zn(II)-dependent HDACs induce an increase of 
histone acetylation by disrupting the balance between HATs and HDACs activity. It is 
expected that the increase in the knowledge of epigenetic mechanisms will allow the 
development of drugs interfering with other chromatin modifying enzymes, such as 
histone methyltransferases. 
Despite being the most studied and known epigenetic drugs, the antitumor 
activity of DNMTs and Zn(II)-dependent HDACs inhibitors is not fully understood. 
Two models, not mutually excluding, are suggested to explain their anticancer 
properties. One of the models considers that the reactivation of tumor-suppressor 
genes silenced in the cancer cells triggers mechanisms of apoptosis and cell cycle 
control. The other model proposes that inhibition of DNMTs or HDACs avoids proper 
chromatin condensation during G2 and M phases of the cell cycle, causing aberrant 
chromosomal segregation and/or mitosis that lead to cell cycle arrest and apoptosis 
(Knox et al. 2000; Rhee et al. 2002, reviewed in Haaf 1995, Johnstone and Licht 
2003). 
Another feature that remains unclear is the selective toxicity of these drugs 
towards cancer cells. Since the chemicals are inhibitors of enzymes present in all kind 
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 of cells, it could be expected that normal cells would suffer their effects. Indeed, one 
of the major disadvantages of these treatments is the possibility that these drugs 
have mutagenic effects in the long term. The deregulation of chromatin structure 
induced by these compounds in normal cells can increase retrotransposons 
expression and the rate of genomic DNA recombination (reviewed in Ehrlich 2003). 
The properties of the known epigenetic drugs as well as their effects in 
normal and cancer cells will be discussed in the next pages. 
3.3.1. Substances altering DNA methylation 
As pointed out, the most studied epigenetic alterations in cancer cells are 
the changes in DNA methylation patterns. Tumor cells suffer global DNA 
hypomethylation at the same time that some CpG island-conatining gene promoters 
become aberrantly hypermethylated. The use of chemicals able of reducing the 
presence of 5-methylcytosine in DNA has been explored in order to reactivate the 
expression of tumor-suppressor genes silenced through hypermethylation in cancer 
cells. According to their mechanism, these substances can be classified in three big 
groups: drugs that reduce DNMTs expression, drugs that inhibit the DNMT enzymes 
and drugs that alter DNA methylation interfering with other cell functions (such as 
signalling cascades) or by non identified mechanisms. 
3.3.1.1. Inhibitors of DNMTs expression 
Reduction of DNMT1 expression by triggering the RNAi response is one the 
way of decreasing the 5-methylcytosine content in genomic DNA of cancer cells. In 
fact, MG98 and other antisense oligonucleotides directed against DNMT1 diminish the 
proportion of 5-methylcytosine in DNA by decreasing both DNMT1 mRNA levels and 
DNMT activity in murine models (Ramchandani et al. 1997). MG98 is a DNMT1 
antisense oligonucleotide with a non-natural backbone that increases its in vivo 
stability: the phosphate groups are replaced by phosphorothioate groups and some 
hydroxyl groups in certain ribose moieties are methylated (reviewed in Szyf 2002). 
Acording to a pharmacokinetic study performed on tumor-bearing nude mice, 
saturation of plasma proteins with phosphorothioate oligonucleotides allows their 
53
 distribution in most tissues, preferentially accumulating in kidney and liver. At high 
doses, also an appreciable concentration of the synthetic oligonucleotide is found in 
the tumors (Qian et al. 1997). The use of MG98 as chemotherapy for solid tumors is 
currently evaluated in a phase II clinical trials (Stewart et al. 2003, Davis et al. 
2003). 
3.3.1.2. Inhibitors of DNMT enzymatic activity 
DNMT1, DNMT3a and DNMT3b catalytic domain have two binding sites, one 
for the cytosine residue and another one for SAM. Chemicals that tightly bind any of 
these pockets inhibit DNMTs activity and the result is a decrease of the genomic DNA 
methylation levels. Three classes of substances are included in this group: DNA 
analogues, cytidine (compound 1 in Fig.9) and 2’-deoxycitidine (compound 2 in 
Fig.9) analogues and SAM-related compounds. 
 
3.3.1.2.1. DNA analogues 
Oligonucleotides containing a phosphorothioate backbone and CpG 
sequences have been tested for specific DNMT1 inhibition. In vitro, several 
oligonucleotides fully methylated at the CpG dinucleotides have shown strong 
inhibitory activity (nanomolar concentrations) by specifically binding DNMT1. 
However, in cultured cells, these substances alter methylation patterns but do not 
cause significant genome wide demethylation. The lack of general demethylation 
could be due to the induced cell growth arrest, which prevents passive demethylation 
(Bigey et al. 1999). The antiproliferative activity of this kind of substances has been 
proved to be reversible (Knox et al. 2000). 
 
3.3.1.2.2 Cytidine and 2’-deoxycytidine analogues 
The effects of cytidine and 2’-deoxycytidine analogues on genomic DNA 
methylation have been very extensively studied. All these compounds only inhibit 
DNMTs when incorporated into dsDNA (Taylor and Jones 1982). Inside the cell, 2’-
deoxycytidine analogues are transformed into the corresponding 2’-deoxynucleotides 
triphosphate before being incorporated into DNA during replication. Cytidine 
analogues are converted first into nucleotides diphosphate (NDP), which can undergo 
54
 two different pathways. On the one hand, part of this NDP pool is reduced to the 
corresponding 2’-deoxynucleotides diphosphate. After phosphorylation, the resulting 
2’-deoxynucleotides triphosphate are incorporated into DNA during S phase. On the 
other hand, the rest of the NDP pool is phosphorylated to nucleotides triphosphate 
and become incorporated into RNA, interfering then with RNA metabolism and 
protein synthesis. Because of that, cytidine analogues have much less specific effects 
on cells than 2’-deoxycytidine analogues. Cells lacking any of the enzymes involved 
in these metabolic reactions are resistant to these drugs. Also cytidine and 2’-
deoxycytidine analogues that do not bind any of these enzymes cannot be 
incorporated into DNA, and so do not affect DNMT activity (reviewed in Haaf 1995). 
Once the chemical is incorporated into DNA, the way DNMTs are trapped 
depends on the characteristics of the cytosine mimic ring. The position 6 of 
analogues that conserve the cytosine 5,6 insaturation (5-azacytidine, 5-aza-2’-
deoxycytidine, 5-fluoro2’-deoxycytidine, 1-β-D-arabinofuranosyl-5-azacytosine and 
pyrimidin-2-one ribofuranoside; compounds 3, 4, 5, 6 and 9 in Fig.9) is attacked by 
the cystein residue in DNMT motif IV (see 3.1.2.1). As result, DNMTs become 
covalently bound to DNA. On the other hand, the analogues that do not have the 5,6 
insaturation (pseudoisocytidine and 5,6-dihydro-5-azacytidine, compounds 7 and 8 in 
Fig.9) cannot be attacked by the cystein residue in DNMT catalytic pocket. In this 
case, the enzyme is not covalently trapped but forms a very stable complex with the 
analog (reviewed in Christman 2002). 
The covalent attachment of DNMTs to DNA not only depletes the nuclear 
DNMT pool, but also triggers DNA repair mechanisms. The repair takes place while 
the DNMTs concentration is low, making DNA methylation not efficient and resulting 
in a decrease of genomic 5-methylcytosine content. Additionally, restoration of DNA 
integrity is error-prone and mutations are more likely to happen than during normal 
replication. This increase in the mutation risk constitutes one of the major drawbacks 
of these drugs. 
The compounds containing 5-azacytosine residues (5-azacytydine, 5-aza-2’-
deoxycytidine, 1-β-D-arabinofuranosyl-5-azacytosine) are particularly mutagenic. The 
5-azacytosine rings can be opened by hydrolysis, which is favoured by the covalent 
attachment of DNMTs to the position 6. The remnant of the base cannot base pair 
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 Fig.9: Chemical structure of cytidine (1), 2’-deoxycytidine (2) and some substances whose 
possible demethylating effects have been studied (see text): 5-azacytidine (3), 5-aza-2’-
deoxycytidine (4), 5-fluoro-2’-deoxycytidine (5), 1-β-D-arabinofuranosyl-5-azacytosine (6, 
fazarabine), pseudoisocytidine (7), 5,6-dihydro-5-azacytidine (8), pyrimidin-2-one 
ribofuranoside (9, zebularine), 1-β-D-arabinofuranosylcytosine (10, cytarabine), 6-azacytidine 
(11), (-)-epigallocatechin-3-gallate (12), 1-hydrazinophthalazine (13, hydralazine), 4-
aminobenzoic acid 2-diethylaminoethylamide (14, procainamide), 4-aminobenzoic acid 2-
diethylaminoethyl ester (15, procaine). 
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 as cytosine and thus, if it is not repaired, induces mutations during replication 
(Jackson-Grusby et al. 1997). 
5-azacytidine (compound 3 in Fig.9) was the first cytidine analogue tested 
as possible inhibitor of DNA methylation. As already mentioned, when incorporated 
into DNA, this chemical traps DNMTs by covalent bond formation. Due to its major 
incorporation into RNA, 5-azacytidine is seldom employed in studies related to DNA 
methylation. However, it has been proposed that irreversible cell cycle arresting 
caused by this compound when used at micromolar concentrations is mostly due to 
its effects on DNMTs (Poot et al. 1990). Other inconveniences for the use of this 
chemical are its mutagenicity and its fast inactivation due to spontaneous hydrolysis 
and degradation by cytidine deaminase (Jackson-Grusby et al. 1997, reviewed in 
Haaf 1995). In any case, 5-azacytidine treatment is at the moment a potential 
chemotherapy for myelodysplastic syndrome (Silverman et al. 2002, Kornblith et al. 
2002). 
5-aza-2’-deoxycytidine (zdC, also known as Decitabine, compound 4 in 
Fig.9) is one of the most used demethylating drugs for assays in cultured cells. In 
contrast to 5-azacytidine, zdC is a 2’-deoxynucleoside and it cannot be incorporated 
into RNA. Because of that, zdC effects on cells are mostly due to the specific 
inhibition of DNMTs. It is well known that zdC reduces DNA methylation levels, stops 
cell proliferation and reactivates the expression of genes whose promoters are 
hypermethylated in cancer cells. However, as 5-azacytidine, zdC is mutagenic, suffers 
hydrolysis in aqueous solutions and is degraded by cytidine deaminase (Jackson-
Grusby et al. 1997, Jüttermann et al. 1994, reviewed in Haaf 1995). Despite all these 
problems, the anticancer effects of zdC are under study. Several clinical trials are 
underway to establish the use of this compound, alone or in combination with others, 
as chemotherapy for diverse types of cancer, including advanced solid tumors and 
different leukaemia and lymphoma (for instance, see Issa et al. 2004; Aparicio et al. 
2003). 
5-fluoro-2’-deoxycytidine (compound 5 in Fig.9) works in a similar manner 
as 5-aza-2’-deoxycytidine, but the stabilisation of the complexes between the DNMTs 
and DNA containing 5-fluoro-2’-deoxycytidine requires the transfer of the methyl 
group from SAM to the 5 position of the 5-fluorocytosine ring. The methylation 
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 reaction is stopped at this stage because the fluor atom in the 5 position cannot be 
abstracted. As result, DNA and enzyme are covalently linked and cannot separate. In 
the cells, 5-fluoro-2’-deoxycytidine is rapidly deaminated to 5-fluoro-2’-deoxyuridine, 
which is toxic. To avoid this phenomenon, simultaneous administration of high doses 
of 2’-deoxythymidine is necessary (Sheikhnejad et al. 1999, Jones et al. 1982, Jones 
and Taylor 1980). 
1-β-D-arabinofuranosyl-5-azacytosine, also named fazarabine or Ara-AC 
(compound 6 in Fig.9), differs from 5-azacytidine in the stereochemistry of the 2’ 
hydroxyl group. Because of this, fazarabine has a double effect: it causes DNA 
demethylation but also interfers the DNA synthesis, like cytarabine (1-β-D-
arabinofuranosylcytosine or AraC). In opposition to 5-azacytidine and 5-aza-2’-
deoxycytidine, fazarabine deamination is not catalyzed by cytosine deaminase (Barchi 
et al. 1996, Kees and Avramis 1995). This compound has been tested in several 
clinical trials, the last one reported in 1999 (Wilhelm et al. 1999). 
Pseudoisocytidine (compound 7 in Fig.9) causes a decrease on genomic 
DNA methylation levels, but only a few studies analysing this effect have been 
published (Jones et al. 1982, Jones and Taylor 1980). As 5-azacytidine, is 
incorporated into both DNA and RNA (Zedek 1979). 
5,6-dihydro-5-azacytidine (DHAC, compound 8 in Fig.9) incorporated into 
DNA forms very stable complexes with the DNMTs because the 5,6-dihydro-5-aza-
cytosine ring mimics the transition state of the cysteine nucleophilic attack to the 
position 6 in the cytosine ring (see Fig.4A). The subsequent depletion of DNMTs 
leads to DNA demethylation (Sheikhnejad et al. 1999, Jones et al. 1982, Jones and 
Taylor 1980). DHAC restores the activiy of hypermethylated genes in several cell 
lines, though the methylation status after treatment has not been studied (Izbicka et 
al. 1999a, Izbicka et al. 1999b). In cells, DHAC is preferentially incorporated into RNA 
because the formation of the corresponding nucleoside triphosphate is favoured 
respect to the 2’-deoxynucleoside triphosphate (Avramis et al. 1989, Kees and 
Avramis 1995). DHAC has undergone several clinical trials as cancer chemotherapy 
either alone or in combination with other drugs (for instance, Vogelzang et al. 1997, 
Samuels et al. 1998). 
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 Pyrimidin-2-one ribofuranoside (zebularine compound 9 in Fig.9) is a well 
known inhibitor of cytidine deaminase (Carlow and Wolfenden 1998). Its antitumor 
activity was already described in 1991 but its effects on DNA methylation were found 
later. Zebularine reduces global DNA methylation in the cells by trapping covalently 
the DNMTs with a similar mechanism to that one of 5-azacytidine or zdC but it is not 
as powerful as these drugs in inducing DNA hypomethylation. However, zebularine 
has some advantages: it is more stable in aqueous solution and less toxic than 5-
azacytidine or zdC (reviewed in Yoo et al. 2004). (Driscoll et al. 1991, Zhou et al. 
2002 Cheng et al. 2003). Like the other nucleosides, RNA incorporates more 
zebularine than DNA (Ben-Kasus et al. 2005).  
The activity in vivo of 5-azacytidine, zdC and other cytidine analogues is 
reduced partially because these chemicals are degraded by cytidine deaminase. The 
administration of zebularine as inhibitor of cytidine deaminase is also explored as a 
way of increasing zdC efficience (Laliberté et al. 1992, Lemaire et al. 2005). 
The effects of 1-β-D-arabinofuranosylcytosine (cytarabine, compound 10 in 
Fig.9) and 6-azacyditine (compound 11 in Fig.9) on DNA methylation have also been 
analysed, but none of these compounds causes DNA hypomethylation in cells (Jones 
and Taylor 1980, Stopper et al. 1995). 
 
3.3.1.2.3 S-adenosylmethionine analogues 
Different substances that can compete with SAM for DNMT binding, like 
sinefungin, have been analysed in vitro and in cultured cells (for instance Zingg et al. 
1996, Boehm and Drahovsky 1983). However, SAM is the universal donor of methyl 
groups in the cell, hence its analogues have pleiotropic effects due to the 
interference with more metabolic pathways than DNA methylation. 
3.3.1.3. Other substances altering DNA methylation 
Many other substances alter DNA methylation either globally or at specific 
promoters but they have not been deeply characterized. In some cases, even the 
mechanism by which these chemicals exert their effect is not known. 
Treatment of cultured cell with inorganic salts of arsenic, cadmium or 
selenium induces DNA hypomethylation. Several mechanisms have been suggested 
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 to explain this phenomenom, from poisoning DNMTs to interference with SAM 
metabolism. In any case, the effects of these compounds are pleiotropic. Whereas 
selenium may have adenoma preventive properties, cadmium and arsenic are 
considered carcinogens (Jacobs et al. 2004, Takiguchi et al. 2003, Rossman 2003, 
reviewed in Davis and Uthus 2004). Nevertheless, arsenic salts are on clinical trials 
as a potential chemotherapy for leukaemia and other diseases (reviewed in Evens et 
al. 2004). 
Hydralazine (1-hydrazinophthalazine, compound 13 in Fig.9) is an 
antihypertensive drug which induces a lupus-like disease in patients treated with it. 
The research about this side effect led to the discovery of the alterations that this 
substance induces in DNA methylation. Hydralazine provokes global DNA 
hypomethylation, apparently through two mechanisms: by inhibiting directly the 
enzymatic activity and by inhibiting the expression of DNMT1 and DNMT3a (Ángeles 
et al. 2005, Deng et al. 2003). Hydralazine also decreases the presence of 5-
methylcytosine at the promoter of genes that are silenced by hypermethylation in 
cultured cancer cells, reactivating their transcription (Segura-Pacheco et al. 2003). In 
patients, low doses of hydralazine recover the expression of hypermethylated tumor-
suppressor genes without major alterations in global DNA methylation (Zambrano et 
al. 2005). 
Procainamide (4-aminobenzoic acid 2-diethylaminoethylamide, compound 
14 in Fig.9) is employed to treat heart arrhythmia in humans. Like hydralazine, 
procainamide induces a lupus-like disease in the patients treated with it. 
Procainamide also reduces the global content of 5-methylcytosine in DNA and at the 
hypermethylated promoters, restoring the expression of tumor-suppressor genes in 
cancer cells and in patients (Segura-Pacheco et al. 2003). However, the mechanism 
of demethylation is not known. In vitro, procainamide intercalates on naked DNA, 
inducing changes in its structure (B to Z transitions). This binding may also take 
place in vivo, interfering with protein-DNA interactions, including DNMT binding to its 
target (Thomas and Messner 1986, Zacharias and Koopman 1990). Other data 
suggest that procainamide may compete with DNA for the binding of DNMTs 
(Scheinbart et al. 1991, Cornacchia et al. 1988, Deng et al. 2003). 
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 Different natural compounds, like (-)-epigallocatechin-3-gallate (compound 
12 in Fig.9) or genistein, induce changes in the DNA methylation patterns of cultured 
cells. The mechanism is not clear and, in addition, these compounds also interfere 
with other metabolic and signalling pathways (reviewed in Davis and Uthus 2004). 
3.3.2. Inhibitors of Zn(II)-dependent HDACs  
In the last ten years, a myriad of substances able of inhibiting Zn(II)-
dependent HDACs have been described. Several of these compounds have been or 
are currently on clinical trials as possible cancer chemotherapy agents. As mentioned 
above, the acetylation pattern of histones is maintained by the coordinated action of 
two types of enzymes: HATs and HDACs. The inhibition of one of this group of 
enzymes disrupts the equilibrium and results in either histone hypoacetylation, if 
HATs are inhibited, or hyperacetylation, when HDACs are inhibited. The finding that 
some compounds that induce cancer cells differentiation are inhibitors of Zn(II)-
dependent HDACs prompted the search for more substances with similar antitumor 
properties but better in vivo availability and less toxicity (Richon et al. 1998). All 
these chemicals are supposed to bind the Zn(II) cation present in the bottom of the 
catalytic pocket of these HDACs. The high number (at least 11) of class I and class II 
human HDACs together with the homology of their catalytic domains makes difficult 
the design of selective inhibitors for a certain enzyme of this group. Nevertheless, 
each given inhibitor has different affinities for the different HDACs. In some cases, 
these differences are minimal but in others not. For instance, the benzamide MS-275 
cannot inhibit HDAC8 (see 3.3.2.3). Additionally, some of the Zn(II)-dependent 
HDACs have substrates other than histones, so inhibition of these enzymes affects 
the acetylation of other proteins, like α-tubulin. There is still little knowledge about 
the different specificities of the HDACs and their inhibitors because their discovery is 
very recent: the first description of a human HDAC was published in 1996 and the 
last ones, in 2002 (Furukawa et al. 1996, Kao et al. 2002, Gao et al. 2002, Petrie et 
al. 2003). 
Even though inhibition of Zn(II)-dependent HDAC activity provokes massive 
histone hyperacetylation, it only affects the transcription of 1-10% of the genes in 
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 human and murine cells. Moreover, the proportion of overexpressed genes is 
comparable to that one of repressed genes (Peart et al. 2005, Kultima et al. 2004, 
Chiba et al. 2004, Gray et al. 2004, Glaser et al. 2003). The mechanism by which 
HDACs inhibitors cause gene activation or repression is not well understood. It seems 
that histone hyperacetylation is not sufficient to increase the expression of many 
genes. Also indirect effects, like changes in the expression of transcription factors, 
can contribute to the expression patterns induced by HDACs inhibitors (reviewed in 
Marks et al. 2003). 
Despite all these drugs induce histone hyperacetylation, most of the effects 
on cell cycle and gene expression depend on the drug concentration and the model 
system employed to test them (Grant 2004). For instance, butanoic acid and 
trichostatin A inhibit G1 to S transition in HeLa cells (Finzer et al. 2001) but in A549 
these chemicals causes predominantly G2 and M arrest, respectively (Blagosklonny et 
al. 2001). Also, the subset of genes whose expression changes upon HDAC inhibition 
depends on the conditions of the experiment. The reason underlying this behaviour 
is not known, but it makes impossible the comparison of studies performed 
independently of each other. 
A common feature of these treatments is the induced overexpression of 
cyclin-dependent kinase inhibitor 1A (CDKN1A), a gene involved in cell cycle control 
and which is repressed in many tumors (Marks et al. 2003). In some systems, HDAC 
inhibition also reactivates the transcription of the growth arrest and DNA-damage-
inducible beta gene (GADD45β). The phase(s) in which the cell cycle is halted due to 
the treatment with HDACs inhibitors may be determined by the transcription levels of 
both CDKN1A, whose overexpression is responsible for the arrest in G1, and 
GADD45β, whose overexpression mediates G2/M arrest (Hirose et al. 2003). 
Three parts can be recognized in the structure of most of the known HDACs 
inhibitors: the Zn(II) binding moiety, which chelates the cation at the bottom of the 
HDAC catalytic pocket; a bulky region that acts as a cap, binding the outer part of 
the catalytic tube; and a hydrophobic linker between the Zn(II) binding group and 
the cap. The linker can be either aliphatic or aromatic. The inhibitors of class I and 
class II HDACs can be clasified according to the functional group that interacts with 
the Zn(II) cation. The biggest set is constituted by the hydroxamic acids, but also 
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 carboxylic acids, benzamides, epoxides and compounds with other functionalities 
have been described. 
3.3.2.1. Hydroxamic acids 
Hydroxamic acids cause the reversible inhibition of the Zn(II)-dependent 
HDACs. The use of combinatorial chemistry allowed the synthesis of thousands 
hydroxamic acids and the screening of these libraries resulted in the identification of 
very potent and specific inhibitors. Indeed, in cultured cells, micromolar or 
submicromolar concentrations of these substances induce global histone acetylation 
and cell cycle arrest or apoptosis (reviewed in Monneret 2005). 
Trichostatin A (TSA, compound 16 in Fig.10) is a chemical produced by 
Streptomyces platensis. It is the first hydroxamic acid whose HDACs inhibitory 
properties were discovered (Yoshida et al. 1990) and it is widely used in cultured 
cells. Additionally, it has shown promising effects in some murine tumor models 
(Marks et al. 2003) whereas in others is completely inactive (Qiu et al. 1999). No 
trials in humans have been reported. 
Suberoylanilide hydroxamic acid (SAHA, compound 17 in Fig.10) was first 
identified as a substance that induces cell differentiation. It is currently tested on 
clinical trials for different sort of cancers: phase III studies for T- and B-cell 
lymphoma and phase I for a variety of solid tumors (Kelly et al. 2003). 
Pyroxamide (suberoyl-3-aminopyridineamide hydroxamic acid, compound 
18 in Fig.10) was found in a screening of chemicals whose design was inspired on 
SAHA. It has undergone clinical trials as treatment for leukemia, lymphoma, multiple 
myeloma and eye cancer, but the results have not been yet reported (Butler et al. 
2001). 
Oxamflatin (compound 19 in Fig.10) was found to inhibit cancer cells 
growth in 1996, but it was identified as a HDAC inhibitor in 1999. It has antitumor 
properties in mice, but has not been tested in humans (Sonoda et al. 1996, Kim et al. 
1999, reviewed in Monneret 2005). 
Cyclic-hydroxamic acid containing peptides (CHAPs) are synthetic cyclic 
peptides made of 4 amino acids, whose structure is based on that one of trapoxin 
(see 3.3.2.4). The side-chain of one amino acid ends in a hydroxamic group, in such 
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 a way that the hydroxamic group chelates the Zn(II) cation in the HDAC, the amino-
acid side chain is the linker and the rest of the peptide constitutes the cap (see 
CHAP30, compound 32 in Fig.11) . The peptidic nature of these substances permits 
the synthesis of large number of analogues by using combinatorial chemistry. The 
part of the peptide that binds the outer area in the catalytic pocket of the enzymes is 
thought to be responsible for the selectivity in the binding to the different HDACs. 
Then, it could be possible to find specific inhibitors for each HDAC by changing the 
amino acids in the CHAPs. These substances have anticancer properties in murine 
xenografs, but no studies in humans have been reported (Furumai et al. 2001). 
PXD101 (compound 20 in Fig.10) and NVP-LAQ824 (compound 21 in 
Fig.10) are hydroxamic acids developed by Topotarget Prolifix and Novartis, 
respectively, in the last few years (Remiszewski et al. 2003, Plumb et al. 2003). At 
the moment, both are under phase I clinical trials (Monneret 2005). 
Tubacin (compound 22 in Fig.10) is a specific inhibitor for HDAC6, found in 
a screening of several thousand chemicals. Cell treatment with this substance results 
in accumulation of acetylated α-tubulin and inhibition of cell motility without altering 
the cell cycle progression (Haggarty et al. 2003). No data on animal models or 
clinical trials are reported. 
Probably in the next few years several other hydroxamic acids with HDAC 
inhibitory activity will enter on clinical trials as cancer chemotherapy because many 
research groups are still working on the design, synthesis and study of the effects of 
these compounds. 
3.3.2.2. Carboxylic acids 
The compounds in this group are short-chain carboxylic acids: butanoic 
acid, phenylbutanoic acid and valproic acid (2-propylpentanoic acid). These 
substances are reversible HDACs inhibitors, but much less potent than hydroxamic 
acids. First, the carboxylic group, which is supposed to chelate the metal cation in 
the catalytic pocket of the HDACs, has less affinity for Zn(II) than the hydroxamic 
acid has. Second, the molecules are smaller than the hydroxamic acid with inhibitory 
capacity, so the surface for the interaction with the enzyme is smaller. As result, the  
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 Fig.10: Structure of some Zn(II)-dependent HDACs inhibitors. Trichostatin A (16), 
suberoylanilide hydroxamic acid (SAHA, 17), suberoyl-3-aminopyridineamide hydroxamic acid 
(pyroxamide, 18), oxamflatin (19), PXD101 (20), NVP-LAQ824 (21) and tubacin (22) are 
hydroxamic acids. Butanoic acid (23), its prodrug froms tributanoylglycerol (24) and 
pivaloyloymethyl butanoate (25) are carboxylic acids, as well as 2-propylpentanoic acid 
(valproic acid, 26). N-acetyldinaline (also named CI-994, compound 27) and MS-275 (28) are 
benzamides. 
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 interactions enzyme-inhibitor are not so strong and, to inhibit the HDACs in vitro, the 
required concentrations of these chemicals are about 3 orders of magnitude higher 
than the required concentrations of hydroxamic acids described in 3.3.2.1. 
These compounds have pleiotropic effects because of their interaction in the 
cell with macromolecules other than HDACs. For instance, valproic acid is an ion 
channel blocker used to treat epilepsy and butanoic acid stimulates Ca(II) release 
(Göttlicher et al. 2001, Hamodeh et al. 2004). Despite being much less specific and 
less potent HDACs inhibitors than hydroxamic acids, butanoic, phenylbutanoic and 
valproic acids are currently at different stages of clinical trials for their use as 
anticancer agents, either alone or in combination with other substances (reviewed in 
Monneret 2005). 
Butanoic acid (compound 23 in Fig.10) is known to induce histone 
hyperacetylation by inhibiting the HDACs since 1978 (Vidali et al. 1978; Candido et 
al. 1978). This aliphatic acid has a very low solubility in water at neutral pH, is 
rapidly degraded in vivo and it has to be administered in multigram doses for 
efficiency. To overcome these disadvantages, different prodrugs with better 
bioavailability, like tributyrin (tributanoylglycerol, compound 24 in Fig.10) and 
Pivanex® (AN-9, pivaloyloxymethyl butanoate, compound 25 in Fig.10), have been 
developed. All of them are undergoing clinical trials as cancer chemotherapy 
(reviewed in Monneret 2005). 
Valproic acid (compound 26 in Fig.10) is an anticonvulsant drug with 
undesirable consequences, like teratogenicity. The research on these side effects 
provoked the discovery of the HDAC inhibitory capacity of the chemical (Göttlicher et 
al. 2001, Phiel et al. 2001). Additionally, in some cell lines (murine teratocarcinoma 
F9, human erythroleukemia K562, human embrionary kidney HEK293T and others), 
valproic acid increases the rate of HDAC2 protein degradation trough the ubiquitin 
proteasome pathway. This fact contributes to increase histone acetylation (Krämer et 
al. 2003) and suggests that valproic acid can be a good treatment for the cancers in 
which HDAC2 is overexpressed (Zhu et al. 2004). This compound is currently on 
clinical trials against some malignancies (reviewed in Monneret 2005). 
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 3.3.2.3. Benzamides 
This family of compounds complexes Zn(II) in the catalytic pocket of the 
HDACs through their N-(2’-aminophenyl) benzamide moiety. This functional group is 
bulkier than the hydroxamic or the carboxylic acids, and, as result, benzamides do 
not inhibit HDACs whose catalytic pocket is narrow, for instance, HDAC8 (Vannini et 
al. 2004). Nevertheless, these chemicals inhibit in a reversible way some Zn(II)-
dependent HDACs and induce histone hyperacetylation in cultured cells (Kraker et al. 
2003, Saito et al. 1999).  
N-acetyldinaline (also known as CI-994, compound 27 in Fig.10) was 
identified already in 1993 as a substance with cytostatic and antileukemic effects on 
rat models, but its HDAC inhibitory properties were not identified until 2003 (el-
Beltagi et al. 1993, Kraker et al. 2003). 
MS-275 (also known as MS-27-275, compound 28 in Fig.10), found in a 
secreening for compounds with HDAC inhibitory properties, also induces 
accumulation of hyperacetylated histones in vivo (Saito et al. 1999).  
Both N-acetyldinaline and MS-275 are on clinical trials as treatments for 
different tumors, either alone or in combination with other drugs. Due to their poor 
solubility in water, both substances require oral administration (reviewed in Monneret 
2005). 
Other compounds with similar structure to MS-275 and N-acetyldinaline 
have been synthesized. Some of them have succeeded in inhibiting HDACs in vitro, in 
cultured cells and in murine models, also stopping the growth of cancer cells, but no 
data about clinical trials have been reported (Fournel et al. 2002). 
3.3.2.4. Epoxides 
In contrast to the HDACs inhibitors mentioned before, epoxides inhibit HDACs in an 
irreversible way, probably because the epoxide functionality reacts with an amino-
acid residue of the enzyme yielding a covalent bond which links the inhibitor to the 
HDAC. Epoxides are very powerful inhibitors in vitro, but they lack any activity in cells 
and in vivo, very likely due to the lability of the epoxide group. Therefore, none of 
them has undergone clinical trials (reviewed in Monneret 2005). 
Trapoxin A (cyclo-(L-phenylalanyl-L-phenylalanyl-D-pipecolinyl-L-2-amino-8- 
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 Fig.11: Structure of some Zn(II)-dependent HDACs inhibitors. Trapoxin A (29), trapoxin B (30) 
and chlamydocin (31) are natural cyclic peptides containing an epoxide functionality. The 
design of the cyclic-hydroxamic acid containing peptide CHAP30 (32) is based on the structure 
of trapoxins. Depudecin (33) is a natural compound with two epoxide rings. Apicidin (34) is a 
cyclic peptide containing an ethylketone. Depsipeptide FK228 (35) is another natural product. 
 
oxo-9,10-epoxy-decanoyl), compound 29 in Fig. 11), trapoxin B (compound 30 in 
Fig. 11), HC-toxin and chlamidocyn (compound 31 in Fig. 11) are natural products 
with a cyclic peptide structure. The HDAC inhibitory properties of trapoxin A in vitro 
and in cultured cells were already described in 1993 (Kijima et al. 1993). The 
structure of these compounds has been taken as model for the design of novel 
HDACs inhibitors, the CHAPs (see 3.3.2.1). 
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 Depudecin (compound 33 in Fig.11) is a substance produced by the fungus 
Alternaria brassicicola. Its effects on the phenotype of transformed cells were already 
described in 1992, but its HDACs inhibitory capacity was not discovered until 1998 
(Sugita et al. 1992, Kwon et al. 1998).  
3.3.2.5. Other inhibitors of Zn(II)-dependent histone deacetylases 
Other compounds that bind Zn(II) through functional groups different than 
hydroxamic acid, carboxylic acid and epoxide also inhibit HDACs. For instance, 
apicidin (compound 34 in Fig.11), apicidin A, apicidin C and apicidin D1 are cyclic 
peptides that chelate Zn(II) through an ethylketone functionality. All the four 
substances inhibit HDACs in vitro and in cultured cells (Singh et al. 2002).  
Depsipeptide FK228 (also known as FR901228, compound 35 in Fig.11) is a 
cyclic antibiotic produced by Chromobacterium violaceum, found in a screening for 
antitumor compounds (Ueda et al. 1994). This chemical is a potent HDAC inhibitor 
(Nakajima et al. 1998). Once in the cell, the disulfide bridge in the molecule is 
reduced and one of the resulting thiol groups is able to interact with the cation Zn(II) 
in the HDAC active site (Furumai et al. 2002). The anticancer properties of this 
depsipeptide are currently evaluated on several phase I and II clinical trials. 
3.3.3 Inhibitors of NAD+-dependent histone deacetylases  
The screening for inhibitors of NAD+-dependent HDACs led to the discovery 
of splitomicin (1,2-dihydro-3H-naphtho[2,1-b]pyran-3-one, compound 36 in Fig.12). 
Based on the structure of that compound, other inhibitors of sirtuins have been 
designed but the effects of these substances have been analysed only in vitro and in 
yeast, not in higher eukaryotic cells (Bedalov et al. 2001, Posakony et al. 2004). 
3.3.4. Histone acetyltransferase inhibitors 
It is known that CBP and p300 act as transcriptional activators of some 
oncogenes (reviewed in Lund and van Louhizen 2004). Additionally, in some types of 
leukemia, chimera proteins produced by translocations cause an abnormal  
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 Fig.12: Other substances that alter the activity of epigenetics-related enzymes: splitomicin 
(36) is an inhibitor of sirtuins; anacardic acid (37), curcumin (38) and garcinol (39) inhibit 
HATs and N-(4-chloro-3-trifluoromethylphenyl)-2-ethoxy-6-pentadecyl-benzamide (40) 
activates selectively p300. 
 
recruitment of the HATs which may contribute to tumor development (Marmorstein 
2002). So the inhibition of HATs may have anticancer properties. There are a few 
chemicals with known HAT inhibitory activity and the effects of some of them have 
been analysed only in vitro.  
Complexes and salts of Cu(II) induce apoptosis in hepatoma cells (Kang et 
al. 2005). This effect is thought to be a direct consequence of the inhibition of the 
HAT activity (Kang et al. 2004). 
Anacardic acid (2-hydroxy-6-pentadecylbenzoic acid, compound 37 in 
Fig.12) is obtained by hydrogenation of a mixture of insaturated compounds 
extracted from cashew nut shell. In vitro, this substance inhibits both p300 and 
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 PCAF, but no studies in cultured cells or in vivo have been reported 
(Balasubramanyam et al. 2003). 
Curcumin ((E,E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-
dione, compound 38 in Fig.12) is a natural compound that inhibits p300 and CBP, 
but also other enzymes, like HIV-1 integrase or the thioredoxin reductase 
(Balasubramanyam et al. 2004, Fang et al. 2005). In cultured cells, it stops cell 
proliferation and causes apoptosis. It is thought that curcumin has also 
chemopreventive properties (reviewed in Dorai and Aggarwal 2004). Indeed, it is 
undergoing clinical trials for colon cancer prevention and advanced pancreas tumors 
treatment. However, if the benefitial effects of this chemical are due to HAT 
inhibition or to other mechanisms is not known. 
Garcinol (compound 39 in Fig.12) is a chemical found in the fruit of Garcinia 
Indica. It inhibits in vitro p300 and CBP acetylation of histones in a competitive way, 
and, in cultured cells, it also represses histone acetylation, causing apoptosis 
(Balasubramanyam et al. 2004b). Garcinol has cancer chemopreventive effects in 
murine cancer models (Yoshida et al. 2005). 
Finally, mimics of acetyl CoA have been designed to selectively inhibit HATs. 
The first of these compounds, named Lys-CoA, is not absorbed by the cells, so it has 
no activity in vivo. The second generation has been tested only in vitro (Cebrat et al. 
2003). 
3.3.5. Histone acetyltransferase activators 
Activation of HATs may lead also to increased histone acetylation and 
hypothetically, it can rescue the transcription of tumor-suppressor genes silenced by 
histone hypoacetylation. 
The compound N-(4-chloro-3-trifluoromethylphenyl)-2-ethoxy-6-pentadecyl-
benzamide (CTBP, compound 40 in Fig.12), a derivative of anacardic acid, enhances 
p300 but no PCAF activity in vitro. No results of experiments in cultured cells or mice 
have been reported (Balasubramanyam et al. 2003). 
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 3.3.6. Other substances altering epigenetic mechanisms 
The increase in the knowledge about the epigenetic mechanisms and their 
deregulation in cancer cells will surely provide in the near future new targets for the 
design of antitumor drugs. Chemicals interfering with mechanisms that silence 
tumor-suppressor genes may cause their reactivation. On the other hand, 
compounds that inhibit the transcription of oncogenes and retrotransposones may 
also inhibit cancer cell proliferation. Alternatively, the alteration of the functioning of 
epigenetic machineries can lead to cell growth arrest and/or dead by avoiding normal 
chromatin condensation and decondensation along the cell cycle. 
3.3.7. Synergy of different drugs 
Sometimes, the combination of chemicals interfering with different cellular 
functions results in the enhancement of their antitumor effect. The epigenetic drugs 
collaborate with different substances to trigger the growth arrest, differentiation 
and/or apoptosis of cancer cells.  
The synergy of DNMTs inhibitors and HDACs inhibitors has been widely 
studied. The treatment with both types of substances allows the reduction of the 
dose of both, decreases undesirable side effects and increases cancer cells death and 
growth arrest. Because of that, simultaneous treatment of a diverse number of 
malignancies with DNMTs and HDACs inhibitors is currently under evaluation on 
clinical trials (reviewed in Feinberg and Tycko 2004, Laird 2005). In some cases, 
inhibition of DNMTs activity is not enough to recover the expression of some genes 
with hypermethylated promoters. In such a situation, simultaneous treatment with 
both demethylating agents and substances that induce histone hyperacetylation 
restores the expression of the genes (Cameron et al. 1999). It is also reported that 
the combination of DNMTs inhibitors and HDACs inhibitors increases histone 
hyperacetylation respect to the treatment with only HDACs inhihibitors (Zhu et al. 
2001).  
The combination of HDACs inhibitors and topoisomerase II inhibitors is also 
currently studied on clinical trials. In cultured cells, the pre-treatment with TSA 
enhances the toxicity of etoposide, doxorubicin, cisplatin and ellipticine. It is thought 
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 that the opening of the chromatin structure upon HDAC inhibition facilitates the 
access of topoisomerase inhibitors to their targets, favoring their action (Kim et al. 
2003b). Also combinations of DNMTs inhibitors and topoisomerase-II inhibitors are 
explored, for instance DHAC and cisplatin (Samuels et al. 1998). 
Another example is the synergy of all-trans retinoic acid (ATRA) and HDACs 
inhibitors for the treatment of leukemias with translocations of the RARα gene. In 
these cases, the resulting fusion proteins abnormally recruit HDACs to certain 
promoters. Both ATRA and the HDAC inhibitor are supposed to collaborate to restore 
the transcription of those genes (Côté et al. 2002). 
73
 74
 4. Objectives 
 
The regulation of epigenetic mechanisms is a promising target for 
development of cancer chemotherapy. Large effort of researchers and 
pharmaceutical companies has been dedicated to the design of antitumor drugs 
which interfere with the aberrant epigenetic patterns. However, the chemicals tested 
to now have also undesired side effects that limit their use. Mutagenicity, induction 
of chromosomal instability in normal cells and toxicity for liver and other organs, 
among other effects reduce or abolish the therapeutic application of these 
substances. Because of that, we were interested on searching for novel compounds 
with fewer side effects. These chemicals should specifically activate the expression of 
tumor-suppressor genes silenced by aberrant epigenetic mechanisms. Our aim was 
to explore the effects of two types of drugs, compounds that reduce DNA 
methylation and HDACs inhibitors, in the same model system, the breast cancer cell 
line MCF7. 
Study of procaine as a DNA-demethylating agent 
Procaine (4-aminobenzoic acid 2-diethylaminoethyl ester, compound 15 in 
Fig.9) is a local anesthetic used in humans. The structural similarity of procaine and 
procainamide (4-aminobenzoic acid 2-diethylaminoethylamide, compound 14 in 
Fig.9) led us to hypothesize that procaine could also influence DNA methylation. To 
prove this hypothesis, procaine treatments were performed on MCF7 breast cancer 
cells. Except otherwise indicated, treatments were 3 days long to permit the cells go 
through at least one replication round after the drug uptake, and so allowing the 
passive demethylation to occur (see 3.1.2.2). The monitored parameters were: 
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 1. Procaine-induced changes on global DNA methylation, including dependence of 
the effects on drug concentration and treatment duration. 
2. Procaine-induced changes on DNA methylation at the hypermethylated promoter 
of a tumor-suppressor gene and if these changes correspond with reexpression of 
the gene. 
3. Procaine-induced alterations in cell proliferation, since anticancer drugs should 
have cytostatic and/or cytotoxic effects on tumor cells. 
Comparative study of seven Zn(II)- dependent HDACs 
inhibitors 
The hydroxamic acids CY  and CX were developed at pharmaceutical 
companies by combining molecular modelling and high-throughput screening of 
chemical libraries. When we started this project, no data about the cellular response 
to these compounds was published. Thus, the comparison of the different effects of 
these compounds with the effects of well characterized HDACs inhibitors (TSA, SAHA, 
MS-275 butanoic acid and valproic acid) was addressed by analysing: 
1. In vitro inhibition of HDAC activity. 
2. Effects in cell proliferation after 24 h treatments. 
3. HDACs inhibition in living cells, evaluated indirectly by determining the increase 
of histone hyperacetylation after 24 h-treatmets. 
4. Alterations in the cellular concentration of HDAC1 and HDAC2 enzymes after 24 
h of drug treatment, since it may contribute to changes in histone acetylation. 
5. Analysis of transcriptional regulation of different genes after 24 h HDACs 
inhibitor treatment, including the possible correlation with alterations in histone 
post-translational modifications and HDACs recruitment at their promoters. 
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 5. Materials and Methods 
5.1. Solutions 
Except otherwise indicated, all the solutions were made with Milli-Q water 
and kept at room temperature. Commercial reagents and solutions were stored 
according the manufacturer’s instructions. Whenever employed, protease inhibitors 
(Complete® Protease Inhibitor Cocktail EDTA Free, Roche) and DTT (Sigma) were 
freshly added. 
Below there is a list of the solutions and buffers home-prepared, ranked by 
alphabetical order: 
0.1 M acetic acid glacial acetic acid (Merck) diluted in water. 
1% acetic acid 1% (v/v) glacial acetic acid in water. 
10 M ammonium acetate  ammonium acetate (Sigma) dissolved in water. 
4.0 M ammonium sulfate  (NH4)2SO4 (Sigma) dissolved in water and pH 
adjusted to 7.9 with NaOH solution. 
10% APS  10% (w/v) ammonium persulfate (Bio-Rad) in 
water, stored at 4ºC. 
10 mg/mL BSA bovine serum albumine (Sigma) dissolved in 
water, aliquoted and stored at –20ºC. 
Cell fixation solution formaldehyde saturated solution in water (Sigma, 
concentration c.a. 37% (w/v)) was ten-fold 
diluted in PBS. Final concentration formaldehyde 
c.a. 4% (w/v). 
Cell permeabilization solution 0.1% (v/v) Triton® X-100 (Sigma) in PBS. 
ChIP dilution buffer 0.01% (w/v) SDS (Merck) , 1.1% (v/v) Triton® X-
100, 1.2 mM EDTA (Sigma), 16.7 mM Tris 
(Merck) pH=8.1, 167 mM NaCl (Merck), 1 tablet 
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 Complete® Protease Inhibitor Cocktail EDTA Free 
in each 50 mL. 
ChIP elution buffer  1% (w/v) SDS, 0.1 M NaHCO3 (Sigma). 
ChIP high salt immune complex wash buffer   0.1% (w/v) SDS, 1% (v/v) Triton® X-
100, 2.0 mM EDTA, 20 mM Tris pH=8.1, 0.50 M 
NaCl. 
ChIP LiCl immune complex wash buffer  1% (v/v) Igepal® CA-630 (indistinguishable 
from NonidetP-40®, Sigma), 1% (w/v) sodium 
deoxycolate (Sigma), 1.0 mM EDTA, 10 mM Tris 
pH=8.1. 
ChIP low salt immune complex wash buffer   0.1% (w/v) SDS, 1% (v/v) Triton® X-
100, 2.0 mM EDTA, 20 mM Tris pH=8.1, 0.15 M 
NaCl. 
ChIP SDS lysis buffer 1% (w/v) SDS, 10 mM EDTA, 50 mM Tris 
pH=8.1, 1 tablet Complete® Protease Inhibitor 
Cocktail EDTA Free in each 50 mL. 
1 µg/mL DAPI  DAPI (Sigma) was dissolved in methanol (Merck) 
at 1 mg/mL concentration. The resulting solution 
was 1000-fold diluted with water and stored at 
4ºC in the darkness. 
6 x DNA loading buffer 30 % (v/v) glycerol (Sigma) in water containing 
0.05% (w/v) bromophenol blue (Bio-Rad). 
DNA lysis-cell buffer 0.65 M sucrose (Sigma), 20 mM Tris pH=7.8, 10 
mM MgCl2 (Merck), 2% (v/v) Triton® X-100. 
Storage at 4ºC. 
DNA proteinase K buffer  50 mM Tris pH=8.5, 10 mM EDTA pH=8, 100 mM 
NaCl, 1% SDS. 
2 mM dNTP mixture  prepared by mixing equimolar amounts of 100 
mM dATP, 100 mM dTTP, 100 mM dGTP, 100 mM 
dCTP (Promega) and diluting the resulting 
solution 12.5-fold (final concentration, 2 mM each 
dNTP) with water. The mixture was aliquoted and 
stored at –20ºC. 
0.5 M EDTA EDTA (Sigma) dissolved in water, NaOH solution 
was added to adjust pH to 8.0. 
70% ethanol 70% (v/v) absolute ethanol (Merck) in water. 
75% ethanol 75% (v/v) absolute ethanol in DEPC-treated 
water. 
2.5 M glycine  glycine (2-aminoetanoic acid, Fluka) dissolved in 
water. 
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 10 mg/mL glycogen commercial solution 20 mg/mL glycogen (Roche) 
was diluted 1:1 with water, aliquoted and stored 
at –20ºC. 
HDAC activity buffer 25 mM Tris pH 7.5, 10% (v/v) glycerol, 1 mM 
EDTA, 50 mM NaCl. 
HDAC quenching solution 1.0 M HCl and 0.4 M acetic acid in water. 
0.25 M hydrochloric acid  37% (w/v) aqueous HCl (Merck) solution 
(saturated solution) 40-fold diluted in water. 
16 mM hydroquinone  hydroquinone (Sigma) dissolved in water. 
Prepared inmediatly before use and protected 
from light. 
IP buffer 20 mM HEPES (Sigma) pH=7.5, 100 mM KCl 
(Merck), 1.0 mM MgCl2, 0.05% Igepal® CA-630. 
80% isopropanol  80% (v/v) 2-propanol (Merck) in water. 
4 x Laemmli buffer 0.20 M Tris pH=6.8, 8% (w/v) SDS, 40% (v/v) 
glycerol, 0.4 M DTT, 0.001% (w/v) bromophenol 
blue (BioRad). 
10% NP-40 10% (v/v) Igepal® CA-630 (Sigma, 
indistinguishable from Nonidet-P40®) in water. 
Nuclear extract buffer A 10 mM Tris pH=7.5, 15 mM KCl, 2.0 mM MgCl2, 
0.1 mM EDTA, 1.0 mM DTT, 1 tablet Complete® 
Protease Inhibitor Cocktail EDTA Free in each 50 
mL buffer. 
Nuclear extract buffer B 50 mM Tris pH=7.5, 1.0 M KCl, 30 mM MgCl2, 0.1 
m EDTA, 1.0 mM DTT, 1 tablet Complete® 
Protease Inhibitor Cocktail EDTA Free in each 50 
mL buffer. 
Nuclear extract buffer C 20 mM Tris pH=7.5, 10% (v/v) glycerol, 2.5 mM 
MgCl2, 1.0 mM EGTA disodium salt (Sigma), 0.5 
mM DTT, 1 tablet Complete® Protease Inhibitor 
Cocktail EDTA Free in each 50 mL buffer. 
200 U/mL nuclease P1  lyophilised nuclease P1 (Sigma) dissolved in 
water, aliquoted and stored at –20ºC. 
0.1 mM oligonucleotides lyophilised primers (Sigma-Genosys) were 
dissolved in the adequate volume of water 
(aliquots stored at –20ºC). Whenever necessary, 
dilutions 1:10 in water were prepared. For 
sequences, see Tables 2-5. 
PBS  137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4 
(Sigma), 2.0 mM KH2PO4 (Sigma), pH=7.4. 
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 0.1% Ponceau S 0.1% (w/v) Ponceau S (Sigma) in 5% (v/v) 
aqueous acetic acid. 
2.5 M potassium chloride KCl (Merck) dissolved in water. 
1 mg/mL propidium iodide propidium iodide (Sigma) solution in water, 
aliquoted and stored at 4ºC in the darkness. 
Protein extract buffer 50 mM Tris pH=7.5, 120 mM NaCl, 0.5 mM 
EDTA, 0.5 % (v/v) Igepal® CA-630 and 1 tablet 
Complete® Protease Inhibitor Cocktail EDTA Free 
EDTA-Free in each 50 mL buffer. 
10 mg/mL proteinase K  proteinase K (Sigma) solution in water, aliquoted 
and stored at –20ºC. 
10 mg/mL RNase A RNase A (Sigma) solution in water, aliquoted and 
stored at –20ºC. 
RSB buffer  10 mM Tris pH=7.5, 10 mM NaCl, 3 mM MgCl2, 1 
tablet Complete® Protease Inhibitor Cocktail 
EDTA Free in each 50 mL buffer. 
10% SDS 10% (w/v) sodium dodecylsulfate (Merck) in 
water. 
SDS-PAGE resolving gel acrilamide/bisacrilamide from commercial solution 
40% acrilamide/bisacrilamide 37.5:1 in water 
(Bio-Rad), 0.38 M Tris pH=8.8, 0.1% (w/v) SDS, 
0.04% (v/v) TMEDA (Sigma), 0.1% (w/v) APS. 
The amount of acrilamide/bisacrilamide solution 
was adjusted to get a final concentration ranging 
from 7.5% to 15% (w/v) acrilamide in the gel, 
depending on the aim of the separation. 
SDS-PAGE running buffer 26 mM Tris, 0.19 M glycine, 0.1% (w/v) SDS in 
distilled water, pH=8.6 (approximately). 
SDS-PAGE stacking gel 5% acrilamide/bisacrilamide 37.5:1 (from the 
same commercial solution as in SDS-PAGE 
resolving gel), 0.125 M Tris pH=6.8, 0.1% (w/v) 
SDS, 0.1% (v/v) TMEDA and 0.1% (v/v) APS. 
Sodium bisulfite solution sodium metabisulfite (Na2S2O5, Sigma) was 
dissolved in water, pH was adjusted at 5.0 with 
concentrated aqueous NaOH and finally water 
was added to get a solution 4.0 M sodium 
bisulfite (NaHSO3). Solution was prepared 
inmediatly before use. 
5.0 M sodium chloride NaCl (Merk) dissolved in water. 
3 M sodium hydroxide  NaOH (Merck) dissolved in water. 
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 3.0 M sodium acetate  sodium acetate (Sigma) solution in water. 
0.5 x TBE  0.044 M Tris, 0.044 M boric acid, 1.0 mM EDTA in 
distilled water, pH=8.3 (approximately). 
TE  10 mM Tris, 1.0 mM EDTA, pH=8.0. 
Transfer buffer 0.19 M glycine, 0.025 M Tris, 15% methanol in 
distilled water. For histones, also 0.02% (w/v) 
SDS. 
1.5 M Tris pH=8.8  Tris base (Merck) dissolved in water, pH adjusted 
with hydrochloric acid. 
1.0 M Tris pH=7.5 Tris base dissolved in water, pH adjusted with 
hydrochloric acid. 
1.0 M Tris pH=6.8 Tris base dissolved in water, pH adjusted with 
hydrochloric acid. 
20 mM Tris pH=6.8 1.0 M Tris pH=6.8, 50-fold diluted in water. 
WB blocking buffer 1 5% non-fat powder milk (Nestlé) in WB wash 
buffer 1. 
WB blocking buffer 2 5% non-fat powder milk in WB wash buffer 2. 
WB wash buffer 1  0.1% (v/v) Tween® 20 (Sigma) in PBS. 
WB wash buffer 2 (NET buffer) 50 mM Tris pH=7.5, 5.0 mM EDTA, 150 mM 
NaCl, 0.25% (w/v) gelatin (Merck), 0.05% (v/v) 
Igepal® CA-630; pH adjusted to 7.4. 
10 mM zinc (II) sulfate  ZnSO4 (Sigma) solution in water. 
5.2. Cell culture reagents and basic methods 
The human breast cancer cell line MCF7 (American Type Culture Cell 
Collection) was grown in DMEM 4.5 g/L glucose (Invitrogen) supplemented with 10% 
fetal bovine serum (Invitrogen), 0.25 µg/mL amphotericine B (Invitrogen), 50 U/mL 
penicillin and 50 µg/mL streptomycin (Invitrogen) under an atmosphere saturated of 
water  and containing 5% CO2. For detachment, medium was aspirated from the 
dish, cells were washed once with PBS and then incubated with trypsin solution 
containing EDTA (Sigma) for 3 min. Then, cells were pipetted to disgregate clumps 
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 and diluted with fresh medium.Splitting was done every 3 days and each time cells 
were 6 to 9 fold diluted. 
5.3. Drug treatments 
All the dishes needed for each experiment were plated at the same density 
and in parallel. Twenty-four hours after seeding, cells were washed with PBS and 
fresh medium containing the desired final concentration of drug was added. All the 
drug stock solutions (see Table 2) were filtered through 0.2 µm pore for sterilization, 
aliquoted and kept at –20ºC. Stock solutions were ten-fold diluted with water if 
necessary. Controls were done by adding only the corresponding solvent to the cells 
(vehicle).  
When serum starving was necessary as control, a dish of cells was 
maintained in medium with no FBS supplement in parallel with the drug-treated 
dishes. 
 
Table 2: Drugs stock solutions 
Drug Supplier Solvent C/mM(1)
procaine  Sigma water       270 
procainamide Sigma water       270 
5-aza-2’-deoxycytidine Sigma water        1.0 
butanoic acid Merck PBS  1000 
valproic acid Sigma PBS  1000 
MS-275 Calbiochem DMSO        1.0 
trichostatin A Sigma ethanol/water 1:9        1.0 
SAHA Galchimia S.A. DMSO        5.0 
CX Kindly provided by xxxxxxxxxxx(2) DMSO/water 1:19        3.8 
CY Kindly provided by yyyyyyyyyyy(2) water        1.0 
(1) Concentration of the stock solution. 
(2) Compounds CX and CY were gifts from pharmaceutical companies. 
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 5.4. Cell growth assay 
For this assay, ice-cold PBS and cell fixation solution are necessary. 
After treatment, cells cultured in 6-well dishes (0.5-1.0·106 cells) were 
washed with PBS, detached with trypsin and harvested in 1.5 mL tubes by 
centrifugation (16·103 RCF for 10 s). Pellets were washed once with cold PBS, then 
resuspended in cell fixation solution and stored at 4ºC until the moment of the 
analysis. In each experiment, number of cells per millilitre was counted for two 
different aliquots per sample by using a Neubauer chamber. The result was the 
calculated average. When necessary, cell suspensions were diluted with PBS. 
5.5. Flow cytometry 
The solutions required for this analysis were: ice-cold PBS, ice-cold absolute 
ethanol, 10 mg/mL RNase and 1 mg/mL propidium iodide. 
After treatment, cells cultured in 6-well dishes (0.5-1.0·106 cells) were 
washed once with PBS, detached with trypsin, harvested in 1.5 mL tubes by 
centrifugation and washed twice with cold PBS. For fixation, pellets were 
resuspended in 0.33 mL ice-cold PBS and, under gentle shaking, 0.66 mL cold 
ethanol were added dropwise. Cells were stored at 4ºC for a time between 0.5 h and 
one week. One or two hours before the analysis, samples were washed once with 
PBS and resuspended in 0.5 mL PBS containing 5 µL RNase A solution. Immediately 
before introducing the cells in the cytometer, DNA was stained by adding 15 µL of 
propidium iodide solution to the cell suspension. All the centrifugations were done at 
16·103 RCF for 10 s. 
Distribution of cell population was analysed in a FACScalibur® Flow 
Cytometry System (Beckton Dickinson) at low cell flow. For each histogram, 10000 
events were counted. The resulting data were processed with Modfit® LT MAC 
(Beckton Dickinson) software. 
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 5.6. TUNEL assay 
Analysis of fluorescence-labelled samples was done by Dr. Jesús Espada. 
Mounting was done according to the published procedure (Espada et al. 2005). The 
following solutions and reagents were employed: PBS, cell fixation solution, cell 
permeabilization solution, TUNEL label mix (Roche), TUNEL enzyme (Roche), 1 
µg/mL DAPI, 70% ethanol, absolute ethanol, p-xylene (1,4-dimethylbenzene, Merck) 
and DePeX (Servan). 
Briefly, after treatment, cells grown on 22 mm2 microscope coverslips were 
washed 3 times with PBS. Coverslips were submerged in cell fixation solution at 37ºC 
during 30 min. After one wash with PBS, samples were placed under cell 
permeabilization solution for 15 min at room temperature and then washed 3 times 
with PBS. Coverslips were placed upside down on 20 µL of mixture 1:10 TUNEL 
enzyme/TUNEL label mix solutions and incubated for 1 h at 37ºC. Then, glasses were 
rinsed twice with PBS, incubated during 10 min at room temperature with DAPI 
solution and washed 3 times with water. Finally, cells were dehydrated with the 
following sequence: one wash with 70% ethanol, one wash with absolute ethanol 
and a last wash with p-xylene. Coverslips were carefully drained and mounted onto 
microscope slides by usin a drop of DePeX. 
Preparations were examined in a fluorescence microscope. For the detection 
of fluorescein (TUNEL), excitation at 450-500 nm and detection at 515-565 nm were 
employed and for DAPI, excitation at 340-380 nm and detection with a 430 nm low-
pass filter (max DAPI emission: 452 nm). 
5.7. Polymerase chain reaction (PCR) 
Depending on the sequence to be amplified, either FastStart® Taq (Roche) 
or EcoTaq® (Ecogen) was used as DNA-polymerase. In general, a master mix was 
prepared containing the indicated amount per sample of the following reagents: 
10 x DNA-polymerase reaction buffer (see below)                                         2.5 µL, 
CG-RICH® solution (see below)                                                                  5.0 µL, 
84
 50 mM MgCl2 (only if 10 x polymerase buffer does not contain Mg(II))          0.75 µL, 
2 mM dNTP mixture                                                                                 2.5 µL, 
0.1 mM oligonucleotide (sense and antisene)      equimolar amounts (1 to 50 pmole), 
Taq DNA-polymerase                                                                                 0.5 U, 
water                             the necessary to have in each 
reaction tube 25 µL final volume, 
including the template solution. 
 
The 10 x DNA-polymerase reaction buffers were supplied by the DNA-
polymerase’s manufacturers. The buffer corresponding to FastStart® Taq contains 
the adequate concentration of Mg(II) for the activity of the enzyme, so reactions 
with this polymerase were not supplemented with MgCl2 solution.  
The addition of 5 x CG-RICH® solution (Roche) to the reaction mixture was 
required to get the expected product when amplifying certain sequences (indicated in 
Tables 4-6). 
The master mix was dispensed in thin-walled 0.2 mL tubes and the 
adequate amount of each DNA sample (template) was added to the corresponding 
tube. A blank reaction with no template was also run in parallel, as control for 
possible contaminations. 
Except other indication, PCR reactions had a first step of denaturation (5 
min at 95ºC), 30 to 40 cycles (30 s at 95ºC, 30 s at the annealing temperature, 30 s 
at 72 ºC) and a final extension step (7 min at 72ºC). 
In Tables 3-6, PCR reaction conditions can be found for each pair of primers 
(concentration, number of cycles, annealing temperature and presence of CG-RICH® 
solution). Other details are given in the corresponding paragraphs of this section 
(methylation-specific PCR, bisulfite genome sequencing, RT-PCR, etc.). 
5.8. DNA agarose gels 
The following reagents were used: agarose LM-sieve (Pronadisa), 0.5 x TBE, 
10 g/L ethidium bromide solution in water (Sigma), 6 x DNA loading buffer. 
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 Agarose was dissolved in hot TBE, ethidium bromide was added to 0.1 
µg/mL final concentration and the solution was poured on the casting tank. Usually, 
2% gels (2.0 g agarose in each 100 mL TBE) were prepared. 
Samples were mixed with the corresponding volume of 6x DNA loading 
buffer, loaded and gels were run in 0.5x TBE at 6 V/cm. Bands were visualized under 
254 nm light. Molecular weight markers encompassing the size of the expected 
product (PCR or restriction-enzyme digestion) were used.  
5.9. DNA extraction 
The reagents used to isolate DNA from cultured cells were: DNA lysis-cell 
buffer, DNA proteinase K buffer, 10 mg/mL proteinase K, 10 mg/mL RNase A, Light 
Phase Lock Gel® (PLG) tubes (Eppendorf), phenol solution saturated with TE 
(Sigma), phenol/chloroform/isoamyl alcohol 25:24:1, saturated with TE (Sigma), 3.0 
M sodium acetate, absolute ethanol and 70% ethanol. 
Cells (2·106 to 6·106) were washed once with PBS, detached and collected 
by centrifugation (387 RCF, 5 min, 4ºC). Next, cytoplasms were lysated: cell pellets 
were resuspended in 2 mL PBS, each suspension was mixed with 2 mL DNA lysis-cell 
buffer and incubated on ice during 10 min. After centrifugation (387 RCF, 5 min, 
4ºC), the extracts rich in nuclei were washed once with PBS and resuspended in 0.5 
mL DNA proteinase K buffer. RNase A solution (10 µL) and proteinase K solution (2.0 
µL) were added and samples were incubated at 37ºC o/n. The resulting viscous 
crudes were emulsionated with 0.5 mL saturated phenol in PLG tubes, then rotated 
at room temperature for 15 min, centrifuged (16·103 RCF, 5 min, room temperature) 
and the aqueous layers were carefully transferred to clean PLG tubes. The same 
washing procedure was repeated with 0.5 mL phenol/chloroform solution. DNA was 
precipitated from the last aqueous solution by addition of 50 µL sodium acetate 
solution and 1.5 mL ethanol. The tubes were inverted several times, centrifuged 
(16·103 RCF, 2 min, room temperature) and the pellets were washed twice with 70% 
ethanol, air-dried and redissolved in water (10 to 20 µL). 
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 DNA concentrations in the final solution (typically 1.0 to 4.0 µg/µL) were 
determined by measuring their absorbance at 260 nm (ε=20 (cm·µg/µL)-1). The 
presence of contaminants (protein and/or phenol residues) was estimated by 
measuring the ratios A260/A220 (usual values 2.0-2.2) and A260/A280 (usual values 1.6-
1.8). 
5.10. Quantitation of the genomic 5-methylcytosine 
DNA content by HPCE 
5.10.1. DNA hydrolysis 
The next solutions and reagents were necessary: 200 U/mL nuclease P1, 10 
mM zinc (II) sulfate, 50 U/mL alkaline phosphatase suspension (Sigma) and 1.5 M 
Tris pH=8.8. 
According to the method described in Fraga et al. 2002, aliquots of DNA 
solutions (5 µL) containing 1-5 µg of highly pure DNA were heated for 3 min in 
boiling water bath and immediately cooled in ice. Then samples were digested o/n at 
37ºC with 1.25 µL nuclease P1 solution in the presence of zinc (II) sulfate (0.75 µL 
stock solution). Finally, 1.0 µL commercial suspension of alkaline phosphatase and 
1.0 µL Tris were added, reaction mixtures were incubated at 37ºC for 2 h, and stored 
at 4ºC. 
5.10.2. Analysis of the nucleoside mixture by HPCE 
The analysis was performed by Dr. Mario F. Fraga according to the method 
described in Fraga et al. 2002. Briefly, an uncoated fused-silica capillary (Beckman-
Coulter; 60.2 cm x 75 µm; effective length 50 cm) was used in a capillary 
electrophoresis system (P/ACE® MDQ, Beckman-Coulter) connected to a data-
processing station (32 Karat software). The running buffer was 14 mM NaHCO3 
pH=9.6 containing 20 mM SDS. Running conditions were 25 ºC with an operating 
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 voltage of 17 kV and on-column absorbance was monitored at 254 nm. Before each 
run, the capillary system was conditioned by washing with 0.1 M sodium hydroxide 
for 3 min and was equilibrated with the running buffer for 3 min. Hydrolyzed DNA 
samples were injected under pressure (0.3 psi) for 3 s. Buffers and samples were 
filtered through 0.45 µm pore filters. All the samples were analysed in duplicate and 
three analytical measurements were made per replicate. The relative methylation of 
each DNA sample was taken as the percentage of 5-methyl-2’-deoxycytidine in total 
cytydine: mdC peak area x 100/(mdC peak area + dC peak area). 
5.11. Analysis of the genomic 5-methylcytosine DNA 
content by DNA digestion with methylation-sensitive 
restriction enzymes. 
Restriction enzymes MspI (20 U/µL), HpaII (10 U/µL) and McrBC (10 U/µL); 
the corresponding concentrated reaction buffers 10 x, 100 mM GTP solution and 10 
mg/mL BSA solution were purchased from New England Biolabs and stored at –20ºC. 
6 x DNA loading buffer and a gel 1% (w/v) agarose NuSieve 3.1 (BioWhittaker) in 
TBE 0.5 x containing 0.1 µg/mL ethidium bromide were prepared as described in 
section 5.8. 
For each reaction, 1 µg DNA mixed with 50 units of enzyme and 5 µL of the 
corresponding concentrated buffer (buffer 2 for MspI and McrBC, buffer 1 for HpaII) 
in 50 µL final volume was incubated at 37ºC during 3 h. The reaction of McrBC was 
supplemented wit 50 nmole GTP (0.5 µL stock solution) and 5 µg BSA (0.5 µL stock 
solution). Controls were performed incubating in parallel 1 µg DNA with 5 µL buffer 2 
in 50 µL final volume. After digestion, enzymes were inactivated by heating (65ºC, 
20 min), crudes were mixed with 6x loading buffer and 5 µL were run in a 1% 
agarose NuSieve gel. 
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 5.12. Analysis of DNA methylation at specific promoters 
To analyse the changes in cytosine methylation at specific sequences, 
genomic DNA samples are modified with bisulfite. When DNA is incubated in the 
presence of bisulfite at acid pH, cytosine residues are deaminated to uracil, but, if 
the cytosine ring is methylated in the 5’ position, the reaction is so slow that it is 
possible to stop it after conversion of the non-methylated cytosine moieties and 
before the transformation of the methylated ones (Wang et al. 1980). This selective 
modification allows the analysis of cytosine methylation at specific DNA sequences by 
different techniques, some of them based on PCR, since uracil residues will be 
amplified as thymines whereas the methylated cytosines will remain as cytosine in 
the PCR product (see Fig.14). 
Two of these PCR-base techniques were employed in this work: 
methylation-specific PCR (MSP) and genomic bisulfite sequencing. Since the strands 
of dsDNA are not fully complementary anymore after cytosine deamination, primers 
must be designed to amplify selectively one of both strands (see scheme in Fig.14). 
MSP provides information about the methylation status of the cytosines 
encompassed by the oligonucleot¡des but bisulfite genomic sequence describes the 
methylation of cytosines in the sequence between the primers (Fig.14). 
For MSP analysis of a given DNA sequence, two PCRs per sample are 
necessary: one with primers specific to amplify the methylated allele and the other 
one with primers specific to amplify the unmethylated one. Each oligonucleotide of 
theses two pairs encompasses at least one CpG dinucleotide. The pair of primers 
designed to amplify the methylated allele only match with the target sequence if all 
the cytosines in the encompassed CpG dinucleotides are methylated and, because of 
that have not been deaminated in the bisulfite reaction. The pair of primers designed 
to amplify the unmethylated allele only match with the target sequence if all the CpG 
dinuclotides are non methylated and so have become uracil after the bisulfite 
treatment (see Fig.14). PCR product is usually a very short fragment (typically 50 to 
150 bp). MSP is a highly sensitivite technique for the detection of small proportion 
(as low as 0.1%) of methylated (or unmethylated) alleles in the sample (Herman et 
al. 1996). 
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 Fig.14: Scheme showing the steps necessary for MSP and bisulfite genomic sequencing. Upper 
panel: bisulfite treatment of DNA is employed to deaminate selectively non-methylated cytosine 
rings. After the reaction, DNA strands are not fully complementary anymore. Middle panel: 
bisulfite genomic sequencing. Primers are designed to amplify the target sequence on one of 
both DNA strands independently of the methylation status. PCR products are sequenced. Lower 
panel: MSP. Oligos are designed to discriminate between the methylated and the non-
methylated forms of the target sequence. 
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 In contrast, for bisulfite sequencing both methylated and unmethylated 
alleles are amplified in the same PCR reaction. Thus, only one pair of 
oligonucleotides is required and the primers should not encompass any CpG. When 
this is not possible, degenerated oligonucleotides considering both the presence and 
absence of methylation must be used to avoid a possible bias in the experiment 
(Frommer et al. 1992). This is the case of the primers BS-RARβ2-S3 and BS-RARβ2-
AS3 in Table 4. PCR products are sequenced. If these PCR products are cloned 
before sequencing, several colonies must be analysed in order to have an overview 
of the population. Then, each sequencing gel or electropherogram shows that there 
is only cytosine or tymine in each cytosine position of the original DNA, depending on 
the methylation status for that specific residue. If PCR products are not cloned and 
the sample is not from a homogeneous population of cells, the sequencing gel or the 
electropherogram shows that each cytosine position is occupied by a mixture of 
cytosine and tymine, in a proportion according to the percentage of methylation for 
each particular residue in the original sample. 
5.12.1. Bisulfite treatment 
DNA was modified with sodium bisulfite as described by Herman et al. in 
1996, by using the next solutions: sodium bisulfite solution, 3 M sodium hydroxide 
and 16 mM hydroquinone. To recover DNA after the reaction, Wizard® DNA Clean-
Up System (Promega), 80% isopropanol, 10 mg/mL glycogen solution, 10 M 
ammonium acetate, ice-cold absolute ethanol and ice-cold 70% ethanol were 
necessary. 
For each sample, 1 µg genomic DNA was diluted up to 50 µL and was 
incubated with sodium hydroxide (5.7 µL of 3 M solution) at 37ºC for 10 min. Then 
hydroquinone (33 µL of 16 mM solution) and sodium bisulfite (0.53 mL of 4.0 M 
solution) were added and samples were heated o/n at 50ºC.  
DNA was desalted and concentrated by using the kit Wizard® DNA Clean-Up 
System: each crude was mixed with 1 mL of DNA-binding resin and the suspension 
was transferred to a column. A vacuum manifold was used to drain supernatants and 
washing solutions. After removal of supernatant, resin was washed twice with 1.0 mL 
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 80% isopropanol and the residual solvent was eliminated by centrifuging (16·103 
RCF, 2 min, room temperature) the column placed onto a 1.5 mL tube. For DNA 
recovery, the column was transferred to a clean tube, 50 µL of preheated (50ºC) 
water were applied on top of the resin and, after 2 min, DNA was eluted by 
centrifugation (16·103 RCF, 1 min, room temperature). 
Once desalted an concentrated, DNA was desulfonated with sodium 
hydroxide (5.7 mL of 3.0 M solution) for 20 min at 37ºC. Immediately after, DNA was 
precipitated by addition of 1 µL glycogen solution, 17 µL ammonium acetate (10 M) 
and 0.22 mL cold absolute ethanol and keeping the resultant mixture at –80ºC for 30 
min-2 h. Tubes were centrifuged (4.5·103 g, 20 min, 4ºC), pellets were washed once 
with cold 70% ethanol and air dried. DNA was redissolved in 25 µL of water (final 
concentration 40 ng/µL approximately). 
5.12.2. Methylation-specific PCR 
For each sample, two parallel PCR reactions were carried: one with specific 
primers for the methylated promoter (labelled as RARβ2-M-S and RARβ2-M-AS in 
Table 3) and another one with primers for the corresponding non-methylated allele 
(RARβ2-U-S and RARβ2-U-AS in Table 3). In both cases, 40 ng of bisulfite-treated 
DNA were amplified with FastStart® Taq DNA-polymerase system as described in 
section 5.7, with no addition of CG-RICH® solution. Details are shown in Table 3. 
Products were separated in a standard agarose gel and visualized with ethidium 
bromide staining. 
5.12.3. Bisulfite genomic sequencing 
In this analysis, 80 ng of bisulfite-treated DNA were amplified with 
FastStart® Taq DNA-polymerase system in 50 µL final volum, with the primers and 
conditions described in Table 4. 
After PCR, reaction crudes were run in a 2% (w/v) agarose gel (prepared as 
described in 5.8) and bands with the products were excised under 254 nm light. DNA 
was extracted from the bands either with QIAquick® Gel Extraction Kit (Qiagen) or 
by freezing the band, centrifuging (16·103 RCF, 10 min, room temperature) it and 
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 purifying the DNA from the supernatant employing E.Z.N.A.® Cycle-Pure Kit (Omega 
Bio-Tek). Both kits were used according to the manufacturer’s protocols. Pure PCR 
products were sequenced at the Unidad de Análisis Genómico (C.N.I.O., Madrid, 
Spain), by using as primers the same oligonucleotides that were employed for the 
PCR reaction. 
5.13. RNA isolation 
Several reagents and solutions were required for RNA isolation: PBS, 
TRIzol® (Invitrogen), chloroform (Merck), isopropanol (Merck), 75% ethanol in 
DEPC-treated water, DEPC treated water, RNase-Free DNase Set (Quiagen) and 
RNeasy® Mini Kit (Qiagen). 
Cell dishes (containing 0.5·106 to 2·106  cells) were washed twice with PBS, then 
TRIzol® was added (40 µL per 1 cm2 of dish surface), cells were detached with a 
scrapper, transferred to sterilised 1.5 mL tubes and incubated at room temperature 
for 5 min. Next, chloroform (0.2 mL per 1 mL TRIzol®) was emulsionated with the 
resulting lysates, shaking (vortex) during 5 min at room temperature. After 
centrifugation (13·103 RCF, 15 min, 4ºC), the aqueous layers (0.5 mL per 1 mL 
TRIzol®) were placed in clean 1.5 mL tubes. RNA was precipitated by adding one 
volume isopropanol to the aqueous solution, mixing by inversion and incubating at 
room temperature during 10 min. Finally, tubes were centrifuged (13·103 RCF, 20 
min, 4ºC), pellets were washed once with 75% ethanol (centrifugation at 5.2·103 
RCF, 5 min, 4ºC) and allowed to air-dry. To dissolve RNA, 50 µL DEPC-treated water 
were added to each pellet and, after that, tubes were heated at 65ºC for 5 min. 
Aliquots of 10 µL were taken for concentration and quality analysis and the remaning 
40 µL were immediately stored at –80ºC. 
RNA concentrations in the final solution (typically 1.0 to 3.0 µg/µL) were 
determined by measuring the absorbance of the solutions at 260 nm (ε=25 
(cm·µg/µL)-1). The presence of contaminants (protein and/or phenol residues) was 
estimated by measuring the ratios A260 / A220 (usual values 2.0 - 2.2)  and  A260 / A280  
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 Table 3: Primers employed for MSP 
Gene Primer name Sequence 
C/µM 
(1) Cycles
Ta/ºC 
(2) 
Rarβ-M-S TGTCGAGAACGCGAGCGATTC RARβ2,methylated 
+105 to +256 
Rarβ-M-AS CGACCAATCCAACCGAAACGA 
Rarβ-U-S TTGGGATGTTGAGAATGTGAGTGA(T)3 RARβ2,unmethylted 
+99 to +262 
Rarβ-U-AS CTTACTCAACCAATCCAACC(A)4CAA 
2.0 35 58 
(1) Final concentration in PCR reaction; (2) annealing temperature. Oligos taken from Esteller et 
al.. 2002. 
 
Table 4: Primers employed for bisulfite genomic sequencing 
Gene (1) Primer name Sequence (2) 
C/µ
M 
(3) 
Cycles 
Ta/ºC
(4) 
CG-rich
(5) 
BS-RARβ2-S2 GTGAGTTAGGAGTAGYGTTTYGG(T)9RARβ2 (6)  
-282 to +64 BS-RARβ2-AS2 CTTTAAC(A)6TAAACCCTCCTAA 1.0 40 48 no 
BS-RARβ2-S3 AAAAYGTYGGTTTGTGYGTTYGTTG RARβ2 (6)  
-197 to +249 BS-RARβ2-AS3 ATCCAACCRAAACR(A)5TTCCC(A)6 
1.0 40 54 no 
BS-p21-S ATTGGGGGAGGAGGGAAGT CDKN1A 
-222 to +94  BS-p21-AS CTCACCTCCTCTAAATACCTC 
0.8 40 55 yes 
BS-gadd45-S GTTGTYGGGAAATTAGGAGAAA GADD45β 
-303 to -31 BS-gadd45-AS CTAAACTAAAAACCTCCRACAC 
1.0 40 50 yes 
BS-igfbp3-S TGTTGAGGTGGTTTGGAGTGT IGFBP3 (7) 
-282 to 
+191 
BS-igfbp3-AS CRAAACAACACCAACAAAATCA 1.0 40 55 yes 
BS-junD-S GGGYGGGYGTTTGGTGGT JUND 
-296 to 
+27 
BS-junD-AS CACTTATACRCCCTCTTATAACC 0.8 40 55 yes 
BS-mt1L-S GGGGGTTGGGGGTGTGTAGAT MT1X 
-322 to -
102 
BS-mt1L-AS TCCTTACACCCRCCCCTACTAAAT 1.0 40 60 yes 
BS-mt2a-S AGTTTTGGTTGTTATAGAGTTGTAA MT2A 
-457 to -
196 
BS-mt2a-AS ATCAATTCCCTAAAAACRACC 1.0 40 50 yes 
(1) Gene symbol and region encompassed by the oligonucleotides relative to the transcription 
start; (2) some of the oligos are degenerated. In that case, Y represents C or T and R 
represents A or G; (3) final concentration in PCR reaction; (4) annealing temperature; (5) 
presence of CG-rich solution in the reaction; (6) primers taken from Arapshian et al. (2000); (7) 
primers from Fraga et al. 2004. 
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 (usual values 1.6-1.8). Also 4 µL per sample were run for 20 min in 1% (w/v) 
agarose gel to visualize the integrity of RNA. 
For analysis of JunD expression (JunD is a monoexonic gene), 20-30 µg 
RNA per sample were brought up to 100 µL, treated with RNase-free DNase and 
recovered from the digestion with RNeasy® Mini Kit. With this procedure, near 30% 
of the starting material was lost. Both digestion and purification with RNeasy® Mini 
Kit were done according to manufacturer’s instructions. 
5.14. Reverse transcriptase PCR 
Semiquantitative RT-PCR was performed to study the alterations in the 
transcription of certain genes after drug treatment. Two different protocols were 
employed: the “one-step protocol”, to analyse the transcription of a single gene 
(RARβ2) for all the samples, and the “two-step protocol”, to detect changes in the 
expression of several genes in the same set of samples. 
5.14.1. One step protocol 
In this case, 0.01 mM oligonucleotides sense and antisense for RARβ2 and 
β-actin mRNA were used, as well as Enhanced Avian RT-PCR kit (Sigma) containing 
the following solutions: 10x PCR buffer, 25 mM MgCl2, dNTP mix (10 mM each 
dNTP), 20 U/µL RNase inhibitor, 20 U/µL enhanced avian myeloblastosis virus 
reverse transcriptase and 5 U/µL AccuTaq® LA DNA-polymerase. 
In a similar way as for simple PCR, a master mix was prepared containing 
(per reaction): 2.5 µL 10 x PCR buffer, 1.5 µL 25 mM MgCl2, 0.5 µL dNTP mix, 0.5 µL 
RNase inhibitor, 1.0 µL each primer solution, 0.5 µL enhanced avian myeloblastosis 
virus reverse transcriptase, 0.25 µL AccuTaq® LA DNA-polymerase. DEPC-treated 
water was added to adjust the final volume of the reaction to 25 µL. The mix was 
dispensed in the 0.2 mL thin-wall reaction tubes containing the RNA samples (12 ng 
each). Tubes were placed in the thermocycler. First, tubes were incubated at 50ºC 
during 45 min for cDNA synthesis. Then, PCR cycling was performed to amplify the 
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 cDNA: denaturation (3 min at 95ºC), followed by 5 cycles with annealing 
temperature 58ºC (30 s at 95ºC, 30 s at 58ºC, 1 min at 72ºC), 30 cycles with 
annealing temperature 51ºC (30 s at 95ºC, 30 s at 51ºC, 1 min at 72ºC) and a final 
extension at 72ºC during 5 min. As for genomic DNA amplification, a tube with 
master mix but no template was the negative control. 
Products were visualized in 2% (w/v) agarose gel with ethidium bromide 
staining, as usually. 
5.14.2. Two-step protocol 
For the first step, consisting in the cDNA synthesis, ThermoScript® RT-PCR 
System for First Strand cDNA Synthesis (Invitrogen) was employed. The kit contains 
50 µM oligo(dT)20, 10 mM dNTP mix, 5 x buffer, 0.1 M DTT, 40 U/µL RNaseOUT®, 
15 U/µL ThermoScript® reverse transcriptase, 2 U/µL RNase H, DEPC-treated water. 
For each sample/blank, in a clean thin-walled 0.2 mL tube, 2.0 µL oligo(dT)20 
solution, 4.0 µL dNTP mix, 4 µg total RNA and DEPC-treated water up to 24 µL were 
mixed. Then RNA was denatured by heating at 65ºC for 5 min followed by quick 
cooling on ice bath. A master mix containing the indicated amounts of reagents per 
sample was made: 8.0 µL 5 x buffer, 2.0 µL DTT, 2.0 µL RNaseOUT®, 2.0 µL DEPC-
treated water and 2.0 µL reverse transcriptase. After dispensing 16 µL master mix in 
each 0.2 mL tube, reaction coktails were incubated in a termocycler for 1 h at 50ºC 
and then for 5 min at 85ºC to inactivate the enzymes. Once tubes were at room 
temperature, RNA was digested with RNase H (1.0 µL commercial solution per 
sample) for 20 min at 37ºC. 
The second step, the amplification of the resulting cDNAs, was carried as 
standard PCR with EcoTaq® DNA-polymerase in presence of 1.5 mM MgCl2. Reaction 
conditions (including the amount of cDNA used as template) for each pair of 
oligonucleotides were searched by amplifying different quantities of cDNA from a 
positive control and chosing the ones that better reflected changes in template 
concentration. Primers and other details are specified in Table 5.  After amplification, 
10 µL each crude were mixed with 2 µL 6 x loading buffer and run in 2% (w/v) 
agarose gel. 
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 Table 5: Primers for RT-PCR 
Gene and 
product size 
(1) 
Primer 
name Sequence 
C/µM
(2) Cycles
Ta/ºC
(3) 
CG-rich
(4) 
RT-RARb-S AGAGTTTGATGGAGTTGGGTGGAC Rarβ2 (5) 
288 bp (33 kbp) RT-RARb-AS GACGAGTTCCTCAGAGCTGGTG 
0.4 
RT-actin-S ACCATGGATGATATCG β-actin (6) 
400 bp (1.0 kbp) RT-actin-AS ACATGGCTGGGGTGTTGAAG 
0.4 
SEE TEXT (One step 
RT-PCR protocol) 
RT-p21-S GGCAGACCAGCATGACAGATT CDKN1A 
70 bp (1.2 kbp) RT-p21-AS GGATTAGGGCTTCCTCTTGGAG 
0.4 33 50 yes 
RT-gadd45-S TCGGATTTTGCAATTTCTCC GADD45β 
320 bp (0.8 kbp) RT-gadd45-AS TGTCACAGCAGAAGGACTGG 
0.08 30 60 no 
RT-igfbp3-S GTCAACGCTAGTGCCGTCAG IGFBP3 (7) 
196 bp (3.5 kbp) RT-igfbp3-AS CATGCCCTTTCTTGATGAT 
0.4 31 60 no 
RT-junD-S GTGCCCAGGAACTCAGAGAG JunD 
342 bp (0.3 kbp) RT-junD-AS CGTTTGTTCCCCGAGTAGAA 
0.08 35 60 no 
RT-mt1L-S GCTCGCCTGTTGGCTCC MT1X (8) 
45 bp (0.6 kbp) RT-mt1L-AS TCTGACGTCCCTTTGCAGATG 
0.08 30 60 no 
RT-mt2a-S CAACCTGTCCCGACTCTAGC MT2A 
314 bp (1.4 kbp) RT-mt2a-AS ATAGCAAACGGTCACGGTCA 
0.08 30 60 no 
RT-gadph-S TCTTCTTTTGCGTCGCCAG GAPDH 
372 bp (2.6 kbp) RT-gadph-AS AGCCCCAGCCTTCTCCA 
0.04 30 57 no 
(1) The expected size for the amplification of contaminant DNA is shown in brackets; (2) final 
concentration in PCR reaction; (3) annealing temperature; (4) presence of CG-rich solution in 
the reaction; (5) primers taken from Bovenzi et al.. 2001; (6) primers taken from Sirchia et al.. 
2000; (7) primers from Fraga et al.. 2004 (8) primers taken from Glaser et al.. 2003. 
5.15. Chromatin immunoprecipitation 
To investigate the modification status of histones at the promoter of 
candidate genes, standard ChIP assays were performed as previously described 
(Gregory et al., 2002) in cells with or without CY (1 µM) treatment. To crosslink the 
macromolecules, 37% formaldehyde in water (Sigma), 2.5 M glycine and ice-cold 
PBS containing 1 tablet Complete® Protease Inhibitor Cocktail EDTA Free (Roche) in 
each 50 mL were used. Chromatin was released with ChIP SDS lysis buffer. For the 
immunoprecipitation, several reagents were required: ChIP dilution buffer, salmon 
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 sperm DNA/protein A agarose slurry 50% (Upstate), antibodies (see Table 7), ChIP 
low salt immune complex wash buffer, ChIP high salt immune complex wash buffer, 
ChIP LiCl immune complex wash buffer, TE and ChIP elution buffer. Finally, DNA was 
isolated from the immunoprecipitated by using 5.0 M NaCl, 0.5 M EDTA, 1.0 M Tris 
pH=6.8, 10 mg/mL proteinase K, phenol/chloroform/isoamyl alcohol 25:24:1 
solution, 3.0 M sodium acetate, 70% (v/v) ethanol, 10 mg/mL glycogen and 
isopropanol. The scheme of the procedure is shown in Fig.15. 
First, chromatin was crosslinked by adding formaldehyde directly to the medium of 
cell dishes containing 3-6·106 cells. Final concentration of formaldehyde was 1% in 
the case of using anti-histone antibodies and 2% if anti-HDAC antibodies were 
employed. After incubating for 15 min at room temperature in a rocking platform, 
excess of aldehyde was quenched by adding glycine to a final concentration 0.125 M. 
The medium was removed after 5 min and dishes were washed twice with cold PBS 
containing Complete® Protease Inhibitor Cocktail EDTA Free. Cells were scrapped, 
collected in conical tubes by centrifugation (690 RCF, 5 min, 4ºC) and decanted. 
For chromatin release, cells were resuspended in cold ChIP SDS lysis buffer 
(0.2 mL per million cells) and incubated on ice for 10 min. Next, lysates were divided 
in 0.3 mL aliquots (in tubes 1.5 mL) and sonicated during 10 s (output 3, 90% duty 
cycler in a Sonifier 250, Branson) to shear DNA in fragments of size about 0.5 kbp. 
Aliquots were pooled. 
In order to balance the concentration of material in the samples, two 
aliquots of 4 µL were taken from each pool, diluted 100-fold with water and 
absorbances at 260 nm were measured. Then pools were diluted approximately 10-
fold with cold ChIP dilution buffer, in such a way that the concentration of starting 
material (and A260) was the same for all the samples. From each one of these 
dilutions, a 2.0 mL aliquot was stored at –20ºC to use as “input” control. The rest of 
the fractions were incubated (rotating wheel, 30 min, 4ºC) with protein A agarose 
beads blocked with salmon sperm (80 µL slurry for each 2.0 mL diluted lysated), to 
eliminate the material that can bind inespecifically the resin. Agarose beads were 
pelleted (690 RCF, 4 min, 4ºC) and each solution was divided in several 2.0 mL 
aliquots, one for each antibody and one to use as “no antibody” control (this one will 
be processed in parallel with the rest). Antibodies (5 µg each) were added to the  
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  Fig.15: Scheme of the ChIP technique. Cultured cells (whose chromatin is representd in the 
upper left corner) are first treated with formaldehyde and then lysated to release the crosslnked 
chromatin (black thick lines represent the covalent bonds arising from the crosslinking). Then, 
DNA is fragmented by sonication and the resulting mixture is aliquoted. Each aliquot is 
incubated with a different antibody recognizing either proteins bound to chromatin (left side) or 
histone modifications (right side) and the fraction bound to the antibody is immunoprecipitated 
with  protein A/agarose beads. Supernatant (“unbound fraction”) is separated and kept. 
Chromatin is eluted from the beads (“bound fraction”) and DNA is purified from both bound and 
unbound fractions after decrosslinking. The presence or absence of a certain sequence in each 
fraction is determinated by PCR using adequate pimers. 
cultured cells
1) crosslinking 
2) lysis 
sonication
crosslinked celular extract
anti-modified histone antibodyanti-proteinX antibody
protein A/agarose protein A/agarose
elution
decrosslinking
DNA purification
elution
decrosslinking
DNA purification
decrosslinking
DNA purification
decrosslinking
DNA purification
unbound fraction bound fraction unbound fraction bound fraction
unbound DNA bound DNA unbound DNA bound DNA
protein A/agarosenucleosome anti-proteinX antibody anti-modified histone antibodyproteins bound to nucleosomes(HDACs, MBDs, etc.)
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 corresponding aliquots and all the tubes (except for the “input”) were rotated at 4ºC 
o/n. Then 60 µL salmon sperm DNA/ protein A agarose beads were added to each 
tube and incubated with rotation at 4ºC during 1 h. The resin (now containing the 
immunoprecipitate) was collected by centrifugation (90 RCF, 1 min, 4ºC) and 
supernatants, which constitute the “unbound” fractions, were saved.Beads were 
washed sequentially with the following solutions (1.0 mL each) in a rotating platform: 
one 5 min wash with 1.0 mL low salt immune complex wash buffer, 
one 5 min wash with 1.0 mL high salt immune complex wash buffer, 
one 5 min wash with 1.0 mL LiCl immune complex wash buffer, 
two 5 min wash with 1.0 mL TE buffer. 
To remove supernatants, resin was pelleted as indicated above (90 RCF, 1 
min, 4ºC). 
Antibody-chromatin complexes were eluted with two washes (15 min each) 
with 0.25 mL ChIP elution buffer. Both eluates were combined in the called “bound” 
fractions. 
DNA was released by heating at 65ºC for 4 h 0.5 mL aliquots of each 
sample (including “input”, “unbound” and “bound” fractions) mixed 20 µL 5 M NaCl. 
After addition of 10 µL 0.5 M EDTA and 20 µL 1.0 M Tris pH=6.8 to each aliquot, 
proteins were digested with 2 µL proteinase K solution for 1 h at 45ºC. The resulting 
solutions were washed twice by emulsionating with 1 vol phenol/chloroform/isoamyl 
alcohol and separating phases by centrifuging (16·103 RCF, 5 min, room 
temperature). DNA was precipitated from the aqueous layer with 0.1 vol sodium 
acetate, 1.0 µL glycogen solution and 0.7 vol isopropanol, incubating at –20ºC o/n. 
Finally, tubes were centrifuged (13·103 RCF, 15 min, 4ºC), pellets were washed once 
with 70% ethanol and, after evaporation of the residual ethanol, DNA was dissolved 
in 25 µL water. 
Average size of the fragments was estimated by running 5 µL input DNA in 
a 2% agarose gel. DNA concentration in each fraction was determined by 
absorbance at 260 nm (dilutions 10- or 100-fold in water) and DNA purity was 
estimated with the ratios A260/A220 (usual values 2.0-2.5) and A260/A280 (usual values 
1.6-1.8). 
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 PCR amplifications were performed as indicated in section 5.7 with specific 
primers for each of the analysed promoters (see Table 6) and either EcoTaq® or 
FastStart® Taq as DNA-polymerase. The sensitivity of amplification was evaluated on 
PCR amplifications were performed as indicated above with specific primers serial 
dilutions of input DNA. The amount of template for reaction depended on the 
amplified sequence (5 to 20 ng). 
 
Table 6: Primers for ChIP 
Gene (1) Primer name Sequence 
C/µ
M 
(2) 
Cycles Ta/ºC(3) 
CG-rich
(4) 
ChIP-p21-S GCAGAGAGGTGCATCGTTT CDKN1A 
-468 to -249 ChIP-p21-AS ACATTTCCCCACGAAGTGAG 
0.8 35 60 no 
ChIP-gadd45-S CCAGAAAAGGCGGAAAAATA GADD45β 
-112 to +61 ChIP-gadd45-AS AATAGGAGGGGCGAATGACT 
0.8 35 55 yes 
ChIP-igfbp3-S CTCCCAACCCCCACTCCT IGFBP3 (5) 
-89 to +87 ChIP-igfbp3-AS GGATGGGGCGACAGTACAC 
0.8 35 55 yes 
ChIP-junD-S GGGAGATCGGTCGTACACA JUND 
-230 to +25 ChIP-junD-AS CTTGTGCGCCCTCTTATAGC 
0.8 35 60 yes 
ChIP-mt1L-S CACGTACTGCCAGGTTCTCA MT1X 
-213 to +5 ChIP-mt1L-AS AGATGAAAAGCGTGGTGGAG
0.8 35 60 yes 
ChIP-mt2a-S TTCCAGTGTTCCCGCTAGTT MT2A 
-961 to -784 ChIP-mt2a-AS CAAGCTTGGTCCTCAGGAAG 
0.8 35 60 yes 
(1) Gene symbol and region encompassed by the oligonucleotides relative to the transcription 
start; (2) final concentration in PCR reaction; (3) annealing temperature; (4) presence of CG-
rich solution in the reaction; (5) primers from Fraga et al.. 2004. 
5.16. In vitro HDAC inhibitory activity assay 
5.16.1. Preparation of active nuclear extracts 
The necessary materials for this preparation are: PBS, nuclear extract buffer 
A, nuclear extract buffer B, nuclear extract buffer C, 4.0 M ammonium sulfate and 
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 dialysis tube Servapor ® Dialysis Tubing 16 mm 10000 MWCO (Servan). All buffers 
and solutions were cooled at 4ºC before use. 
Exponentially growing MCF7 cells (15 to 18·106) were collected in a 15 mL 
tube by centrifugation (110 RCF, 5 min, 4ºC) and washed with PBS. Pellet was 
resuspended in a mixture of 10 mL nuclear extract buffer A and 0.68 mL nuclear 
extract buffer B. Cells were centrifuged again (689 RCF, 5 min, 4ºC), washed once 
with 10 mL nuclear extract buffer A and finally resuspended in 4 mL nuclear extract 
buffer A. Cytoplasms were broken with a dounce homogenizer (15 strokes), 0.3 mL 
nuclear extract buffer B were added and suspension was stroken 5 more times. After 
centrifugation (7.7·103 RCF, 8 min, 4ºC), pellet was suspended in 4 mL nuclear 
extract buffer A and stroken 5 additional times. Nuclei were transferred to a 
centrifuge tube, 0.4 mL ammonium sulfate solution were added and the mixture was 
rotated at 4ºC for 30 min. Solution was cleared by centrifugation (12·103 RCF, 30 
min, 4ºC). The resulting supernatant was dialyzed against 250 mL nuclear extract 
buffer C during 2.5 h at 4ºC. Aliquots of 0.4 mL were made and immediatly frozen at 
–80ºC. 
5.16.2. HDACs immunoprecipitation from active nuclear extracts 
The reagents employed to immunoprecipitate active HDACs from the 
nuclear extracts prepared as described in 5.16.1 were: 2.5 M KCl, IP buffer, 
antibodies anti-HDAC1 and anti-HDAC5 (Upstate, see Table 7), protein A sepharose 
50% suspension (Upstate), protein G sepharose 50% suspension (Upstate), 10 
mg/mL BSA and HDAC activity buffer. 
For this experiment, the required volume of nuclear extract is 0.28 mL for 
each planned in vitro reaction (including the negative control), i.e., for 10 reactions, 
2.8 mL are necessary. 
First, ionic strength in the nuclear extract was increased with KCl (12 µL KCl 
solution per 0.28 mL extract). The pool was separated in 3 aliquots: the first and the 
second (for 5 reactions each one) were rotated for 1 h at 4ºC with 40 µg anti-HDAC1 
and anti-HDAC5 antibodies, respectively. The third one, the negative control (only 
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 one reaction, i.e., 0.29 mL), was brought up to 0.30 mL with IP buffer and incubated 
in parallel with the others. 
In the meantime, 0.33 mL protein A sepharose slurry was mixed with 0.22 
mL protein G sepharose. Beads were centrifuged (16·103 RCF, 1 min, 4ºC) and 
blocked with 2 mL IP buffer containing 300 µg BSA (30 min at 4ºC in a rotating 
platform). The pool of beads was divided into 3 aliquots, one containing 0.18 mL 
suspension and the other two, 0.91 mL each one. 
After centrifugation (16·103 RCF, 1 min, 4ºC), supernatant of the beads was 
removed and the mixtures containing the nuclear extracts were added: each one of 
the extracts incubated with antibody was pooled with one of the big sepharose 
aliquots, whereas the non-antibody control was mixed with the small aliquot of 
sepharose. These suspensions were rotate at 4ºC during 2 h. 
Finally, the slurries were centrifuged (16·103 RCF, 0.5 min, 4ºC), washed 4 
times with IP buffer (0.3 mL buffer for each 0.3 mL nuclear extract) and a last time 
with HDAC activity buffer. For each immunoprecipitate (HDAC1 and HDAC5), the 
content of the tubes was resuspended in 1.5 mL HDAC activity buffer, aliquoted in 5 
tubes (0.3 mL per tube), centrifuged (16·103 RCF, 0.5 min, 4ºC) and decanted. In 
parallel, the control beads were washed once with 0.3 mL HDAC activity buffer. Each 
pellet was resuspended in 100 µL fresh HDAC activity buffer and used immediately 
for the activity assay (see 5.16.3). 
5.16.3. In vitro HDAC activity assay 
In addition to the active nuclear extract (see 5.16.1) or immunoprecipitated 
HDACs (5.16.2); drugs solutions (Table 2), [3H]acetate-labelled histones (1.8 nCi/µg) 
dissolved in water (4 µg/mL), HDAC activity buffer, HDAC quenching solution, ethyl 
acetate (Merck) and Optiphase HiSafe 3® (Wallac) scintillation cocktail were 
necessary for this assay. 
For each reaction, either 40 µL MCF7 active nuclear extract diluted with 50 
µL HDAC activity buffer or 100 µL beads suspension from the immunoprecipitation of 
HDAC1 and HDAC5 were taken as source of enzyme and incubated with the drugs 
for 10 min at room temperature. Dilutions of the chemicals were prepared in such a 
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 way that volumes of 1.0 µL were added to each mixture. Then, 10 µL [3H]acetate-
labelled histones were added to each tube and the reaction was allowed to proceed 
at 30ºC during 60 min (in case of using the beads, reaction tubes were shaken in a 
Thermomixer at 600 rpm to keep the resin in suspension). Deacetylation was 
stopped with of 37.5 µL HDAC quenching solution and the released [3H]-acetic acid 
was extracted with 0.7 mL ethyl acetate. Phases were separated by centrifugation 
(16·103 g, 5 min, room temperature). Finally, 0.45 mL aliquot of each organic layer 
was counted in 3 mL scintillation cocktail in a 1409 Liquid Scintillation Counter 
(Wallac). 
5.17. Histone acidic extraction 
The following solutions were required for this protocol: PBS, RSB, 10% NP-
40, 0.25 M HCl, acetone (Merck), 20 mM Tris pH=6.8. 
Cells (2·106 to 6·106) were washed once with PBS, detached and collected 
by centrifugation (200 RCF, 5 min, 4ºC). After one wash with PBS, cells were 
resuspended in 4 mL RSB with 0.4 mL NP-40 solution and incubated on ice for 10 
min. Nuclei were centrifuged (690 RCF, 5 min, 4ºC), washed once with 4 mL cold 
RSB buffer, resuspended in 0.5 mL 0.25 M HCl and rotated at 4ºC during 4 h. 
Samples were centrifuged (16·103 RCF, 5 min, 4ºC), supernatants were transferred 
to clean tubes and histones were precipitated with 8 vol acetone and incubation at 
4ºC for 4 h. Finally, samples were centrifuged (16·103 RCF, 5 min, 4ºC), washed 
twice with acetone and, once the residual solvent evaporated, 0.2-0.4 mL Tris 
solution were used to dissolve histones. Typically, 0.2 to 0.4 mg protein were 
obtained. 
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 5.18. Preparation of whole-cell protein extracts 
Dishes containing 0.5-2·106 cells were washed with cold PBS. Protein extract 
buffer (40 µL per 1 cm2) was added and plates were incubated on ice for 15-30 min 
(until cells detach). Suspensions were pipetted thoroughly, transferred to 1.5 mL 
tubes and the extracts were cleared by centrifugation (16·103 RCF, 30 min, 4ºC). 
Supernantants were placed in a clean tube and stored at –80ºC. 
5.19. Determination of protein concentration 
Histone concentration and protein concentration in whole protein extracts 
were determined with Bio-Rad Protein Assay Kit and DC Protein Assay Kit (Bio-Rad), 
respectively, following the manufacturer’s instructions. The first reagent is based on 
Bradford’s method and for that, 0-8 µg of protein (contained in 0-20 µL of protein or 
standard solution) were mixed with 1 mL diluted Coomassie brilliant blue solution. 
Absorbances were measured at 595 nm. DC Protein Assay Kit is based on Lowry’s 
method and is compatible with the presence of detergent in the sample. For the 
assay, 0-30 µg of protein sample or standard (contained in 20 µL) were mixed in a 
final volume of 0.92 mL colorimetric cocktail. After 15 min incubation at room 
temperature, absorbances at 750 nm were measured. 
In both cases, calibration curves were performed with BSA standard 
solutions. When necessary, protein solutions were diluted to get an absorbance value 
in the linear range. 
5.20. Denaturing polyacrilamide gel electrophoresis of 
proteins (SDS-PAGE) 
First, gel was made. SDS-PAGE resolving gel (7.5 mL) was prepared by 
mixing the reagents in the order of citation (see 5.1). The resulting solution was 
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 immediately poored into a plastic cassette for XCell SureLock® Mini-Cell (Invitrogen) 
for gels 1.0 mm thick, overlayed with 1.5 mL either ethanol or isopropanol and 
allowed to polymerize for 30 min at room temperature. Alcohol was drained 
completely and 3 mL freshly prepared SDS-PAGE stacking gel mixture was added on 
top of the resolving gel. Combs (10 or 12 wells) were placed and the gel was left 30 
min at room temperature for polymerization. 
To perform the electrophoresis, one or two cassettes were placed in the 
XCell SureLock® Mini-Cell system, the cell was filled with SDS-PAGE running buffer, 
the combs in the gels were removed and the samples, previously mixed with 4 x 
Laemmli buffer and denatured (3 min at 100ºC, then ice), were loaded. For histone 
analysis, 1 µg per sample of acidic extract (5.17) were separated in a 15% SDS-
PAGE gel, for HDACs (HDAC1 and HDAC2) 25 µg of whole-cell protein extract per 
sample were separated in 7.5% or 10% SDS-PAGE gel. Electrophoresis were run at 
25 mA (one single gel) or 50 mA (two gels) until the bromophenol blue present in 
the Laemmli buffer started leaving the gel. Adequate molecular weight standards 
were used. 
5.21. Detection of proteins by Western blotting 
After separation in a SDS-PAGE gel, proteins were transferred to Immoblilon-PSQ 
PVDF membrane (0.22 µm pore size, Millipore) in a Mini Trans-Blot Cell (Bio-Rad). 
One piece of Immobilon membrane of the size of the gel was cut and equilibrated for 
2 min in methanol (Merck) and then in transfer buffer. Four pieces of Whatman® 
3MM paper and two fibber pads with surface slightly bigger than the gel were also 
soaked in transfer buffer. The transfer sandwich was assembled (see Fig.), placed in 
the tank full with transfer buffer and transference was performed at 60 V during 2.5 
h at room temperature. Then, membrane was soaked for 1 min in 1% acetic acid 
and stained with Ponceau S solution to visualize the proteins and verify that the 
transfer was properly done. 
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 Table 7: Antibodies 
Antigen Epitope Host Manufacturer Dilution(1)  Buffer (1)
HDAC1 Amino acids 53-482 of mouse 
HDAC1 
rabbit Upstate 1/1000 System 2  
HDAC5 KLH conjugated peptides 
corresponding to amino acids 536-
545 and 194-206 of human 
HDAC5 
rabbit Upstate  Only used in 
IP 
Acetyl H4 AGGKGGKGMGKVGAKRHSC 
with all K acetylated 
rabbit Upstate 1/2000 System 1  
Acetyl H3 ARTKQTARKSTGGKAPRKQLC 
K9 and K14 acetylated 
rabbit Upstate 1/5000 System 2  
H3 Synthetic peptide corresponding 
to amino acids 124-135 of human 
H3 
rabbit Abcam 1/1000 System 1  
H4 Calf thymus histone H4 rabbit Upstate 1/1000 System 2  
HDAC1 Synthetic peptide corresponding 
to amino acids 467 to 482 of 
human HDAC1 
rabbit ABR  Only used in 
ChIP 
HDAC2 Synthetic peptide corresponding 
to amino acids 475 to 488 of 
human HDAC2 
rabbit ABR  Only used in 
ChIP 
LAP2 Amino acids 34-156 of rat Lap2 mouse Transduction 
laboratories 
1/1000 System 2 
HDAC2 KLH conjugated synthetic peptide 
corresponding to amino acids 471 
to 488 of human HDAC2 
rabbit Abcam 1/1000 System 2 
(1) Dilution and buffer system employed for Western Blotting. System 1 is the PBS-based buffer 
and System 2, the NET-based one. 
 
 
Membrane was washed twice with PBS and then blocked with either WB 
blocking buffer 1 or 2 (see below) for 1 h at room temperature. After that, the 
Immobilon® piece was rinsed with the corresponding wash buffer (WB wash buffer 1 
or 2, see below), hybridized with the primary antibody (see Table 7 for antibodies 
and conditions) during 2 h at room temperature or o/n at 4ºC, washed 3 times with 
WB wash buffer, incubated with the secondary antibody for 45 min and rinsed 4 
times with WB wash buffer. For developing, Ortho CP-G Plus films (Agfa) and ECL® 
Western Blotting Detection Reagent (Amersham) were used according to 
manufacturers’ instructions. 
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 For blocking, washing and antibodies dilutions, two systems of buffers were 
employed, one based on PBS/Tween® 20 (WB wash buffer 1 and WB blocking buffer 
1) and the other one consisnting on a more complex solution, the NET buffer (WB 
wash buffer 2 and WB blocking buffer 2). The first one was used for routine except 
in the cases were antibodies gave strong background signal. Then, NET-based 
buffers were employed instead of PBS/Tween® 20. 
5.22. Quantitation of global histone modifications by 
high-performance capillary electrophoresis 
This analysis was performed as in Fraga et al. 2005, a method which is a 
variation of that one reported by Lindner et al. 1992. 
5.22.1. Histone fractionation by reverse phase high-perfomance 
liquid chromatography 
Histones isolated from 2·106 to 6·106 cells were dissolved in 0.2 mL and 
separated in a Jupiter® 5 µm C18 column (Phenomenex), protected by a 
SecurityGuard® C18-widepore guardacolumn cartridge (Phenomenex), in a Beckman 
HPLC gradient system (Beckman-Coulter). Flow was set at 1.0 mL/min, detection at 
220 nm and the mobile phase was: 
0-5 min 20% eluent B, 
5-65 min linear gradient from 20% to 80% eluent B, 
65-70 min linear gradient from 80% to 100% eluent B, 
70-75 min 100% eluent B, 
75-80 min linear gradient from 100% to 20% eluent B; 
where eluent A is 3% (v/v) HPLC-grade TFA (Merck) in water and eluent B 3% TFA 
in HPLC-grade acetonitrile (Merck). Between two consecutive injections, the system 
was allowed to equilibrate for 5 min with 20% eluent B. 
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 Eluate was collected in 0.5 mL fractions (FC 203B fraction collector, Gilson) 
and the ones containing H3 or H4 were freeze dried. Since we found H3 usually in 3 
consecutive fractions, these were pooled before lyophilization. 
5.22.2. High-perfomance capillary electrophoresis analysis of 
isolated histone fractions 
Capillary electrophoresis analysis of HPLC-fractionated histones was done by 
Dr. Mario F. Fraga according to the reported procedure (Fraga et al. 2005, Lindner et 
al. 1992) The non-, mono, di-, tri- and tetra-acetylated derivatives of H3 or H4 were 
resolved by high performance capillary electrophoresis (HPCE). A non-coated fused-
silica capillary (Beckman-Coulter) (60.2 cm x 75 mm, effective length 50 cm) was 
used in a CE system (P/ACE® MDQ, Beckman-Coulter) connected to a data-
processing station (32 KaratTM Software). The running buffer was 110 mM 
phosphate buffer, pH 2.0 containing 0.03% (w/v) (hydroxypropyl)methyl cellulose 
(Sigma). Running conditions were 25º C and operating voltage of 12 kV. On-column 
absorbance was monitored at 214 nm. Before each run, the capillary system was 
conditioned by washing with 0.1 M NaOH for 3 min, washing with 0.5 M H2SO4 for 2 
min and equilibrated with the running buffer for 3 min. Samples were injected under 
pressure (0.3 psi) for 3 s. 
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 6. Results 
6.1. Procaine: a novel DNA demethylating agent 
6.1.1. Procaine decreases global DNA methylation 
6.1.1.1. Concentration dependence of procaine induced DNA 
demethylation 
In order to investigate procaine-induced changes of 5-methylcytosine levels 
in genomic DNA, MCF7 cells were grown during 3 days in the presence of different 
concentrations of the drug (from 0.005 mM to 0.5 mM). Positive and negative control 
treatments were performed in parallel using either the well characterized DNA 
demethylating agent zdC (at 2.5 and 5.0 µM concentrations) or the solvent, 
respectively. DNA was extracted, hydrolysed and the resulting 2’-deoxynucleosides 
were separated by HPCE and detected by measuring the absorbance at 254 nm. This 
technique allows the quantitation of the proportion of the different bases present in 
DNA. Examples of electropherograms from different 2’-deoxynucleoside mixtures are 
shown in Fig. 15A (see Figure legend for details).  
The effect of procaine on the global content of 5-methylcytosine is shown in 
the next plot Fig. 15B. When procaine concentration increases, the area of the peak 
for mdC decreases respect to the area of the dC peak, however the effect is much 
less stronger than that one of zdC: 0.5 mM procaine is not enough to reduce DNA-
methylation as much as 2.5 µM zdC (Fig. 15B and C). 
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 Fig. 15: HPLC analysis of global DNA methylation. A) Two examples of electropherograms from 
different 2’-deoxynucleosides mixtures are shown. The upper graph corresponds to a standard 
solution containing equimolar amounts of each 2’-deoxynucleoside (dC, mdC, dA, dT, dU and 
dG). The lower plot is the electropherogram for hydrolysed genomic DNA from MCF7 cells. The 
yellow rectangle marks the peak for mdC. B) Enlargement of mdC peaks of DNA samples from 
MCF7 cells treated with different concentrations of procaine or zdC. Intensities are normalized 
taking as reference the peak for 2’-deoxycytidine. C) The diagram shows the percentage of 
mdC in genomic DNA relative to global dC content for different doses of procaine and zdC after 
3 days treatment.  
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 Further analysis of global DNA methylation was performed using 
methylation-sensitive restriction enzymes. Aliquots of genomic DNA from cells 
cultured with vehicle, 5.0 µM zdC, 0.25 mM or 1.0 mM procaine were digested with 
MspI or HpaII or McrBC. MspI and HpaII are isoschizomers: both recognize the 
sequence CCGG but, whereas MspI is insensitive to the methylation status of the 
second cytosine residue, HpaII only cuts if that residue is unmethylated. On the 
other hand, McrBC recognizes sites in the form (G/A)mC(N)40-3000 mC(G/A), where mC 
represents a 5-methylcytosine residue and (N)40-3000 any DNA sequence from 40 to 
3000 bp long (but the optimal length is 55 to 103 bp). McrBC cuts if one or both DNA 
strands are methylated. 
Digestion products were run in an agarose gel and visualized with ethidium 
bromide staining (Fig. 16). The strongest effects on DNA methylation were found 
with 5 µM zdC, since for this sample the smear with HpaII is very similar to that one 
got with MspI, but McrBC digestion was not as extensive as in the other cases. Both  
Fig. 16: Methylation-sensitive restriction enzyme analysis of genomic DNA isolated from 
procaine or zdC treated cells. HpaII does not cut if the recognition sequence is methylated, 
MspI is its methylation-insensitive isoschizomer and McrBC only cuts if the recognition site is 
methylated. DNA was visualized by ethidium-bromide staining after gel electrophoresis.The 
same picture is displayed in positive (upper panel) and negative (lower panel) colours. 
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 DNA samples from procaine treated cells seem to be slightly more digested by HpaII 
than the control DNA, but no effect could be observed in the McrBC reaction. These 
results reveal the same tendency as the ones obtained by HPCE: procaine induces 
some loss of DNA methylation but not as much as zdC. However, restriction enzyme 
digestion is not as quantitative and sensitive to variations in global methylation as 
high-performance capillary eletrophoresis. 
6.1.1.2. Time dependence of procaine induced DNA demethylation 
Next, the time dependence of DNA demethylation induced by procaine was 
studied and compared to the effects of procainamide and zdC. The same 
concentration of procaine and procainamide was chosen in order to make easier the 
comparison, given the structural similitude of both chemicals. MCF7 cells were 
cultured in parallel with 0.5 mM procaine, 0.5 mM procainamide or 5.0 µM zdC. After 
24 h, 48 h and 72 h treatments, DNA was extracted to measure the percentage of 
methylcytosine  by  HPCE.  The  result  of  the  quantitations is  displayed  in Fig. 17.  
Fig. 17: Time-dependence of DNA demethylation caused by procainamide, procaine and zdC at 
the indicated concentrations. The proportion of mdC was determined by HPCE. 
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 Procainamide and procaine reach their maximum effect about 24-48 h after drug 
addition. In contrast, the loss of methylation induced by zdC decreases continuously 
along the three days. Also the final mdC content in DNA is much lower in samples 
treated with zdC than in samples treated with procainamide or procaine. 
6.1.2. Procaine induces the expression of tumor-suppressor 
genes silenced by DNA hypermethylation 
6.1.2.1. Procaine reduces methylation at RARβ2 promoter. 
Once demonstrated that procaine is able to induce demethylation in a global 
genomic scale, we wondered whether the reduction of 5-methylcytosine content also 
occurs in aberrantly hypermethylated gene promoters. We selected the isoform 2 of 
retinoic acid receptor beta (RARβ2) gene, a well-known tumor suppressor gene 
silenced in MCF7 cells by hypermethylation of its promoter (Arapshian et al. 2000, 
Sirchia et al. 2000, Bovenzi et al. 2001, Esteller et al. 2002, Paz et al. 2003). 
In order to study procaine effects on RARβ2 promoter, cells were cultured 
for 3 days in medium containing different concentrations of procaine or zdC, DNA 
was extracted and modified with bisulfite. By using MSP, the presence of a 
population of non-methylated RARβ2 promoter alleles could be detected when 10 µM 
or more procaine was added to the cells as well as when 2.5 µM or 5.0 µM zdC were 
employed (Fig. 18A).  
To monitor the loss of methylation at single CpG resolution, bisulfite 
genomic sequencing of RARβ2 promoter was performed on DNA from non-treated 
cells, cells treated with 5.0 µM zdC and cells treated with 0.5 mM procaine. 
Amplification with the adequate primers (one pair was BS-RARβ2-S3 and BS-RARβ2-
AS3 and the other, BS-RARβ2-S2 and BS-RARβ2-AS2) was performed on bisulfite-
deaminated DNA, PCR products were isolated and sequenced. The analysis showed 
that zdC had the strongest effects on methylation but the loss of 5-methylcytosine is 
not as marked as one would expect from the effects of the same chemical on global 
DNA methylation. Procaine also reduces the level of methylation in the promoter 
(Fig. 18B). 
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 Fig. 18: Analysis of RARβ2 promoter methylation and gene expression. A) MSP analysis of 
RARβ2 promoter after treatment with procaine and zdC. Lines labelled with “U” correspond to 
the reaction with primers specific for the non-methylated sequence, whereas “M” labels the 
reactions with primers specific for the methylated sequence. Concentrations range from 0 (no 
drug) to 1.0 mM procaine and from 0 to 5.0 µM zdC. B) Genomic bisulfite sequencing of the 
RARβ2 promoter region by using the pair of primers BS-RARβ2-S2 and BS-RARβ2-AS2 for the 
region upstream to the transcription start site and the pair BS-RARβ2-S3 and BS-RARβ2-AS3 for 
the region downstream to it. Left: upper panel, part of the electropherogram for the untreated 
cells; middle panel, part of the electropherogram for the cells treated with 5.0 µM zdC and 
lower pannel, part of the electropherogram for the cells treated with 0.5 mM procaine. Right: 
Scheme displaying the percentage of methylation for each CpG in the promoter. Each circle 
represents a CpG dinucleotide and the colour code is given in the upper part of the figure. The 
boxes mark the CpG dinucleotides shown in the left panels. C) Semiquantitative RT-PCR 
measurement of changes in RARβ2 (upper panel) and β-actin (lower panel) expressions upon 
drug treatment. The different concentrations of drugs are indicated. RNA extracted from normal 
lymphocytes was used as positive control. 
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 6.1.2.2. Procaine reactivates RARβ2 transcription 
In order to see if that decrease of 5-methylcytosine was enough to recover 
gene expression, the presence of RARβ transcript was monitored by semiquantitative 
RT-PCR after 3 days of treatment. RNA extracted from normal lymphocytes was used 
as a positive control. As expected, concentrations of procaine over 50 µM increase 
the amount of RARβ2 transcript (Fig 18C).  
Fig. 19: Cell growth effects of procaine. A) Effect of different procaine and zdC concentrations 
on cell growth after 3 days treatment. B) Mitotic index expressed as % found in each of the 
indicated immunostained samples after 3 days of drug treatment. C) Time course of the effect 
of procaine and procainamide on cell growth. Left: 0.5 mM procaine and 0.5 mM procainamide; 
middle: 1.0 mM procaine and 1.0 mM procainamide and right: 2.0 mM procaine and 2.0 mM 
procainamide. In all the plots, untreated cells and 5.0 µM zdC were used as controls. 
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 6.1.3. Procaine reduces cell proliferation 
Finally, the influence of drug treatment in cell proliferation was examined. 
Firstly, cells were treated during 3 days with different concentrations of procaine 
(from 0.05 mM to 1.0 mM) or zdC (either 2.5 or 5 µM). Attached cells were 
harvested and counted in a Neubauer chamber. The number of procaine treated cells 
decreases in a dose-dependent manner. However, for all the tested concentrations 
zdC has a stronger effect than procaine (Fig. 19A). 
In order to investigate time-dependence of drug effects on cell proliferation, 
non-treated cells and cells grown with 5.0 µM zdC, 0.5, 1.0 or 2.0 mM procaine and 
0.5 1.0 or 2.0 mM procainamide for 24, 48 and 72 were counted. The results are 
plotted in Fig. 19C. For all the analysed concentrations, procaine slows cell 
proliferation more than procainamide. No alteration in the number of cells (relative to 
the controls) is observed with 0.5 mM procainamide at any time point whereas the 
same concentration of procaine retarded cell growth after the second day. When 
both chemicals were added at 1.0 or 2.0 mM, the number of cells per dish did not 
change during the first 24 h. If the concentration of the substances was 1.0 mM, the 
amount of cells increased in the second and third days, more in the plates treated 
with procainamide. The highest dose of procaine (2.0 mM) completely inhibited cell 
proliferation. 
Cytological changes upon 0.5 mM procaine and 0.5 mM procainamide 
treatments were studied in more detail using microscopical techniques. After 3 days 
with the corresponding drug, cells were fixed and stained with DAPI, to visualize the 
nuclei. We observed that both procaine and procainamide induced an increase in the 
number of mitotic figures, which was higher in the case of procaine treatment (Fig. 
19B and Fig. 20). In order to explore the extent of the apoptosis induced by these 
drugs, TUNEL assay was also performed. Serum starved cells were taken as positive 
control. This immunofluorescence technique is based on the enzymatic labelling of 
the free terminal 3’ hydroxyl groups in the DNA nicks that are generated during 
apoptosis. Fluorescein-dUTP was selected as the nick label in this work because it 
can be directly observed under a fluorescence microscope. As shown in Fig20, 
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 neither 0.5 mM procaine nor 0.5 mM procainamide triggered the apoptotic response 
in MCF7 cells.  
Fig. 20: TUNEL assay for analysis of apoptosis. DAPI (left panels) and TUNEL (right panels) 
staining of MCF7 cells after 3 days treatment. From left to right: untreated cells, cells after 3 
days serum starvation (TUNEL positive control), cells treated with 0.5 mM procaine, cells 
treated with 0.5 mM procainamide. Some mitotic figures are pointed by an arrow. 
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 6.2. Comparative study of seven HDACs inhibitors 
6.2.1. In vitro comparison of the HDAC inhibitory properties. 
6.2.1.1. Inhibition of the HDAC activity present in nuclear extracts  
In order to compare the ability of valproic acid, butanoic acid, MS-275, TSA, 
SAHA, CX and CY to inhibit Zn(II)-dependent HDACs contained in nuclei, in vitro 
HDAC activity assays were performed. To this end, MCF7 nuclear extracts were 
incubated in the presence of the drugs or vehicle, with hyperacetylated histones 
containing tritium-labelled acetyl groups. The acetic acid resulting from the hydrolysis 
was extracted with ethyl acetate and the liberated counts were measured. The 
released radioactivity is proportional to the acetate groups hydrolysed from histones. 
The results displayed in Fig. 21A are the average of two independent 
experiments. All the substances inhibit to some extent the HDAC activity contained in 
MCF7 nuclear extract. Hydroxamic acids are the most potent chemicals, showing 
significant effect already at micromolar concentrations: 60% of the activity is 
abolished by 0.1 µM TSA and 10 µM CX, near 70% is inhibited by 1.0 µM SAHA and 
1.0 µM CY abolishes about 50% of the HDAC acitvity. All these four compounds at 50 
µM concentration block almost completely the HDAC activity in the extracts. On the 
other hand, to reach a similar degree of inhibition, millimolar concentrations of 
carboxylic acids (butanoic and valproic acid) are necessary. 
In the same extract, benzamide MS-275 has very little effect on HDAC 
activity at concentrations up to 50 µM. The increase in the concentration of this 
compound caused the appearance of a precipitate in the reaction mixture, thus the 
dose of this chemical which is necessary for the inhibition of more than 50% of the 
activity present in the extract could not be determined. 
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 Fig. 21: In vitro HDAC assays A) In vitro inhibitory activity assay. Aliquots of MCF7 nuclear 
extract were incubated for 10 min at r.t. with the indicated concentration of chemicals (butanoic 
acid, valproic acid, MS-274, TSA, SAHA, CX, CY), then radiolabelled histones were added and 
reaction was allowed to proceed for 2 h at 37ºC. After quenching, acetic acid was extracted 
with ethyl acetate and counts of the organic phase were measured. In the graphic, the resulting 
counts for each reaction are normalised to the reaction in absence of HDAC inhibitor. B) In vitro 
inhibitory activity assay with immunoprecipitated HDAC1 and HDAC5. Values are relative to the 
activity of the equivalent volume of crude nuclear extract. “No extract” is the control reaction 
with no addition of any enzyme, “no antibody” is the control immunoprecipitation with no 
primary antibody and “no drug” is the reaction of the immunoprecipitated extracts with histones 
in the absence of inhibitor. Both immunoprecipitations were performed in parallel. The results 
for HDAC1 are shown in brown and, for HDAC5, in yellow. 
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 6.2.1.2. Inhibition of immunoprecipitated HDAC1 and HDAC5 
In order to explore a potential specific inhibition for particular HDACs, 
HDAC1 and HDAC5 were immunoprecipitated from nuclear extracts. Only the anti-
HDAC1 antibody immunoprecipitated a significant amount of activity (Fig. 21B). At 
the employed concentrations, all the substances tested with these preparations (MS-
275, valproic acid, CY and TSA) reduced HDAC1 activity to the background level. 
6.2.2. HDACs inhibitors stop MCF7 cell proliferation 
6.2.2.1. Determination of the IC50 for 24 h treatments 
An important characteristic of anticancer drugs is the ability to inhibit cancer 
cell proliferation and/or cause apoptosis of cancer cells. In a first approach to 
compare the antiproliferative effects of the seven HDACs inhibitors on MCF7 cells, 
the IC50 for 24 h-treatments was determined. The IC50 is defined as the 
concentration of substance necessary to get, at the end of the treatment, half as 
many cells as if there would not be any drug. Additionally, the use of the IC50 for the 
experiments on cells provides a good reference to compare the effects of compounds 
with diverse chemical nature.  
It is widely reported that 24 h incubations with HDAC inhibitors are long 
enough to result in extensive histone hyperacetylation in cultured cells. These reports 
include the drugs employed in this study (see for instance, Göttlicher et al. 2001, 
Plumb et al. 2003, Munster et al. 2001, Catley et al. 2003, Saito et al. 1999). 
Because of this reason, all the treatments we performed on MCF7 cells with the 
HDACs inhibitors were 24 h long. 
Cells were cultured for 24 h with different concentrations of each 
compound, harvested and counted. The resulting IC50 values are shown in Fig. 22A. 
Millimolar concentrations of valproic and butanoic acid are required to alter cell 
proliferation, whereas hydroxamic acids and MS-275 slowed proliferation at 
micromolar concentrations. 
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Fig. 22: Effects of the seven HDACs inhibitors on cell cycle. A) IC50 concentrations of each drug 
for MCF7 cell growth after 24 h treatment. B and C) Cell cycle analysis of cells treated for 24 h 
with different HDACs inhibitors at their IC50 concentration. B) Examples of histograms which 
were used to calculate the data shown in C. C) Table with the percentage of cells in each phase 
(values are the average of two independent experiments). 
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 6.2.2.2. Structure-activity relationship between the chemicals and 
the induced cell cycle arrest 
Cells treated during 24 h with each inhibitor at the corresponding IC50 
concentration were harvested, fixed and submitted to flow cytometry analysis with 
propidium iodide staining of the nuclei. Examples of the resulting histograms are 
shown in Fig. 22B and the results of the integration, in Fig. 22C. All the chemicals  
reduced the proportion of cells in S phase. Hydroxamic and carboxylic acids induced 
arrest in G2/M, but the second ones also produced the block of the G1 to S 
transition. MS-275 stopped the cycle only in G1/G0. With all the hydroxamic acids 
and with butanoic acid a small amount of cells in the sub-G0 region (related to cell 
death) was observed. 
6.2.3. HDACs inhibitors induce global H3 and H4 
hyperacetylation in MCF7 cells 
6.2.3.1. All the seven inhibitors induce similar changes in 
acetylation of H3 and H4 
Next, it was addressed if, the inhibition of certain HDACs causes the 
accumulation of hyperacetylated histones in cells. Thus, we compared the ability of 
valproic acid, butanoic acid, MS-275, TSA, SAHA, CX and CY to induce an increase of 
histone acetylation in MCF7 cells. Histone extracts from cells treated with the 
chemicals or vehicle were prepared. After HPLC isolation of H3 and H4 from the 
extracts, both histones were analysed sequentially by HPCE. Under the selected 
running conditions, the electrophoretic mobility of histones is determined by the 
degree of acetylation, allowing the separation of non-, mono-, di-, tri- and 
tetraacetylated H3 or H4. If absorbance at 220 nm is employed for detection, the 
integration of the peaks in the electropherogram can be used to calculate the 
proportion of the different species. The scheme of the analysis is depicted in Fig. 23. 
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 Fig. 23: H3 and H4 acetylation analysis by HPCE. A) Scheme of the general procedure. B and 
C) Typical electropherograms of H4 and H3 (respectively) in MCF7 cells: upper plots, untreated 
cells; lower plot, cells treated for 24 h with 1.0 µM CY. 
 
Firstly, the response of the cells to the IC50 concentration of the drugs was 
analysed. All the compounds induced very similar changes in H3 acetylation (Fig. 24A 
and C): the proportion of species with at least one acetyl group is doubled respect to 
the untreated cells and with all the treatments, the diacetylated form is the 
predominant, the amount of monoacetylated is slightly less and the tetraacetylated 
species constitutes a very small proportion. 
However, the influence of the inhibitors on H4 is more heterogeneous (Fig. 
24B and D). In general, the proportion of monoacetylated H4 doubles upon 
treatment, but some substances, like MS-275, increase this value more than others 
like CX or TSA. Also the distribution of the acetylated species is not uniform, ranging 
from the changes induced by CX (in this case the monoacetylated H4 is the 
predominant and the tetraacetylated represents a very small proportion) to the ones 
caused by MS-275 (the major form is the triacetylated but the di- and the 
tetraacetylated species are in comparable amounts). 
We also analysed the effects of the drugs on H4 at lower concentrations. To 
simplify the experiment, we selected 3 substances, one from each chemical class: 
butanoic acid, MS-275 and CY. All these  three  drugs  were  added  to  the  
extract enriched in nuclear 
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 Fig. 24: Acetylation changes induced by the drugs when added to the cells at the IC50 
concentration during 24 h. Proportion of the different species was measured by HPCE. A, B) 
Acetylation of H4 and H3 (respectively) expressed as percentage of species with at least one 
acetyl group. C, D) Proportion of non-acetylated (black), mono- (red), di- (yellow), tri- (green) 
and tetraacetylated (blue) H4 or H3 (respectively). 
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 Fig. 25: Analysis of changes in histone H4 acetylation. Distribution of histone H4 with different 
degree of acetylation after 24 h treatment with MS-275 (left), butanoic acid (middle) and CY 
(right) at the following concentrations: 0.1-fold, 0.4-fold, 0.7-fold and 1.0-fold IC50. Colour code 
as in Fig. 24: black means no acetyl groups; red, monoacetylation; yellow, diacetylation; green, 
triacetylation and blue, tetraacetylation. 
 
 
cells at 0.1-fold, 0.4-fold, 0.7-fold and 1.0-fold IC50 concentration, histones were 
extracted and analysed as described above. The results are displayed in Fig. 25. With 
all the three compounds, monoacetyl H4 is the major species at 0.1-fold IC50 and no 
other of the tested concentrations induced as much monoacetylation. The proportion 
of diacetylated species seems to reach its maximum from 0.4-fold to 0.7-fold IC50 
while the fractions corresponding to tri- and tetraacetyl H4 increase continuously 
with the concentration of drug. Almost no difference is seen when comparing the 
plot for butanoic and the plot for MS-275, while the response to CY seems to be less 
concentration-dependent: when the amount of drug varies from 0.1-fold to 1.0-fold 
IC50, the drop in the proportion of the low-acetylated species (non- and 
monoacetylated) and the augment in the percentage of the high-acetylated forms 
(tri- and tetraacetylated) is not as pronounced as in the other two cases. 
6.2.3.2. Changes in global histone acetylation analysed by Western 
blotting 
An alternative way of investigating changes in histone acetylation is the use 
of Western blotting with antibodies that recognize the acetylated N-termini of 
histones. We have chosen one for H4 raised against the fully acetylated histone tail 
and another which is specific for H3 tail with both K9 and K14 acetylated (see Table 
7 for details). The load control was performed with antibodies that bind the C-termini 
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 Fig. 26: Effects of drug treatments on H3 and H4 acetylation. Western blotting against 
diacetylated H3 (AcH3, left panel) and tetraacetylated H4 (AcH4, right panel). Cells were 
treated with each drug for 24 h at the IC50 concentration, histones were extracted and Western 
blotting was performed. Antibodies against C-terminus of H4 and H3 were used as load control. 
Membranes were probed sequentially with the anti-acetylated histone and the corresponding 
control antibodies. 
 
of H3 and H4 respectively. 
Both Western blotting and HPCE have their advantages and inconveniences 
in the study of acetylation. Capillary electrophoresis is a quantitative technique but 
requires higher amount of sample than Western blotting. On the other hand, 
Western blotting and other antibodies-based techniques can give some information 
about the positions whose acetylation is changing. 
In Fig. 26 Western blottings against acetyl H4 and acetyl H3 are shown. For 
that experiment, histones were extracted from cells maintained for 24 h with the 
drugs at their corresponding IC50 concentration. Neither acetylation in H3 nor in H4 
could be detected in the untreated cells with the employed antibodies but all the 
treated samples gave some signal. In the case of H4, the intensities of the bands 
correlate with the percentage of tetraacetylated species calculated by HPCE: the 
strongest bands are for MS-275 and CY and the weakest one for CX. In agreement 
with the HPCE results, no major differences could be observed in acetylation of H3 
induced by the different chemicals. 
6.2.4. None of the seven HDACs inhibitors alters HDAC1 or 
HDAC2 protein levels in MCF7 cells 
Some HDACs inhibitors are known to alter the expression and the 
degradation of diverse HDACs and these phenomena can also affect global histone 
acetylation (Ajamian et al. 2003, Krämer et al. 2003). For instance, valproic acid  
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 Fig. 27: Effects of drug treatments on HDACs expression. Western blotting against HDAC2 and 
HDAC1. The nuclear protein LAP2 was used as loading control. Cells were treated for 24 h with 
the indicated drug at the IC50 concentration, whole cell extract were prepared and samples 
employed for Western blotting. 
 
induces degradation of HDAC2 (Krämer et al. 2003). Because of that, we analysed 
the protein levels of HDAC1 and HDAC2 after drug treatment. 
Whole cell protein extracts were prepared after treating the cells with the 
chemicals at the IC50 concentration. No changes in HDAC1 or HDAC2 protein 
amounts were observed in Western blots (Fig. 27). 
6.2.5. Histone acetylation restores the expression of tumor-
suppressor genes 
6.2.5.1. Tumor-suppressor genes silenced by histone 
hypoacetylation. 
Once analysed the HDAC inhibitory properties of these chemicals in vitro 
and their ability of inducing global histone hypoacetylation in cultured cells, the 
possible changes in histone modifications at the promoters of certain genes were 
addressed. The six target genes were selected among those whose expression has 
been reported to increase upon treatment with HDACs inhibitors. The details and the 
references are listed in Table 8. 
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13
0
 CDKN1A is one of the proteins that control cell transition from G1 to S 
phase. Its expression is considered to be reactivated by all the HDAC inhibitors in all 
the systems where it is silenced through promoter deacetylation. GADD45β is 
thought to be responsible for the cell cycle arrest in G2/M that HDACs inhibitors 
induce under certain circumstances. JUND is a transcription factor belonging to the 
AP-1 family. Its ability to slow cell growth has been reported. IGFBP3 codes for a 
protein not only involved in modulation of IGF signalling but also in growth arrest or 
apoptosis in different cells, such as our model MCF7. Metallothionein IX and 2A are 
part of the metallothionein cluster (chromosome 16), constituted by genes coding for 
proteins that are involved in the metabolism of transition metal ions either essential 
(zinc, copper) or toxic (cadmium, mercury). Depending on the type of tumor, 
different profiles of overexpression or downregulation of metallothioneins are found. 
These proteins could also be responsible for the resistance to some antineoplastic 
treatments like cisplatin and radiation. 
6.2.5.2. Selective response of gene expression to HDACs inhibitors 
The changes in transcription were analysed for all the 6 genes by 
semiquantitative RT-PCR after culturing the cells for 24 h with the different chemicals 
at the IC50 dose. The house-keeping gene GAPDH was used as load control. The 
results are shown in Fig. 28A. Under the employed PCR conditions, CDKN1A mRNA is 
not detected in the untreated cells, but all of the inhibitors induce its expression in 
similar extents. Transcription of JUND is similarly increased, but in this case CY is 
much less efficient than the other drugs. Except for MS-275, all the chemicals 
enhance the expression of GADD45β and IGFBP3, however the response of the latter 
gene seems to be more drug-dependent. The transcription of MT1X and MT2A seem 
to be unaltered by the addition of the chemicals to the cells. 
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Fig. 28: Analysis of the expression and promoter methylation of CDKN1A, GADD45β, JUND, 
IGFBP3, MT1X and MT2A. A) Results of the semiquantitative RT-PCR. MCF7 cells were treated 
for 24 h with the seven compounds at the IC50 concentration. GAPDH was used as load control. 
B) Maps showing the promoter areas of the six analysed genes. Transcription start is indicated 
by the grey arrow and the position of the oligos employed for ChIP, by the black arrows. The 
result of the bisulfite genomic sequencing analysis for each gene is summarized in the graphics 
with circles: each circle represents a CpG dinucleotide, white if methylation is not detected and 
black if the cytosine residues are fully methylated. 
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 6.2.5.3 None of the studied genes is silenced by DNA 
hypermethylation 
The promoters of CDKN1A, GADD45β, JUND, IGFBP3, MT1X and MT2A are 
CpG islands. As indicated in the Introduction, the hypermethylation of CpG islands 
associated to promoters causes gene silencing. To know whether this phenomenom 
contributes in MCF7 cells to the silencing of the six studied genes, the corresponding 
promoters were analysed by bisulfite genomic sequencing. The result shows clearly 
that all of them are devoid of 5-methylcytosine. Maps of the sequenced regions are 
displayed in Fig. 28B. 
6.2.5.4. HDACs inhibition alters HDAC2 recruitment and histone 
modifications at gene promoters 
Finally, chromatin immunoprecipitation assays were carried out to evaluate 
the possible alterations at the promoters of these genes caused by the drugs. In 
order to reduce the number of samples to handle, only untreated cells (“control” 
cells) and cells grown for 24 h in the presence of 1.0 µM CY were compared. 
It has been discussed in section 3.1.6 that the epigenetic mechanisms 
interact with each other. Thus, the presence of histone modifications different than 
acetylation could also be affected by HDACs inhibition. Therefore, we not only 
analysed the association of tetraacetylated H4 to the promoters, but also the 
presence of dimethylated K4H3 and K9H3 before and after CY treatment. The 
locations of the primers used for each gene are shown in the maps in Fig. 28B. For 
all the promoters studied, treatment with CY results in an increase of the two 
modifications associated with transcriptionally active chromatin: acetylated H4 and 
dimethylated K4H3. The signals indicating the presence of dimethylated K9H3 in the 
promoters of both MT1X and MT2A disappear upon CY treatment (Fig. 29). 
The binding of HDAC1 and HDAC2 to the promoters was also studied, in 
order to see if there was any release of these enzymes due to the inhibition. The 
result showed that HDAC2 disappears from most of the promoters (CDKN1A, JUND, 
133
 IGFBP3, MT1X and MT2A) in the cells treated with CY. The presence of HDAC1 is 
only visible at the MT2A promoter (Fig. 29). 
Fig. 29: ChIP analysis of the changes in histone modifications and HDACs recruitment at the 
promoters of CDKN1A, GADD45β, JUND, IGFBP3, MT1X and MT2A upon CY treatment. 
Immunoprecipitations were performed with anti-dimethylated K4H3 (MeK4H3), anti-
tetraacetylated H4 (AcH4), anti-dimethylated K9H3 (MeK9H3), anti-HDAC1 and anti-HDAC2 
antibodies. “control” are the untreated cells, “CY” are the samples treated with 1 µM CY, “bd” 
means bound fraction and “unb”, unbound fraction. 
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 7. Discussion 
7.1. Procaine: a novel DNA demethylating agent 
7.1.1. Possible mechanisms of procaine-induced DNA 
demethylation 
Procaine is a substance that reduces the content of 5-methylcytosine in 
genomic DNA of MCF7 cells. However, the behaviour of this chemical is different than 
that of zdC. Firstly, after 3 days of treatment, doses of procaine as high as 0.5 mM 
are not as potent in decreasing DNA methylation as micromolar concentrations of 
zdC (Fig. 15 and 16). Second, the evolution of 5-methylcytosine proportion in DNA 
along the 3 days of treatment is very different from one drug to the other one: 
whereas zdC treatment results in a continuous strong reduction in DNA methylation, 
procaine (also procainamide) reaches its maximum effect between the first and the 
second day and,after that,the amount of 5-methylcytosine remains constant (Fig.17). 
The different behaviour can be explained by considering that zdC and 
procaine induce DNA demethylation through different mechanisms. As mentioned in 
the introduction, zdC is a deoxynucleoside that becomes phosphorylated in the cell 
and the resulting dNTP is incorporated into the DNA during the S phase of the cell 
cycle (Taylor and Jones 1982). Once incorporated into DNA, zdC inhibits the DNMTs 
by trapping covalently these enzymes (reviewed in Christman 2002). Although the 
mechanism of procaine action is not clear, since this chemical is not a nucleoside or 
derivative, it seems obvious that its activity does not come from its incorporation into 
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 DNA. Thus, contrary to zdC, procaine does not need any DNA replication round to be 
able of inhibiting the DNMTs. This fact could explain why procaine reaches its 
maximum effect faster than zdC. 
Procainamide, structurally related with procaine (see Fig. 9), inhibits DNA 
methylation in vitro, probably due to DNA-competitive inhibition of the DNMT activity 
(Scheinbart et al. 1991, Cornacchia et al. 1988, Deng et al. 2003). Procainamide and 
also hydralazine bind naked DNA (either linear or circular) and induce B to Z 
transitions in DNA structure. The alteration of DNA structure could interfere with 
protein-DNA interactions, including DNMTs activity (Thomas and Messner 1986, 
Zacharias and Koopman 1990). Since both procaine and procainamide are 
substances with a very similar chemical structure, it can be suggested that both act 
through the same mechanism. 
However, demethylation can be induced by other mechanisms different than 
DNMT enzymatic activity inhibition. Hydralazine produces a decrease in DNMT1 and 
DNMT3A expression by affecting the MAPK pathway. This is thought to be the 
mechanism by which this chemical induces genomic DNA demethylation, rather than 
the alteration of DNA structure that hydralazine causes in vitro (Deng et al. 2003). It 
has not been studied if procainamide or procaine have a similar effect on DNMTs 
expression levels. 
In any case, the fact that procaine is not incorporated into DNA could be an 
advantage over zdC. As described in the introduction, zdC incorporated into DNA is 
mutagenic due to the lability of the 5-azacytosine ring and to the covalent trapping 
of DNMTs. 
7.1.2. Low procaine concentrations cause demethylation of 
tumor-suppressor genes 
Procaine causes demethylation of RARβ2 promoter and restores the 
expression of this gene. However, the concentrations of drug required to achieve 
these two effects are higher for procaine than for zdC (Fig. 19A and C). Bisulfite 
genomic sequencing shows that 0.5 mM procaine is not able of inducing as much 
demethylation as 5.0 µM zdC (Fig. 19B). 
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 Similarly, procainamide (the analog of procaine) reduces promoter 5-
methylcytosine content in other cancer cell lines and even in murine models. That is 
the case of the genes encoding for 11β-hydroxysteroid dehydrogenase type 2 
(Alikhani-Koopaei et al. 2004) and glutathione S-transferase P (GSTP1) (Lin et al. 
2001). Moreover, procainamide causes demethylation of promoters of several tumor 
suppressor genes in cancer patients (Segura-Pacheco et al. 2003). 
One of the major drawbacks for the use of DNA demethylating agents as 
chemotherapy drugs is that global DNA hypomethylation causes chromosomal 
instability (see 3.2.2.3). The fact that low concentrations (10-50 µM) of procaine 
induce tumor-suppressor genes expression and promoter demethylation without 
major changes in global DNA methylation could be an advantage for a possible use 
of procaine as anticancer agent. 
7.1.3. Causes for cell cycle arrest: global DNA-demethylation vs. 
tumor-suppressor genes reactivation 
In 3-days treatments, procaine has a stronger effect on MCF7 cells 
proliferation than procainamide but weaker than zdC (Fig. 19). The absence of 
TUNEL-positive cells and the increase in the proportion of mitotic figures after 
treating the cells with 0.5 mM procaine suggest that this substance triggers mitotic 
arrest in MCF7 rather than apoptosis (Fig. 19 and 20). Procainamide also arrests 
MCF7 cell cycle in mitosis (19% mitotic index), but less efficiently than procaine does 
(32% mitotic index). 
The alterations induced by procaine and procainamide in cell cycle may be 
mediated by the reactivation of tumor suppressor genes silenced through 
hypermethylation, by the defects in chromatin condensation due to global DNA 
hypomethylation or by side effects unrelated to its demethylating properties. These 
three possibilities are not excludent. The two first ones were already discussed in 
section 3.3. Regarding the third one, both procaine and procainamide are known ion 
channel blockers, thus these chemicals can interfere with metabolic reactions 
different than the epigenetic mechanisms. 
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 7.2. Comparative study of seven HDACs inhibitors 
7.2.1. Structure-activity relationship for the in vitro inhibition of 
HDACs 
In order to compare the HDAC inhibitory capacity of valproic acid, butanoic 
acid, MS-275, TSA, SAHA, CX and CY, we performed in vitro assays using MCF7 
nuclear extracts as source of HDACs and hyperacetylated free histones as substrate. 
As indicated in the introduction, HDAC1, HDAC2, HDAC3 and HDAC8 are the class I 
HDACs and all of them are nuclear proteins. Additionally, class II enzymes can be 
present in the nucleus. Thus, in the MCF7 nuclear extract there are several Zn(II)-
dependent HDACs. Although the catalytic domain of these enzymes is highly 
conserved, its amino acid composition varies slightly among them. As result, the 
HDACs inhibitors show different degrees of specificity for the different HDACs (see 
Table 9). For instance, HDAC4 is less senstitive to TSA than HDAC1 is (Furumai et al. 
2001); HDAC3 is less sensitive to MS-275 than HDAC1, HDAC4 or HDAC6 (Hu et al. 
2003, Glaser et al. 2004); and the concentration of SAHA and TSA necessary to 
inhibit HDAC8 is higher than the concentration to inhibit HDAC1 or HDAC3 (Vannini 
et al. 2004). Moreover, not in all the enzymes Zn(II) cation is accessible for a bulky 
functional group like the benzamide. For example, recent molecular modelling and 
crystallographic data show that the catalytic pocket of HDAC8 is narrower than that 
one of the other HDACs (Schultz et al. 2004,Vannini et al. 2004, Somoza et al. 2004). 
This finding explains why MS-275 inhibits HDAC1 and HDAC3, enzymes with a wide 
catalytic tube, but not HDAC8 (Vannini et al. 2004). In summary, not all the HDACs 
present in MCF7 nuclear extract are inhibited to the same extent by each drug. 
In our assay, all the seven substances inhibit the HDAC activity contained in 
the nuclear extracts, with a clear structure-activity relationship (Fig. 21A). According 
to the results of the in vitro activity assay, the chemicals can be grouped in 3 sets. 
The first one is constituted by the hydroxamic acids, TSA, SAHA, CX and CY, which 
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 are effective at low micromolar concentrations. The chemicals in the second group, 
the small carboxylic acids, are active at millimolar concentrations. Finally the 
benzamide MS-275 has an intermediate inhibitory capacity since 50 µM MS-275 
reduces only 40% the activity of the whole nuclear extract. However, 50 µM MS-275 
suppresses completely the activity of immunoprecipitated HDAC1 (Fig. 21). 
In Table 9 there is a summary of representative in vitro data published for 
these substances. The reported results for valproic acid inhibition of HeLa nuclear 
extracts are compatible with the values we obtained (Phiel et al. 2001). In the case 
of butanoic acid, the IC50 values found in the literature for in vitro assays are lower 
than the ones obtained in our system (see Table 9). Also for the hydroxamic acids 
(TSA, SAHA, CX and CY) most of the published inhibitory concentrations are one or 
two orders of magnitude lower than the ones found in this study. We could only 
observe partial inhibition with 50 µM MS-275, whereas most of the reported 
inhibitory concentrations for MS-275 range between 0.3 and 6.0 µM (see Table 9 for 
details). All these discrepancies can be due to the different experimental systems 
employed: for this work whole nuclear extracts were used and, in the literature, 
either pure HDACs (recombinant or endogenous) or partially purified nuclear extracts 
were the source of the HDAC activity. The whole nuclear extracts may contain 
proteins or factors that influence HDAC activity and which are not present in the 
reactions with recombinant, immunoprecipitated or purified HDACs. Also the 
existence of several HDACs in the nuclear extracts may affect the reaction. For 
instance, HDAC8 may account for the poor effect of 50 µM MS-275 in our nuclear 
extract (Vannini et al. 2004). Moreover, in some reported experiments, the 
substrates for the enzymes were not histones but synthetic peptides. The variability 
of the HDAC catalytic domain may also be responsible for different substrate 
specificity, resulting in different kinetic constants for each HDAC-substrate couple. 
Despite the differences, there are some common features between our 
results and the published data. In all the reported studies the concentration of 
butanoic acid necessary for the significant HDAC inhibition is in the same order of 
magnitude than the concentration of valproic acid and about 4 orders of magnitude 
higher than the concentration of hydroxamic acids, like in our experiments. Also, the 
required concentration of MS-275 is higher than that one of the hydroxamic acids 
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 and SAHA is slightly less efficient than TSA both in the literature and in our 
experiments (Remiszewski et al. 2003, Vannini et al. 2004). 
 
 
 
Table 9: Representative data of in vitro HDACs inhibition 
Drug Activity (1) Substrate  IC50/µM References 
valproic 
acid 
HeLa nuclear extract histones from HeLa 500-2000 Phiel et al. 2001 
valproic 
acid 
HeLa endogenous HDAC1 histones from HeLa 400 Phiel et al. 2001 
butanoic 
acid 
Jurkat endogenous HDAC1 H4-tail peptide 100 Emiliani et al. 1998 
butanoic 
acid 
Jurkat endogenous HDAC3 H4-tail peptide 100 Emiliani et al. 1998 
butanoic 
acid 
partially purified FM3A n.e.  histones 120 Kim et al. 1999 
MS-275 partially purified K562 n.e. histones from K562 1.5-2.0 Saito et al. 1999, 
Glaser et al. 2004 
MS-275 rec. Flag-tagged HDAC1  histones 1.2 Fournel et al. 2002 
MS-275 rec. His-tagged HDAC1  H4-tail peptide 0.3 Hu et al. 2003 
MS-275 rec. His-tagged HDAC3  H4-tail peptide 8.0 Hu et al. 2003 
MS-275 rec. His-tagged HDAC8 H4-tail peptide >100 Hu et al. 2003 
MS-275 HDAC1/2 from K562 H4-tail peptide 1.5 Glaser et al. 2004 
MS-275 rec. His-tagged HDAC3  H4-tail peptide 6.1 Glaser et al. 2004 
MS-275 rec. His-tagged HDAC4 2) H4-tail peptide 0.8 Glaser et al. 2004 
MS-275 rec. His-tagged HDAC6  H4-tail peptide 0.6 Glaser et al. 2004 
MS-275 partially purified K562 n.e. histones from K562 2.4 Li et al. 2004 
MS-275 rec. His-tagged HDAC1  histones from K562 6.0 Li et al. 2004 
MS-275 partially purified H1299 n.e. biot. H4-tail peptide >10 Remiszewski et al. 2003 
MS-275 rec. Flag-tagged HDAC1  histones 0.18 Vannini et al. 2004 
MS-275 rec. Flag-tagged HDAC3 histones 0.20 Vannini et al. 2004 
MS-275 rec. His-tagged HDAC8 histones >10 Vannini et al. 2004 
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 Table 9 (cont.) 
Drug Activity (1) Substrate IC50/µM References 
TSA Jurkat endogenous HDAC1 H4-tail peptide 0.002 Emiliani et al. 1998 
TSA Jurkat endogenous HDAC3 H4-tail peptide 0.002 Emiliani et al. 1998 
TSA partially purified FM3A n.e. histones 0.0014 Kim et al. 1999 
TSA rec. His-tagged HDAC1 H4-tail peptide 0.1-0.3 Hu et al. 2003 
TSA rec. His-tagged HDAC3 H4-tail peptide 0.1-0.3 Hu et al. 2003 
TSA rec. His-tagged HDAC8  H4-tail peptide 0.1-0.3 Hu et al. 2003 
TSA partially purified K562 n.e. histones from K562 0.004 Li et al. 2004 
TSA rec. His-tagged HDAC1  histones from K562 0.001 Li et al. 2004 
TSA rec. HDAC1 histones from Jurkat 0.005 Woo et al. 2002 
TSA rec. Flag-tagged HDAC1 histones 0.006 Furumai et al. 2001 
TSA rec. Flag-tagged HDAC4 histones 0.04 Furumai et al. 2001 
TSA rec. HA-tagged HDAC6  histones 0.009 Furumai et al. 2001 
TSA partially purified H1299 n.e. biot. H4-tail peptide 0.026 Remiszewski et al. 2003 
TSA rec. Flag-tagged HDAC1  histones 0.001 Vannini et al. 2004 
TSA rec. Flag-tagged HDAC3 histones 0.0006 Vannini et al. 2004 
TSA rec. His-tagged HDAC8 histones 0.49 Vannini et al. 2004 
SAHA partially purified K562 n.e. histones from K562 0.1 Glaser et al. 2004 
SAHA HDAC1/2 from K562 H4-tail peptide 0.03 Glaser et al. 2004 
SAHA rec. His-tagged HDAC3  H4-tail peptide 0.04 Glaser et al. 2004 
SAHA rec. His-tagged HDAC4 (3) H4-tail peptide 0.04 Glaser et al. 2004 
SAHA rec. His-tagged HDAC6  H4-tail peptide 0.06 Glaser et al. 2004 
SAHA partially purified K562 n.e. histones from K562 0.12 Li et al. 2004 
SAHA rec. His-tagged HDAC1  histones from K562 0.15 Li et al. 2004 
SAHA rec. His-tagged HDAC3 histones from K562 0.12 Li et al. 2004 
SAHA partially purified H1299 ne biot. H4-tail peptide 0.2 Remiszewski et al. 2003 
SAHA Rec. Flag-tagged HDAC1  histones 0.12 Vannini et al. 2004 
SAHA Rec. Flag-tagged HDAC3 histones 0.11 Vannini et al. 2004 
SAHA Rec. His-tagged HDAC8 histones 4.0 Vannini et al. 2004 
CX HeLa nuclear extract H4-tail peptide 0.027 XXXXXXXXXXXXXXX 
CY Partially purified H1299 n.e. biot. H4-tail peptide 0.03 YYYYYYYYYYYYYYY 
(1) Rec. stands for recombinant, n.e. for nuclear extract, biot. for biotinylated. All the 
mentioned cell lines are human, except for FM3A, which is derived from mouse. (2) 
HeLa cells are used to express HDAC4. After the purification, some endogenous 
HDAC3 remains in the preparation. 
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 7.2.2. Effects on global histone acetylation may depend on the 
inhibition of only a subset of HDACs 
As determined by Western blots with anti-diacetylated H3 and anti-
tetraacetylated H4 antibodies as well as by HPCE analysis of the purified histones, all 
the seven chemicals induced a similar degree of hyperacetylation of both H4 and H3 
when employed at the IC50 concentration for 24 h treatments in MCF7 cells (Fig. 24 
and 26). Surprisingly, H3 and H4 histone hyperacetylation caused by 5 µM MS-275 is 
comparable to that one caused by the other drugs when used at their respective 
IC50. Considering that 5 µM MS-275 is not able to inhibit significantly in vitro the 
HDAC activity contained in MCF7 nuclear extracts, the H3 and H4 hyperacetylation 
induced by 5 µM MS-275 strongly suggests that only a subset of Zn(II)-dependent 
HDACs is responsible for most of the deacetylation of H3 and H4 in MCF7 cells, and 
that this function cannot be replaced by other enzymes. 
All the drugs seem to have similar efficiency in inducing the acetylation of 
H3, but the response of H4 varies slightly. Some substances, such as MS-275, CY 
and TSA, induce a higher proportion of tri- and tetraacetylated species than others, 
namely SAHA, CX and valproic acid. Many reasons can be argued to explain these 
differences, from the different affinity of the chemicals for specific HDACs that could 
play different roles in H4 deacetylation, to different side-effects, the solubility of the 
drugs, etc. 
There are no major differences in the proportion of non-, mono-, di-, tri- 
and tetraacetylated H4 induced by MS-275, butanoic acid and CY if the concentration 
of the drugs referred to their respective IC50 is the same (Fig. 25). Moreover, the 
plots for MS-275 and butanoic acid are almost superimposable. 
In summary, according to the data obtained by HPCE and Western blotting 
with antibodies against diacetylated H3 and tetraacetylated H4, there is no clear 
structure-activity relationship between the chemicals and the effects on global 
histone H3 and H4 acetylation if the inhibitors are added to the cells at the same 
concentration (referred to the IC50). Also, the induction of H3 and H4 
hyperacetylation may not require the inhibition of all the Zn(II)-dependent HDACs. 
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 7.2.3. Structure-activity relationship for the induced cell cycle 
arrest: effects on global acetylation vs. effects on gene 
expression 
There are two non-excludent models to explain the mechanism by which 
HDACs inhibitors cause cell cycle arrest and apoptosis. As described in the 
introduction, the first one considers that these effects are due to the induced 
overexpression of tumor suppressor genes. The second one proposes that the 
disruption of the chromatin structure caused by bulk histone hyperacetylation 
triggers the mechanisms for cell cycle control and apoptosis. 
In our experiments, in general, the concentrations for the inhibition of cell 
growth after 24 h treatment and that ones necessary for the inhibition of the activity 
in nuclear extracts were similar (millimolar concentrations for butanoic and valproic 
acids and micromolar concentrations for the hydroxamic acids), except for MS-275. 
Cells were more sensitive to MS-275 than the nuclear extracts (Fig. 22A). This fact 
can be attributed to the presence, in the nuclear extracts, of Zn(II)-dependent 
HDACs that MS-275 cannot inhibit, like HDAC8. The inhibition of a subset of HDACs 
seems to be sufficient to alter global H3 and H4 acetylation. Therefore, according to 
the mentioned models, the induced hyperacetylation could be sufficient to induce cell 
growth arrest either by disrupting the chromatin structure or by inducing 
overexpression of tumor-suppressor genes or both. Another possibility could be that 
MS-275 interferes in the function of other proteins affecting, at least to some extent, 
cell growth. 
Different degrees of cell cycle arrest either in G1/G0 or in G2/M have been 
reported for these drugs, depending on the studied cell line and the dose of the 
compound. For instance, butanoic acid and TSA were found to inhibit G1 to S 
transition in HeLa cells (Finzer et al. 2001) but in A549 these chemicals caused 
predominantly G2 and M arrest, respectively (Blagosklonny et al. 2001); CY was 
reported to stop leukaemia cells in G1/G0 (Weisberg et al. 2004), etc. In our 
experiments, except for MS-275, all the studied drugs stopped the cell cycle in the 
G2/M phase (Fig. 22B and C). The distribution of the cells in the different steps of 
the cell cycle was very similar for all the hydroxamic acids (near 50% in G1/G0 and 
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 around 40% in G2/M). The carboxylic acids showed a slightly different effect: in 
addition to the G2/M arrest, the maintenance of the proportion of cells in G1/G0 (65-
70%) together with the reduction in the S phase suggests a G1/G0 arrest. MS-275 
produced accumulation of cells mainly in G1/G0. Consequently, there is a relationship 
between the structure of the chemical and its effects on the cell cycle. As already 
discussed, there are 11 known human Zn(II) dependent HDACs and some of them 
have splicing variants. Although small, these differences between the enzymes make 
possible that the HDAC inhibitors have different specificities for different HDACs. As 
result, even though the effects of the chemicals on bulk histone H3 and H4 
acetylation are identical, subtle differences in the induced acetylation patterns may 
arise and cause differential gene expression profiles which would account for the 
diversity of effects on the cell cycle. Additionally, some HDACs have targets different 
than histones, like p53 or α-tubulin.  
As widely reported in the literature, all the seven chemicals compared in this 
work restore the expression of CDKN1A and all except for MS-275 induce GADD45β. 
According to Hirose et al. (2003), recovery of CDKN1A transcription by HDACs 
inhibitors is responsible for the arrest in G1/G0, whereas the arrest in G2/M can be 
due to the induction of GADD45β. The data presented here fit with that hypothesis. 
7.2.4. Histone hyperacetylation is not sufficient to increase 
gene expression 
As mentioned in sections 6.2.5 and 7.2.3., all these chemicals induce the 
expression of CDKN1A (Fig. 28A). The unique compound which does not cause the 
increase of GADD45β  transcription is MS-275 (Fig. 28A). In addition, all the drugs 
reactivate JUND but CY in much less extent than the others (Fig. 28A). JUND was 
found to be repressed through recruitment of mSinA3 complex to its promoter (Kim 
et al. 2003). The expression of IGFBP3 is increased by all the compounds except for 
MS-275 (Fig. 28A). In the literature it is found that TSA and butanoic acid cause 
significant IGFBP3 overexpression in MCF7 cells (Walker et al. 2001). 
In the conditions used in this work, no alteration in the mRNA levels of 
MT1X and MT2A was appreciated (Fig. 28A). It is reported that in lymphosarcoma 
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 cells MT1 is not expressed and acetylation of histones caused by HDACs inhibitors is 
not enough to recover the expression because its promoter is methylated. 
Demethylation due to zdC treatment is also not sufficient and both HDACs inhibitors 
and demethylating agents are necessary to restore the expression (Ghoshal et al. 
2002). In other cases (such as the lung cancer cell line H460 or the breast cancer 
cells T24, MDA-468 and MDA-435), HDAC inhibition is enough to increase the 
expression of MT1X and MT2A (Joseph et al. 2004, Glaser et al. 2003). The 
promoters of the six genes we studied contain CpG islands. Genomic bisulfite 
sequencing revealed that all of them are devoid of 5-methylcytosine in MCF7 cells 
(Fig. 28B). In consequence, aberrant DNA hypermethylation can not explain the 
insensitivity of the expression of MT1X and MT2A towards HDACs inhibition. 
Next, the alterations that HDACs inhibition causes on histone modifications 
and HDAC recruitment at the promoters were analysed by chromatin 
immunoprecipitation (Fig. 29). Samples treated with 1 µM CY were compared to 
untreated cells. Firstly, possible changes in the acetylation of H4 were studied by 
using an antibody raised against the tetraacetylated H4 tail. As expected, there is an 
increase of acetylation in H4 for all the genes, including MT1X and MT2A. In some 
cases (JUND, IGFBP3) the differences are much stronger than in others (CDKN1A, 
MT1X and MT2A). 
Methylation in lysine 4 of H3 (K4H3) is considered to be a mark of 
transcriptionally active chromatin (Jiang et al. 2004, Noma et al. 2001, Schneider et 
al. 2004), being associated to mRNA elongation by RNA polymerase II in yeast (Ng 
et al. 2003) or induced by the Paf1 complex in Drosophila (Krogan et al. 2003b). 
Recently, it has been described that di- and trimethylation of K4H3 colocalizes with 
acetylation in K9H3 and K14H3 in the promoter region of the transcriptionally active 
genes (Liang et al. 2004). So, in order to see if methylation of K4H3 at the promoter 
of the six genes was altered after HDACs inhibition, ChIP using anti-dimethylK4H3 
antibody was performed. The enrichment of this modification at the promoter in cells 
cultured with CY was confirmed for all the six genes. This fact constitutes an 
additional evidence of the crosstalk existing between different histone modifications: 
acetylation of lysine residues induces an increase of K4H3 dimethylation. The 
opposite relationship, methylation of K4H3 influencing histone H3 acetylation, has 
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 been reported. Methylation of K4H3 precludes lysine deacetylation by displacing 
NuRD (a complex containing HDAC1 and HDAC2) from H3 tail (Nishioka et al. 2002, 
Zegerman et al. 2002). 
On the other hand, methylation (di- and tri-) of lysine 9 in H3 (K9H3) is 
related with heterochromatin and transcriptional repression (Stewart et al. 2005, 
Scotta et al. 2002, Nakayama et al. 2001, Rea et al. 2000). Also methylation of K9H3 
by SUV39H1 is impaired by methylation in K4H3 (Nishioka et al. 2002) and it was 
suggested that HDACs could recruit SUV39H1 to nucleosomes (Vaute et al. 2002). In 
our case, we only found dimethyl K9H3 in the promoter of a few genes in untreated 
cells, but after 24 h treatment with CY, that mark disappeared. This might be caused 
directly by histone acetylation but could also be a consequence of K4H3 methylation 
or of the loss of HDACs recruited to the promoter. Further studies are necessary to 
determinate the sequence of these modifications. 
It is also remarkable that dimethylated K9H3 is only clearly present in the 
promoters of MT1X and MT2A, the only genes in the studied set whose expression is 
not altered by the treatment with HDACs inhibitors. It could be that this mark is 
associated with other transcriptional regulators that are not released from the 
promoters in our experiment but are responsible of keeping the expression of these 
genes unaltered during the 24 h drug treatment. Another possibility is that the 
elongation cannot proceed even though the changes in the promoters of these genes 
upon HDAC inhibition allow the assembly of the transcription machinery. Histone 
acetylation may not be sufficient for the release of repressor complexes or for the 
recruitment of elongation factors to the transcribed region. 
Finally, it seems that upon CY treatment, HDAC2 leaves the promoters 
where it was present, as it happens in other cases with other HDACs inhibitors (Duan 
et al. 2005). 
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 8. Conclusions 
 
Procaine: a novel DNA demethylating agent 
1. Procaine reduces global DNA methylation, reaching its maximum effect in MCF7 
cells between the first and the second day of treatment. However, when 
compared to 5-aza-2’-deoxycitidine, procaine effects are milder. 
2. Procaine reactivates genes that are silenced by DNA hypermethylation. The 
concentration of drug to restore gene expression only causes a slight reduction in 
the proportion of 5-methylcytosine on global DNA. 
3. Procaine reduces cell cycle proliferation and induces cell cycle arrest at mitosis. 
4. All these properties together with the fact that procaine is not incorporated into 
DNA make procaine a potentially interesting drug for cancer chemotherapy. 
Comparative study of seven HDACs inhibitors 
5. TSA, SAHA, PXD101, NVP-LAQ824, MS-275, valproic acid and butanoic acid inhibit 
Zn(II)-dependent HDACs. Their effects on HDAC activity in vitro and on cell cycle 
show a tight structure-activity relationship. The carboxylic acids are the least 
efficient compounds. 
6. All the seven chemicals increase in to a similar extent the global acetylation of H3 
and H4 in cultured cells. 
7. None of the seven inhibitors alter the protein concentration of HDAC1 or HDAC2 in 
the cell. 
8. The different effects of the HDACs inhibitors in the expression levels of CDKN1A 
and GADD45β may be related with the distinctive effects on cell cycle arrest: MS-
275 induces arrest in G1/G0 and transcription of CDKN1A, but not GADD45β; 
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 whereas the rest of drugs induce arrest in G2/M and overexpression of both 
CDKN1A and GADD45β. 
9. Not all the compounds reactivate the same set of genes. 
10. The expression of MT1X and MT2A is insensitive to any of these treatments, even 
though the histones associated with their promoters become hyperacetylated and 
their respective promoters do not exhibit DNA hypermethylation. 
11. Inhibition of HDACs causes an increase in acetylated H4 associated at the 
promoters of the six studied genes.  
12. Inhibition of HDACs also results in the accumulation of dimethylated lysine 4 of 
H3 (a mark associated with gene activation) and the loss of dimethylated lysine 9 
of H3 (a mark associated with silent chromatin) in the promoters of the studied 
genes where this modification was present. This fact supports the existence of a 
crosstalk between different histone modifications. 
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